US Pat. No. 10,167,536

TUNGSTEN ALLOY, TUNGSTEN ALLOY PART, DISCHARGE LAMP, TRANSMITTING TUBE, AND MAGNETRON

Kabushiki Kaisha Toshiba,...

1. A method for producing a tungsten alloy for a discharge lamp, a transmitting tube or a magnetron, the method comprising:mixing a HfC powder comprising primary particles having an average particle diameter of 15 ?m or less and a tungsten powder having an average particle diameter of 0.5 to 10 ?m to obtain a raw powder;
molding the raw powder to obtain a molded body;
sintering the molded body to obtain a sintered body; and
performing at least one process selected from the group consisting of forging, rolling, wiredrawing, cutting, and polishing, after the sintering step;
wherein a processing ratio [(A?B)/A]×100 of the at least one process is within a range of 30 to 90%, wherein A is a sectional area of the sintered body before the at least one process and B is a sectional area of the sintered body after the at least one process.

US Pat. No. 10,167,534

FRESH WATER DEGRADABLE DOWNHOLE TOOLS COMPRISING MAGNESIUM AND ALUMINUM ALLOYS

Halliburton Energy Servic...

1. A downhole tool comprising:at least one component of the downhole tool made of a doped alloy that at least partially degrades by micro-galvanic corrosion in the presence of fresh water, the fresh water having a salinity of less than about 1000 ppm,
wherein the doped alloy is selected from the group consisting of:
a doped magnesium alloy comprising a dopant selected from the group consisting of a nickel dopant in the range of about 2% to about 6%, a copper dopant in the range of about 6% to about 12%, an iron dopant in the range of about 2% to about 6%, and any combination thereof;
a doped magnesium alloy selected from the group consisting of a doped WE magnesium alloy, a doped AZ magnesium alloy, a doped ZK magnesium alloy, a doped AM magnesium alloy, and any combination thereof; and
a doped aluminum alloy comprising greater than about 50% by weight of aluminum and a dopant selected from the group consisting of a copper dopant in the range of about 8% to about 15%, a gallium dopant in the range of about 0.2% to about 4%, a nickel dopant in the range of about 1% to about 7%, an iron dopant in the range of about 2% to about 7%, and any combination thereof.

US Pat. No. 10,167,532

METHOD FOR ISOLATING RARE EARTHS AND/OR ADJACENT METAL ELEMENT(S) CONTAINED IN THE MAGNETIC PHASE OF PERMANENT MAGNETS

1. A process for isolating rare earth metals and ancillary metal element(s) distinct from rare earth metals present in a magnetic phase of magnets or derived products, comprising:(i) having a material forming said magnetic phase available in the form of a demagnetized powder, with a mean particle size of less than or equal to 700 ?m, devoid of contamination with nonconstituent particles of said magnetic phase;
(ii) dissolving said powder from stage (i) in an acid medium comprising a first quantity of acid and supplemented with at least one oxidizing agent capable of adjusting the ancillary metal element(s) to an oxidation state compatible with their consecutive precipitation in stage (iii), in the presence of hydroxide ions, at a pH strictly of less than 7, to form a first solution;
(iii) precipitating the ancillary metal element(s) in the hydroxide state to form a metal hydroxide precipitate by adding at least one hydroxylated base to the first solution obtained on conclusion of stage (ii), under pH conditions such that the rare earth metals are in a dissolved form;
(iv) isolating the metal hydroxide precipitate formed on conclusion of stage (iii), and optionally recovering it, leaving a second solution that is depleted in, and optionally devoid of, ancillary metal element(s);
(v) precipitating the rare earth metals in an oxalate state from the second solution obtained on conclusion of stage (iv) by adding a second quantity of acid comprising an oxalic acid to said second solution; and
(vi) recovering said rare earth metals in a form of a precipitate of rare earth metal oxalate,
wherein the process does not include an oxidation heat treatment step.

US Pat. No. 10,167,531

PROCESSING OF LITHIUM CONTAINING MATERIAL

Reed Advanced Materials P...

1. A process for treatment of a lithium containing material, the process comprising the steps of:(i) passing a lithium containing material to a leach step comprising a first leach stage and a second leach stage in which said lithium containing material is leached with hydrochloric acid to produce a pregnant leach solution;
(ii) passing said pregnant leach solution to a thickening step comprising a first thickening stage coupled subsequent to the first leach stage and a second thickening stage coupled subsequent to the second leach stage and subsequently pyrohydrolysing an overflow from said first thickening stage and an overflow from said second thickening stage, thereby converting any chlorides of aluminum and iron into insoluble oxides, removing same, and recovering residual hydrochloric acid that is utilized in the leach step (i), wherein an underflow from the first thickening stage coupled subsequent to the first leach stage is passed to the second leach stage and the second thickening stage coupled subsequent to the second leach stage, and wherein an underflow from the second thickening stage coupled subsequent to the second leach stage is passed to waste;
(iii) passing said pregnant leach solution from step (ii) to a series of impurity removal steps thereby providing a substantially purified lithium chloride solution;
(iv) passing the purified lithium chloride solution of step (iii) to an electrolysis step in which lithium chloride and added water are consumed thereby producing a lithium hydroxide solution, chlorine, and hydrogen;
(v) combining chlorine and hydrogen produced in the electrolysis step (iv) to produce hydrochloric acid that is utilized in the leach step (i); and
(vi) carbonating the lithium hydroxide solution produced in step (iv) by passing compressed carbon dioxide there through, thereby producing a lithium carbonate precipitate, or
b) wherein the lithium hydroxide solution produced in step (iv) is thickened by evaporation of water to provide lithium hydroxide monohydrate crystals, or
c) a portion of the lithium hydroxide solution is carbonated to produce a lithium carbonate precipitate, and another portion is thickened by evaporation of water to provide lithium hydroxide monohydrate crystals;
wherein the lithium containing material is an alpha-spodumene ore or ore concentrate and the process further comprises a first step in which that alpha-spodumene ore or ore concentrate is calcined to produce beta-spodumene.

US Pat. No. 10,167,530

METHOD OF MANUFACTURING HOT PRESS FORMED PART, AND HOT PRESS FORMED PART

JFE Steel Corporation, T...

1. A method of manufacturing a hot press formed part by hot pressing a coated steel sheet that is obtained by forming a Zn-based coating layer on a surface of a steel sheet, the method comprising:heating the coated steel sheet to a temperature range of 750° C. or more and 1000° C. or less;
cooling a surface of the coated steel sheet; and
hot press forming the coated steel sheet under a condition that a surface temperature of the coated steel sheet is 400° C. or less and an average temperature of the coated steel sheet is 500° C. or more.

US Pat. No. 10,167,529

HARDFACING PROCESS AND PARTS PRODUCED THEREBY

Caterpillar Inc., Deerfi...

1. A hardfaced component that is subject to wear, comprising:a boron steel body that includes SAE 51B27 steel; and
a clad layer, greater than about 1 mm thick (0.04 in), metallurgically bonded on a surface of the steel body using an arc welding process, wherein a lowest hardness of the steel body in an interfacial region that is about six times the thickness of the clad layer is within about 15% of a hardness of the body below the interfacial region.

US Pat. No. 10,167,528

COMPOSITION DESIGN AND PROCESSING METHODS OF HIGH STRENGTH, HIGH DUCTILITY, AND HIGH CORROSION RESISTANCE FEMNA1C ALLOYS

APOGEAN METAL CO., LTD., ...

1. A wrought alloy consisting essentially of, by weight, 23 to 34 percent manganese (Mn), 6 to 12 percent aluminum (Al), 1.58 to 2.2 percent carbon (C), and balance essentially iron (Fe);wherein said alloy is solution heat-treated at 980° C. to 1200° C. followed by quenching to room-temperature water or ice water, and
wherein the as-quenched microstructure of said alloy is composed of a single austenite matrix and nano-size (Fe,Mn)3AlCx carbides (??-carbides); said ??-carbides are formed within the austenite matrix during quenching via a spinodal decomposition.

US Pat. No. 10,167,527

METHOD AND ARRANGEMENT FOR PROGRESSIVE SURFACE HARDENING

THYSSENKRUPP ROTHE ERDE G...

1. A method for a progressive induction surface hardening of a closed curved trace of a workpiece by a hardening device, comprising:providing:
a hardening device having:
an inductor configured to heat the workpiece to harden a surface thereof;
a sprayer configured to quench the heated workpiece; and
a sensor configured to sense a position of the workpiece with respect to the inductor; and
the workpiece;
wherein the workpiece is aligned vertically and is supported on an underside by rollers, wherein at least one of the rollers is driven by a motor; and
wherein the hardening device and workpiece are movable relative to one another in a direction of treatment when in a feeding mode;
applying a marking to the workpiece, the marking being detachable from the workpiece;
moving the closed curved trace of the workpiece and the hardening device relative to each other along a direction of treatment of the closed curved trace, while the hardening device is deactivated;
sensing the marking by the sensor of the hardening device as the marking moves to a predetermined position adjacent the sensor;
after said sensing of the marking, further moving the closed curved trace of the work piece and the hardening device relative to each other along the direction of treatment while the hardening device is still deactivated;
detecting, upon a sensing of the marking by the sensor, each of the beginning and end of the marking, as the closed curved trace and sensor move relative to each other along the direction of treatment; and
activating the hardening device when the end of the marking is detected during a first sensing of the marking at an initial zone of the closed curved trace;
moving the closed curved trace of the workpiece and the hardening device relative to each other along the direction of treatment of the closed curved trace while the hardening device is activated, such that unhardened portions of the closed curved trace become hardened as the hardening device moves thereby; and
deactivating the hardening device when the beginning of the fixed mark is detected during a second sensing of the marking at an end zone of the closed curved trace when the marking is sensed a second time by the sensor, such that the hardening device hardens the surface of the closed curved trace from the initial zone to the end zone along the direction of treatment, and leaving an unhardened slip zone disposed between the initial zone and the end zone, wherein the width of the unhardened slip zone corresponds to the width of the marking.

US Pat. No. 10,167,515

MOLECULAR ANALYSIS USING A MAGNETIC SIFTER AND NANOWELL SYSTEM

The Board of Trustees of ...

1. A method for identification of circulating tumor cells (CTCs), the method comprising:magnetically labeling the CTCs in a blood sample with cancer cell markers conjugated to magnetic nanoparticles;
separating the magnetically labeled CTCs by passing the blood sample through a magnetic sifter during application of an external magnetic field;
collecting the separated magnetically labeled CTCs to produce enriched CTCs;
loading the enriched CTCs into a microfluidic single-cell molecular assay comprising an array of 25,600 or more nanowells, where each of the nanowells is adapted to contain at most a single one of the CTCs;
performing multiple simultaneous multiple-color multiplexed gene expression analysis of the CTCs using the microfluidic single-cell molecular assay and multiple fluorescent gene markers;
imaging the array of nanowells using fluorescence signal acquisition from individual nanowells, producing images of the array of nanowells;
analyzing the images using a signal processor to identify CTCs based on the concurrent expression of two or more genes.

US Pat. No. 10,167,514

METHODS AND SYSTEMS FOR DETERMINING PROPORTIONS OF DISTINCT CELL SUBSETS

The Board of Trustees of ...

1. A method for identifying at least one of a plurality of cell populations in a sample, said method producing a significance value for said identification and comprising:a) providing a sample comprising said plurality of cell populations;
b) processing said sample to generate a feature profile from said sample, wherein said feature profile comprises a gene expression profile, protein-protein interaction profile, protein phosphorylation profile, cellular electrical activity profile, chromatin modification profile, chromosome binding profile, enzymatic activity profile, metabolite profile, nuclear magnetic resonance (NMR) spectra, electromagnetic radiation absorbance or emission spectra, circular dichroism spectra, Raman spectra, mass spectra, or chromatograms, or a combination thereof;
c) processing said feature profile, using a deconvolution module, to identify said at least one of said plurality of cell populations in said sample; and
d) processing said feature profile, using a significance value module, to produce said significance value for said identification.

US Pat. No. 10,167,505

INTEGRATED SEQUENCING APPARATUSES AND METHODS OF USE

ILLUMINA, INC., San Dieg...

1. A method of sequencing a nucleic acid molecule, the method comprising the steps of:(a) providing a droplet manipulation apparatus for performing droplet operations, the droplet manipulation apparatus comprising a substrate surface comprising an array of dynamic pads, wherein a droplet dispensed onto the substrate surface moves along a desired path defined by the dynamic pads, and wherein at least one of the pads comprises a hydrophilic patch;
(b) transporting a droplet comprising one or more nucleic acid molecules to be sequenced to the hydrophilic patch;
(c) immobilizing the one or more nucleic acid molecules;
(d) sequencing the one or more nucleic acid molecules.

US Pat. No. 10,167,502

MOLECULAR CHARACTERIZATION OF SINGLE CELLS AND CELL POPULATIONS FOR NON-INVASIVE DIAGNOSTICS

Fluxion Biosciences, Inc....

4. A method of sequestering of cells comprising the steps of:(a) enriching a sub-population of said cells from a blood sample and feeding said sub population via a microfluidic channel into a reservoir; and
(b) sequestering one or more cells of said sub-population by trapping said one or more cells under negative pressure at a junction between an inside of a well caused by a punch-hole in said reservoir and another microfluidic channel and thereafter lysing said one or more cells by introducing a lysing agent in said well.

US Pat. No. 10,167,500

TAGGED OLIGONUCLEOTIDES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION METHODS

GEN-PROBE INCORPORATED, ...

1. A method for the selective amplification and detection of at least one target nucleic acid sequence from a nucleic acid sample, said method comprising the steps of:(a) treating a nucleic acid sample comprising a target nucleic acid sequence with a tagged oligonucleotide comprising first and second regions, said first region comprising a target hybridizing sequence which hybridizes to a 3?-end of said target nucleic acid sequence and said second region comprising a tag sequence situated 5? to said target hybridizing sequence, wherein said second region does not stably hybridize to a target nucleic acid containing said target nucleic acid sequence;
(b) reducing in said nucleic acid sample the effective concentration of unhybridized tagged oligonucleotide having an active form in which a target hybridizing sequence of said unhybridized tagged oligonucleotide is available for hybridization to said target nucleic acid sequence;
(c) after step (b), initiating a nucleic acid polymerase dependent primer extension reaction from the 3? end of the tagged oligonucleotide hybridized to the target nucleic acid, thereby producing an extension product;
(d) separating the primer extension product from the target nucleic acid; and
(e) producing amplification products in an isothermal nucleic acid amplification reaction using first and second oligonucleotides, wherein said first oligonucleotide comprises a hybridizing sequence which hybridizes to a 3?-end of the complement of said target nucleic acid sequence and said second oligonucleotide comprises a hybridizing sequence which hybridizes to the complement of said tag sequence, wherein said second oligonucleotide does stably hybridize to said target nucleic acid, and wherein each of said amplification products comprises a base sequence which is substantially identical or complementary to the base sequence of said target nucleic acid sequence and further comprises a base sequence which is substantially identical or complementary to all or a portion of said tag sequence; and
(f) detecting the amplification products generated in step (e), wherein detecting the amplification products comprises exposing the amplification products to a probe having a hybridizing sequence which hybridizes to the amplification product.

US Pat. No. 10,167,499

LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS

CAPITALBIO TECHNOLOOGY CO...

1. A method of labeling a plurality of target molecules with a luminophore for detecting the target molecules using a microarray, the method comprising:a) coupling each target molecule of a plurality of target molecules to a particle to form a target-particle complex, wherein each target molecule comprises a modification moiety and the particle comprises a plurality of functional moieties, wherein each target molecule is coupled to the particle via interaction between the modification moiety and the functional moiety, and wherein each target molecule comprises a target portion and a portion capable of specific binding to a probe molecule immobilized on the microarray, wherein the microarray comprises a plurality of immobilized probe molecules; and
b) providing a luminophore on the target-particle complex, thereby directly or indirectly labeling the plurality of target molecules with the luminophore,
wherein the providing step comprises:
introducing the luminophore into or onto the particle to label the particle, and incubating the luminophore-labeled particle with the plurality of target molecules, whereby the plurality of target molecules are coupled to the particle,
wherein the target molecule comprises a first polynucleotide, and the probe molecule comprises a second polynucleotide that is complementary to the first polynucleotide.

US Pat. No. 10,167,498

GRADIENT ELUTION MOVING BOUNDARY ELECTROPHORESIS FOR USE WITH COMPLEX SAMPLES AND DETECTION OF TOXINS

1. A method of indirectly detecting the presence of toxins in a complex sample using electrophoretic separations, the method comprising:introducing a run buffer into a separation channel having an inlet end;
introducing the complex sample into a sample reservoir in fluid contact with the separation channel, wherein the complex sample was subject to no sample preparation or was subject to sample preparation selected from the group consisting of dilution, suspension, filtration, and combinations thereof;
reacting the complex sample with a signaling enzyme in a reaction medium containing a substrate for the signaling enzyme, wherein the signaling enzyme converts the substrate to a product;
separating the substrate and the product by:
applying an electric potential across the separation channel to achieve electrophoretic migration of the substrate and the product, and
varying with respect to time the bulk flow of the run buffer through the separation channel to achieve selective introduction of the substrate and the product into the inlet end of the separation channel and differential migration of the substrate and the product therethrough such that the substrate and the product are sequentially detected and quantified; and
determining a rate of conversion of the substrate to the product, wherein a change in the rate of conversion is indicative of the presence of toxins.

US Pat. No. 10,167,497

STABLE NAD/NADH DERIVATIVES

Roche Diabetes Care, Inc....

1. A method for detecting an analyte in a fluid sample comprising the steps of(a) providing a test element, the test element carrying an enzyme and a compound of the general formula (I?);

in which
A=adenine or an analogue thereof,
T=in each case independently denotes O, S,
U=in each case independently denotes OH, SH, BH3?, BCNH2?,
V=in each case independently denotes OH or a phosphate group,
W=COOR, CON(R)2, COR, CSN(R)2 in which R in each case independently denotes H or C1-C2-alkyl,
X1, X2=in each case independently denote O, or NH,
Y=NH, S, O, CH2
Z=a saturated or unsaturated carbocyclic or heterocyclic five-membered ring of the general formula (II)

in which a single or double bond can be present between R5? and R5?,
R4=in each case independently denotes H, F, Cl, and CH3,
R5=CR42,
if a single bond is present between R5? and R5?, then
R5?=O, S, NH, NC1-C2-alkyl, CR42, CHOH, CHOCH3,
R5?=CR42, CHOH, CHOCH3
if a double bond is present between R5? and R5?,
then R5?=R5?=CR4,
R6, R6?=in each case independently denote CH, CCH3
provided that if R5=CH2, T=O, U=in each case OH, V=OH, W=CONH2, X1, X2?O and
Y=O, then R5? and R5? are not simultaneously CHOH,or a salt or optionally a reduced from thereof; and(b) analyzing an enzymatic reaction involving the analyte and correlating a change in the compound or the enzyme to a quantity of the analyte.

US Pat. No. 10,167,495

MICROBE QUANTIFYING APPARATUS AND MICROBE QUANTIFYING METHOD

HITACHI, LTD., Tokyo (JP...

1. A microbe quantifying apparatus comprising:a filtering mechanism that is configured to filter microbes contained in a fluid sample with a filter having an upper layer of a hydrophilic filter and a lower layer of a hydrophobic filter;
a quantifying mechanism that is configured to quantify the microbes with a specified biological material contained in the microbes on the filter as an index; and
an anti-drying mechanism that is configured to prevent drying of the microbes on the filter, wherein
the anti-drying mechanism includes:
a level gauge that is configured to detect fluid quantity on the filter to output a fluid quantity detection signal,
a buffer solution injector that is configured to supply buffer solution fluid onto the filter, and
a control unit that is configured to:
perform a filtration control based on the fluid quantity detection signal, wherein the control unit is configured to: (i) activate the buffer solution injector to supply buffer solution onto the filter when determining based on the fluid quantity detection signal that the fluid quantity has decreased to a predetermined quantity or less, and (ii) stop the filtering mechanism when the fluid quantity on the filter decreases to the predetermined quantity or less, based on the fluid quantity detection signal from the level gauge, and
perform a control to couple and decouple the suction head to the filtering mechanism.

US Pat. No. 10,167,487

METHODS, CELLS AND REAGENTS FOR PRODUCTION OF ISOPRENE, DERIVATIVES AND INTERMEDIATES THEREOF

1. A method for synthesizing 3-hydroxy-3-methylglutaryl-CoA comprising:enzymatically converting 4-methyl-2-oxopentanoate to 3-methylbut-2-enoyl-CoA by:
(a) enzymatically converting 4-methyl-2-oxopentanoate to 3-methylbutanal; enzymatically converting 3-methylbutanal to 3-methylbutanoate; and enzymatically converting 3-methylbutanoate to 3-methylbutanoyl-CoA;
(b) enzymatically converting 4-methyl-2-oxopentanoate to 3-methylbutanoyl-CoA; or
(c) both (a) and (b);
enzymatically converting 3-methylbutanoyl-CoA to 3-methylbut-2-enoyl-CoA;
enzymatically converting 3-methylbut-2-enoyl-CoA to 3-methyl-glutaconyl CoA; and
enzymatically converting 3-methyl-glutaconyl-CoA to 3-hydroxy-3-methylglutaryl-CoA.

US Pat. No. 10,167,481

PLANT REGULATORY ELEMENTS AND USES THEREOF

Monsanto Technology LLC, ...

6. A transgenic plant cell comprising a heterologous DNA molecule comprising a sequence selected from the group consisting of:a) a sequence with at least 98 percent sequence identity to SEQ ID NO: 1, wherein the sequence has promoter activity;
b) a sequence comprising SEQ ID NO: 1; and
c) a fragment of SEQ ID NO: 1 comprising SEQ ID NO: 2, wherein the fragment has promoter activity;
wherein said sequence is operably linked to a heterologous transcribable polynucleotide molecule.

US Pat. No. 10,167,480

STRONG ACTIVATION DOMAIN

Mendel Biotechnology, Inc...

11. A method for increasing expression of a target polynucleotide sequence, the method comprising:(a) generating a nucleic acid construct encoding a chimeric polypeptide consisting of a transactivation domain covalently linked to a heterologous transcription regulatory polypeptide, wherein said transactivation domain consists of SEQ ID NO: 37 or a sequence having at least 25% identity thereto and comprising SEQ ID NO:55, and, wherein said transcription regulatory polypeptide comprises a DNA binding domain; and
(b) introducing the nucleic acid construct into a host cell.

US Pat. No. 10,167,476

5?-TRIPHOSPHATE OLIGORIBONUCLEOTIDES

1. A synthetic oligoribonucleotide at least 41 nucleotides in length that can form a hairpin structure comprising at least 17 base pairs, the synthetic oligonucleotide further comprising a triphosphate group at a 5? end of the oligoribonucleotide wherein the synthetic oligoribonucleotide comprises SEQ ID NO: 10.

US Pat. No. 10,167,451

COMBINATIONAL USE OF MECHANICAL MANIPULATION AND PROGRAMIN DERIVATIVES TO INCREASE OCT4, SOX2, OR NANOG EXPRESSION IN FIBROBLASTS

The Chinese University of...

1. A method for increasing Oct4, Sox2, or Nanog expression in fibroblasts, the method comprising:(a) culturing the fibroblasts in a vessel;
(b) mechanically agitating the fibroblasts that are unattached to the vessel to form a non-adherent cellular aggregate; and
(c) exposing the non-adherent cellular aggregate to an effective amount of a compound of Formula II-IX having any one of the following structures:

thereby increasing Oct4, Sox2, or Nanog expression in the fibroblasts of the non-adherent cellular aggregate.

US Pat. No. 10,167,445

CELL CULTURE MONITORING SYSTEM WITH LOW POWER CONSUMPTION

1. A method for reducing power consumption and wirelessly monitoring biological cell culture medium in a dynamic environment of a biological culture incubator/shaker, comprising:utilizing a container to hold a liquid biological culture medium in which biological cells are incubated, and at least a part of the container's wall is optically transparent;
positioning a light emission source relative to the transparent wall of said container and irradiating light through the wall of said container and interacting with said biological culture medium;
positioning and aiming at least one photodetector to detect light from the interacting section of the incident light with the biological culture medium;
positioning at least one temperature sensor close to said light emission source and said photodetector;
providing temperature compensation means for improving measurement accuracy without a temperature control of said light emission source and said photodetector, said temperature compensation means includes steps for controlling the driving current of the light emission source, and then pre-measuring, pre-calculating and pre-storing superimposed temperature coefficients of the controlled light emission source and the photodetector, and then correcting the measurable property values of the biological cell culture medium based on measured temperature of the light emission source and the photodetector and measured turbidity of the cell culture medium;
providing processing means for amplifying electrical signal from the photodetector, and for processing the signal and presenting properties of the biological cell culture medium.

US Pat. No. 10,167,444

BIOREACTOR AND METHOD OF FORMING COMPLEX THREE-DIMENSIONAL TISSUE CONSTRUCTS

The Regents of The Univer...

1. A bioreactor for forming a complex three-dimensional tissue construct, comprising:a first substrate for culturing a first cell source;
a second substrate for culturing a second cell source, wherein the first substrate and the second substrate comprise two walls of a culture chamber; and
at least one translation mechanism in the culture chamber that at least partially extends between the first substrate and the second substrate so that a first tissue construct of the first cell source cultured on the first substrate or a second tissue construct of the second cell source cultured on the second substrate can be translated via the translation mechanism to form the complex three-dimensional tissue construct having the second tissue construct of the second cell source cultured with the first tissue construct of the first cell source.

US Pat. No. 10,167,443

WET CLEAN PROCESS FOR REMOVING CXHYFZ ETCH RESIDUE

INTERNATIONAL BUSINESS MA...

1. An etch chemistry for removing hydrocarbon etch residues comprising an aqueous solution including cerium ammonium nitrate (Ce(NH4)2(NO3)6)(CAN) and NH4OH, the cerium ammonium nitrate (Ce(NH4)2(NO3)6)(CAN) being present in the aqueous lanthanoid solution in a concentration ranging from 100 g/L to 500 g/L, wherein the etch chemistry removes the hydrocarbon etch residues without removing metal from metal gate electrodes that are adjacent to the hydrocarbon etch residues.

US Pat. No. 10,167,441

LAUNDRY SCENT ADDITIVE

1. A composition comprising a plurality of pastilles, wherein said pastilles comprise:polyethylene glycol; and
free perfume;
wherein each of said pastilles has a mass from about 0.95 mg to about 2 g; and
wherein said pastilles have a shape selected from the group consisting of hemispherical and compressed hemispherical.

US Pat. No. 10,167,439

ULTRAVIOLET CURABLE RESIN COMPOSITION AND SLIDING MEMBER

MINEBEA MITSUMI INC., Ki...

1. An ultraviolet curable resin composition for a self-lubricating liner, comprising:a (meth)acrylate compound having an isocyanuric acid ring represented by formula (1):
where X is a group that contains an acryloyl group and is composed only of C, H, and O, andY and Z are groups each composed only of C, H, and O;at least one of (meth)acrylate having a phosphoric acid ester group and (meth)acrylate having a silane group;
a polythiol compound; and
a polytetrafluoroethylene resin as a solid lubricant.

US Pat. No. 10,167,438

COMPRESSOR FOR REFRIGERATION AND AIR CONDITIONING, AND REFRIGERATION AND AIR CONDITIONING DEVICE

Hitachi-Johnson Controls ...

1. A compressor for refrigeration and air conditioning, characterized in that a refrigerator oil containing a polyol ester having a structural unit represented by the following general formula (1):(wherein R1 and R2 each independently represent a linear or branched alkyl group; and n represents an integer of 2 or more), and a refrigerant containing difluoromethane are enclosed, andthe polyol ester is composed of only one or both of a cyclic polyol ester, which is obtained by cyclically polymerizing a molecular chain having the structural unit, and a crosslinked polyol ester, which is obtained by crosslinking molecular chains having the structural unit with each other through a crosslinkable structural unit polymerized with the structural unit, and in which n in the structural unit is 3 or more.

US Pat. No. 10,167,437

SYSTEMS AND APPARATUS FOR PRODUCTION OF HIGH-CARBON BIOGENIC REAGENTS

Carbon Technology Holding...

1. A high-carbon biogenic reagent production system, the system comprising:(a) a material feed system configured to introduce a carbon-containing feedstock;
(b) an optional dryer, disposed in operable communication with the material feed system, configured to remove moisture contained within a carbon-containing feedstock;
(c) a multiple-zone reactor, disposed in operable communication with the material feed system or the option dryer, wherein the multiple-zone reactor comprises at least one pyrolysis zone disposed in operable communication with a spatially separated cooling zone, and wherein the multiple-zone reactor comprises an outlet to remove condensable vapors and non-condensable gases from solids;
(d) a cooler, disposed in operable communication with the multiple-zone reactor; and
(e) a carbon recovery unit, disposed in operable communication with the cooler.

US Pat. No. 10,167,436

METHODS AND APPARATUSES FOR PROCESSING HUMAN WASTE INTO FUEL

Sanivation LLC, Wilmingt...

1. A method for making fuel briquettes using feces to bind the fuel briquettes, the method comprising:heat treating the feces to inactivate pathogens resident therein and to cause cellulose material in the feces to undergo a bond transition;
mixing the treated feces and water to create a homogenous binder; and
forming briquettes from a mixture comprising the binder and non-carbonized and/or carbonized biomass material, wherein the treated feces acts to bind the mixture such that the mixture may be formed into briquettes.

US Pat. No. 10,167,434

INTEGRATED HYDROCRACKING PROCESS

SAUDI BASIC INDUSTRIES CO...

1. An integrated hydrocracking process for production of olefinic and aromatic petrochemicals from a hydrocarbon feedstock comprising crude oil, the process comprising:treating the hydrocarbon feedstock comprising crude oil and a residual liquid product in a first hydrocracking zone in the presence of hydrogen under effective conditions producing a first effluent having an increased hydrogen content;
separating the first effluent into a liquefied petroleum gas (LPG) comprising stream and a liquid phase stream;
separating said LPG comprising stream into one or more streams chosen from a stream comprising hydrogen, a stream comprising methane, a steam comprising ethane, a stream comprising butanes, a stream comprising propane, a stream comprising C1-minus, a stream comprising C3-minus, a stream comprising C1-C2, a stream comprising C3-C4, a stream comprising C2-C3, a stream comprising C1-C3, a stream comprising C1-C4, a stream comprising C2-C4, a stream comprising C2-minus and a stream comprising C4-minus;
further processing said one or more streams in a steam cracker unit and at least one unit chosen from the group of a butanes dehydrogenation unit, a propane dehydrogenation unit, a combined propane-butanes dehydrogenation unit, and a combination of units thereof to produce mixed product stream(s);
feeding the mixed product stream(s) from said steam cracker unit and said at least one unit, chosen from the group of said butanes dehydrogenation unit, said propane dehydrogenation unit, said combined propane-butanes dehydrogenation unit, and said combination of units thereof, to a second separation section;
thermally cracking at least a portion of the liquid phase stream in a resid hydrocracking zone to produce slurry intermediate product; and
separating the mixed product stream(s).

US Pat. No. 10,167,433

PROCESS FOR PRODUCING DIESEL FROM A HYDROCARBON STREAM

UOP LLC, Des Plaines, IL...

1. A process for producing diesel from a hydrocarbon stream comprising:hydrocracking a hydrocarbon feed stream over hydrocracking catalyst in the presence of hydrogen to provide a hydrocracked effluent stream;
separating said hydrocracked effluent stream into a hydrocarbonaceous vaporous hydrocracked stream and a liquid hydrocracked stream;
hydrotreating said hydrocarbonaceous vaporous hydrocracked stream over hydrotreating catalyst in the presence of hydrogen, all provided in the vaporous hydrocracked stream, to provide a hydrotreated effluent stream;
separating said hydrotreated effluent stream into a vaporous hydrotreated stream and a liquid hydrotreated stream; and
stripping said liquid hydrotreated stream to provide a product stream comprising ultra low sulfur diesel.

US Pat. No. 10,167,432

PROCESSES TO MAKE ALKYLATE GASOLINE BY SULFUR-CONTAMINATED IONIC LIQUID CATALYZED ALKYLATION

Chevron U.S.A. Inc., San...

1. A process for making an alkylate gasoline blending component, comprising:a. providing an olefin feed comprising a sulfur contaminant;
b. drying the olefin feed comprising the sulfur contaminant with a promoted alumina-based selective adsorbent that is customized to provide adsorption for polar organic compounds to produce a dried olefin feed comprising from 100 to 1000 wppm of a sulfur contaminant comprising mercaptans, alkyl sulfides including methyl tert-butyl sulfide, and alkyl disulfides, wherein methyl tert-butyl sulfide is formed during treatment with the selective adsorbent;
c. feeding the dried olefin feed to a chloroaluminate ionic liquid catalyst, wherein a level of the sulfur contaminant accumulates in the chloroaluminate ionic liquid catalyst to make a sulfur-contaminated ionic liquid catalyst comprising 300 to 20,000 wppm of sulfur; and
d. alkylating the dried olefin feed with an isoparaffin using the sulfur-contaminated ionic liquid catalyst to produce an alkylate gasoline blending component, wherein the alkylate gasoline blending component has a final boiling point below 221° C. (430° F.).

US Pat. No. 10,167,431

PINNED FURNACE TUBES

NOVA Chemicals (Internati...

1. A tube for use in the radiant section of a furnace for cracking hydrocarbons to produce olefins having on its exterior surface a series of pins in one or more linear arrays parallel to and substantially the length of the longitudinal axis of the tube, said pins having:i) a maximum height from about 12% to about 50% of tube outer diameter of the tube;
ii) a contact surface with the tube, having an area from about 0.1% to about 10% of the tube external cross section area;
iii) length to diameter ratio from about 4:1 to about 3:1; and
iv) an arrangement into a linear array of different heights to provide a profile to the array;
wherein the distance between consecutive pins with a given linear array is from about 1 to about 5 times the maximum cross section of the pin.

US Pat. No. 10,167,430

CATALYTIC HYDROTHERMAL LIQUEFACTION FOR BIO-OIL PRODUCTION

Battelle Memorial Institu...

1. A method for producing oil, comprising:hydrothermally liquefying a lignocellulosic feedstock comprising (i) 5-30 wt % of a lignocellulosic biomass and (ii) water to produce a composition comprising a crude oil, an aqueous fraction, and inorganic solids;
separating the inorganic solids from the crude oil and the aqueous fraction to provide a process stream comprising the crude oil and the aqueous fraction;
contacting the process stream comprising the crude oil and the aqueous fraction with a sulfided-ruthenium catalyst, in the absence of added hydrogen, at an operating temperature and pressure effective to reduce an oxygen content of the crude oil, reduce a nitrogen content of the crude oil, reduce a total acid number of the crude oil, increase a H:C mole ratio of the crude oil, reduce a density of the crude oil, reduce a moisture content of the crude oil, reduce viscosity of the crude oil, or any combination thereof, thereby producing an upgraded oil and an upgraded aqueous fraction, wherein the sulfided-ruthenium catalyst comprises Ru, S, and a support, and has a Ru:S weight ratio within a range of from 10:1 to 25:1 prior to contact with the process stream; and
subsequently separating the upgraded oil and the upgraded aqueous fraction.

US Pat. No. 10,167,429

CONVERSION OF SOLID BIOMASS INTO A LIQUID HYDROCARBON MATERIALS

SHELL OIL COMPANY, Houst...

1. A process for producing liquid hydrocarbon products from a solid biomass feedstock comprising:a) providing, in a hydropyrolysis reactor vessel, a hydropyrolysis catalyst composition that comprises one or more active metals selected from cobalt, molybdenum, nickel, tungsten, ruthenium, platinum, palladium, iridium and iron on an oxide support, wherein the one or more active metals are present in an oxidic state, and wherein the term ‘oxidic state’ means that 95% or more of the one or more active metals are present in an oxidation state greater than zero as oxides;
b) contacting the solid biomass feedstock with the hydropyrolysis catalyst composition and molecular hydrogen in the hydropyrolysis reactor vessel at a temperature in the range of from 350 to 600° C. and a pressure in the range of from 0.50 to 7.50 MPa, to produce a product stream comprising partially deoxygenated hydropyrolysis product, H2O, H2, CO2, CO, C1-C3 gases, char and catalyst fines;
c) removing the char and catalyst fines from the product stream;
d) hydroconverting the partially deoxygenated hydropyrolysis product in a hydroconversion reactor vessel in the presence of one or more hydroconversion catalyst and of the H2O, CO2, CO, H2, and C1-C3 gas generated in step a), to produce a vapour phase product comprising substantially fully deoxygenated hydrocarbon product, H2O, CO, CO2, hydrogen and C1-C3 gases.

US Pat. No. 10,167,428

METHODS FOR BIOMASS TORREFACTION WITH CARBON DIOXIDE CAPTURE

CENTRAL MICHIGAN UNIVERSI...

1. A torrefaction process for biomass, the process comprising:preheating raw biomass in a dryer, thereby generating preheated raw biomass;
torrefying the preheated raw biomass in a torrefaction reactor, wherein the torrefaction reactor is configured to receive a heated carbon dioxide (CO2) stream;
providing volatiles from the torrefaction reactor to a combustor;
providing torrefied biomass from the torrefaction reactor to a first heat exchanger, the first heat exchanger configured to receive recycled carbon dioxide (CO2);
cooling the torrefied biomass in the first heat exchanger, including contacting the torrefied biomass with the recycled carbon dioxide (CO2), thereby heating the recycled carbon dioxide (CO2);
combusting the volatiles in the combustor, thereby generating a combustion outlet steam including carbon dioxide (CO2) and water (H2O);
providing the combustion outlet stream to a second heat exchanger;
providing the recycled carbon dioxide (CO2) from the first heat exchanger to the second heat exchanger;
in the second heat exchanger, heating the recycled carbon dioxide (CO2) with the combustion outlet stream, thereby generating the heated carbon dioxide (CO2) stream and a reduced temperature combustion outlet stream;
providing the reduced temperature combustion outlet stream to the dryer;
providing a dryer gas outlet stream to a condenser, the dryer gas outlet stream including carbon dioxide (CO2) and water vapor;
cooling the dryer gas outlet stream in the condenser, thereby generating a condensed water stream and a cooled CO2 stream; and
providing a portion of the cooled CO2 stream as the recycled carbon dioxide (CO2) to the first heat exchanger.

US Pat. No. 10,167,427

FLAME-RETARDANT VANILLIN-DERIVED CROSS-LINKERS

International Business Ma...

1. A flame-retardant vanillin-derived cross-linker with a formula of:
wherein M is a flame-retardant substituent;
wherein FR is a phosphorus-based moiety; and
wherein R is a substituent selected from a group consisting of an allyl substituent, an epoxide substituent, a propylene carbonate substituent, and a thioether substituent.

US Pat. No. 10,167,426

REACTIVE PERPENDICULAR ALIGNED ORGANOSILICON MATERIAL AND MANUFACTURE METHOD OF LIQUID CRYSTAL DISPLAY PANEL

SHENZHEN CHINA STAR OPTOE...

1. A manufacture method of a liquid crystal display panel, comprising following steps:step 1, providing a CF substrate, a TFT substrate, and a liquid crystal mixture;
wherein a first electrode is disposed on a surface of a side of the CF substrate, a second electrode is disposed on a surface of a side of the TFT substrate;
the liquid crystal mixture comprising liquid crystal molecules, reactive perpendicular aligned organosilicon materials, and reactive monomers, wherein a general structural formula of the reactive perpendicular aligned organosilicon material is A-R, A is —SiCl3; R represents a linear chained or a branched chained alkyl group with 5˜20 C atoms, a CH2 group in the alkyl group is substituted by a phenyl group, a naphthenic base, —CONH—, —COO—, —O—CO—, —S—, —CO— or —CH?CH—, or a F atom or a Cl atom substitutes for a H atom in the alkyl group;
dropping the liquid crystal mixture on a surface of a side of the TFT substrate whereon the second electrode disposed by a liquid crystal dropping process, gluing frame adhesive on margins of a surface of a side of the CF substrate whereon the first electrode disposed, pasting the CF substrate and the TFT substrate in vacuum;
meanwhile, a CI atom in the reactive perpendicular aligned organosilicon material and —OH on a surface of the substrate forming a hydrogen bond, leading to array perpendicularly on the substrate, in order to make liquid crystal molecules be perpendicular to the CF substrate and the TFT substrate;
step 2, UV radiating for solidification and heating for solidification of the frame adhesive, in the process of heating for solidification of the frame adhesive, —Si—Cl in the reactive perpendicular aligned organosilicon material and —OH on surfaces of the CF substrate and the TFT substrate reacting, removing HCl to form a —Si—O— bond, which can anchor the reactive perpendicular aligned organosilicon material on surfaces of the CF substrate and the TFT substrate by means of a —Si—O— bond;
step 3, applying voltage to two sides of the liquid crystal mixture by the first electrode and the second electrode, redirecting liquid crystal molecules;
step 4, applying voltage to two sides of the liquid crystal mixture and simultaneously radiating UV light on the liquid crystal mixture to polymerize the reactive perpendicular aligned organosilicon materials and the reactive monomers on surfaces of the CF substrate and the TFT substrate, in order to anchor liquid crystal molecules;
step 5, removing voltage from the two sides of the liquid crystal mixture, making liquid crystal molecules to engender a pre—tilt angle.

US Pat. No. 10,167,422

ELECTRICALLY-CONDUCTIVE PROPPANT AND METHODS FOR DETECTING, LOCATING AND CHARACTERIZING THE ELECTRICALLY-CONDUCTIVE PROPPANT

CARBO CERAMICS INC., Hou...

1. A method of making electrically-conductive proppant particles, comprising:contacting a plurality of sintered, substantially round and spherical particles with an activation solution comprising palladium and/or salts thereof to provide activated particles comprising reduced palladium, wherein each of the plurality of sintered, substantially round and spherical particles has a specific gravity of less than 4 g/cm3 and a size of about 100 mesh to about 10 mesh; and
contacting the activated particles with an alkaline plating solution comprising one or more electrically-conductive metals to form electrically-conductive proppant particles comprising an outer coating of the electrically-conductive metal of about 100 nm to about 3,500 nm thickness.

US Pat. No. 10,167,421

PHENOL-ALKOXYLATE CO-SOLVENT SURFACTANT COMPOSITION

Board of Regents, The Uni...

1. A method of converting an unrefined petroleum acid into a surfactant, the method comprising:(i) contacting a petroleum material with an aqueous composition comprising water, an anionic surfactant, an alkali agent, and a co-solvent having the formula
whereinR1 is independently hydrogen or unsubstituted C1-C4 alkyl;
R2 is independently hydrogen or unsubstituted C1-C2 alkyl; and
n is an integer from 1 to 30, thereby forming an emulsion in contact with the petroleum material;
wherein the co-solvent is present in an amount of from 0.25% to 3% by weight, based on the weight of the aqueous composition, wherein the aqueous composition has a salinity of at least 5,000 ppm and a pH of from 9.5 to 12, and wherein the anionic surfactant consists essentially of one or more anionic surfactants that are not alcohol phosphate surfactants or phosphate alkyl ester surfactants, and
(ii) allowing the unrefined petroleum acid within an unrefined petroleum material to enter into the emulsion, thereby converting the unrefined petroleum acid into the surfactant.

US Pat. No. 10,167,420

LOSS CIRCULATION COMPOSITIONS (LCM) HAVING PORTLAND CEMENT CLINKER

SAUDI ARABIAN OIL COMPANY...

1. A method to control lost circulation in a lost circulation zone in a wellbore, comprising:introducing a lost circulation material (LCM) into the wellbore such that the LCM contacts the lost circulation zone and reduces a rate of lost circulation into the lost circulation zone as compared to a period before introducing the LCM, wherein the LCM comprises:
Portland cement clinker, wherein the Portland cement clinker consists of non-hydraulic, non-cementiceous unground Portland cement clinker particles; and
a polyuronide, the polyuronide selected to crosslink in the presence of calcium dissolved from the clinker.

US Pat. No. 10,167,419

BENEFICIATING WEIGHTING AGENTS

Halliburton Energy Servic...

1. A method comprising:centrifuging a wellbore fluid to produce a slurry, wherein the wellbore fluid comprises an oleaginous fluid, a particulate additive, and a drill solid;
removing the oleaginous fluid from the slurry to produce a dried particulate composition comprising the particulate additive and the drill solid;
introducing the dried particulate composition into a dry solids separation system that comprises an air classifier and an electrostatic separator in series; and
separating a quantity of the drill solid from the dried particulate composition thereby producing a beneficiated particulate additive, wherein a first portion of drill solid is separated via the air classifier and a second portion of drill solid is separated via the electrostatic separator; and
wherein the separating with the dry solids separation system that comprises the air classifier and the electrostatic separator in series results in the beneficiated particulate additive:
i) comprising less than 40% of drill solids by weight of the beneficiated particulate additive, and
ii) having a specific gravity greater than the specific gravity of the dried particulate composition.

US Pat. No. 10,167,417

QUANTUM DOT ARTICLE WITH REDUCED EDGE INGRESS AND IMPROVED COLOR STABILITY

3M INNOVATIVE PROPERTIES ...

1. A quantum dot film article comprising:a first barrier layer;
a second barrier layer; and
a quantum dot layer between the first barrier layer and the second barrier layer, the quantum dot layer comprising quantum dots dispersed in a matrix comprising a cured adhesive composition, wherein the adhesive composition comprises:
an epoxide;
a curing agent comprising:
(a) a compound of Formula I:
H2N—CnH2n-A-CmH2m—NH2  Formula 1wherein A is a monocyclic or a polycyclic alkylene group, or a monocyclic or a polycyclic heteroalkylene group, and m and n are integers each independently selected from 0 to 5; and(b) a polyether amine compound of Formula V or VI:
R10—(O—R11)q—NH2  Formula Vwherein, in Formula V, group R10 is an alkyl having 1 to 4 carbon atoms, and R11 is independently a branched or linear alkylene having 1 to 4 carbon atoms, and q is equal to at least 2H2N—R12—(OR13)p—NH2  Formula VIwherein, in Formula VI, R12 and R13 are each independently a branched or linear alkylene having 1 to 4 carbon atoms, and p is equal to at least 2; anda radiation curable methacrylate compound.

US Pat. No. 10,167,415

REDUCTION IN LARGE PARTICLE COUNTS IN POLISHING SLURRIES

FUJIFILM PLANAR SOLUTIONS...

1. A method of polishing a semiconductor wafer surface, comprising the step of contacting the wafer surface with a pad and a polishing composition, the polishing composition comprising:glycine as a removal rate enhancer;
a corrosion inhibitor; and
an abrasive;
wherein the glycine has a conductivity C in deionized water, and wherein the glycine obeys the following inequality:
C?a*W+b,
wherein W is the wt % of the glycine, based on the total weight of the composition, wherein 0.0005 wherein W is greater than zero and less than or equal to twenty percent, based on the total weight of the composition,
wherein the composition has a large particle count, wherein the large particle count is defined by the number of particles per milliliter of the composition having a size greater than 0.56 micrometers,
and wherein the conductivity C and the large particle count have a positive correlation, such that the lower the conductivity, the lower the large particle count.

US Pat. No. 10,167,414

ALKYL SILICONES AS PIGMENT COATINGS

1. A reactive silicone polymer having the following structure:
wherein:
c is an integer ranging from 10 to 25;
R? is a mixture of:
a) an alkyl having the following structure:
—(CH2)xCH3
wherein:
x is an integer ranging from 7 to 21;
and
b) a silane having a structure selected from the group consisting of
i. —CH2CH2Si(OCH3)3
ii. —CH2CH2Si(OCH2CH3)3.

US Pat. No. 10,167,412

PHENOL POLYMER WITH 5,5?-BIARYL BONDS, METHOD FOR PREPARING SAME, AND USES THEREOF

INSTITUT NATIONAL DE LA R...

1. A phenol polymer obtained by oligomerization catalyzed by an enzyme of oxidase type, said phenol polymer comprising a plurality of monomers, said monomers being of one or more macropolyphenol(s), each macropolyphenol having a structure with at least two phenol rings corresponding to general formula (I):
wherein:
p represents an integer between 1 and 30,
R1, R?1, R2, R?2, R3 and R?3, which may be identical or different, each represent a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a fluorine atom, or an alkyl, benzyl, Xalkyl, where appropriate substituted, Xbenzyl, where appropriate substituted, Xacyl, B(OR?)2, NHR?, NO2, SR?O or SO2R? group,
where X represents N, O, S or P
and R? represents an alkyl group or an aryl group,
R1 and R?1 do not represent a hydrogen atom,
Y and Y?, which may be identical or different, each represent:
either an oxygen atom, a sulfur atom or a deconjugating group, said deconjugating group comprising neither an epoxide ring, nor an aziridine ring, nor a phenol group which is not substituted on all its carbon atoms, said deconjugating group not comprising a bond conjugated with the phenol ring to which said deconjugating group is bonded,
or a group corresponding to formula (II):

wherein:
q represents an integer between 1 and 8,
Y1 represents an oxygen atom, a sulfur atom or a deconjugating group, said deconjugating group comprising neither an epoxide ring, nor an aziridine ring, nor a phenol group which is not substituted on all its carbon atoms, said deconjugating group not comprising a bond conjugated with the phenol ring of the group of formula (II),
Z1 represents a heteroatom or a spacer group comprising neither an epoxide ring, nor an aziridine ring, nor a phenol group which is not substituted on all its carbon atoms, nor an alkenyl group, nor an alkynyl group,
and Z represents:
either a heteroatom or a spacer group comprising neither an epoxide ring, nor an aziridine ring, nor a phenol group which is not substituted on all its carbon atoms, nor an alkenyl group, nor an alkynyl group,
or a group corresponding to formula (III):

wherein q represents an integer between 1 and 8,
the bonds between the monomers of the one or more macropolyphenol(s) of general formula (I), within said polymer, being exclusively 5,5-biaryl bonds.

US Pat. No. 10,167,411

NEUTRAL LAYER POLYMERS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME

DOW GLOBAL TECHNOLOGIES L...

1. A composition comprising:a block copolymer comprising a first segment and a second segment that are covalently bonded to each other and that are chemically different from each other; where the first segment has a first surface free energy and where the second segment has a second surface free energy;
an additive copolymer; comprising segment A and segment B and a surface energy reducing moiety X, where segment A comprises repeat units of unit A and segment B comprises repeat units of unit B, where the surface free energy reducing moiety X has a lower surface free energy than that of the segment A and the segment B; where segment A or segment B has an affinity for either the first segment or the second segment; where the surface free energy reducing moiety X is chemically different from the first segment and from the second segment and comprises a fluorine atom, a silicon atom, an unsubstituted or substituted C1-C12 hydrocarbyl, or a combination thereof; where the additive copolymer is not water miscible; where the additive copolymer is not covalently bonded with the block copolymer; where the additive copolymer is operative to form a neutral layer on a surface of the block copolymer and to facilitate formation of domains in the block copolymer that are perpendicular to a surface of a substrate that the composition is disposed on; where the surface free energy reducing moiety X is covalently bonded to either segment A or segment B; and where the surface free energy reducing moiety X is a single repeat unit, an oligomeric repeat unit, or a polymeric repeat unit; and
a solvent.

US Pat. No. 10,167,410

USING CHEMICAL VAPOR DEPOSITED FILMS TO CONTROL DOMAIN ORIENTATION IN BLOCK COPOLYMER THIN FILMS

Board of Regents, The Uni...

1. A layered structure comprising first, second and third layers on a surface, wherein said first layer comprises a surface energy neutralizing layer, wherein said second layer comprises a block copolymer film, wherein said block copolymer comprises a triblock copolymer, and wherein said third layer comprises a poly(p-xylylene) polymer.

US Pat. No. 10,167,409

METHOD AND APPRATUS FOR MANUFACTURE OF 3D OBJECTS

MASSIVIT 3D PRINTING TECH...

1. A pseudoplastic material configured for printing of cantilevered three-dimensional objects in an uncured form comprising an uncured composition formulated from:30-70 weight-% of at least one curable oligomer;
30-70 weight-% of at least one reactive diluent;
0.2-7 weight-% of at least one curing agent;
1-10 weight-% of at least one rheology modifier; and
0-30 weight-% of at least one performance additive/filler, wherein the pseudoplastic material is formulated to form the cantilevered three-dimensional objects by extruding in image wise manner a first portion of the pseudoplastic material and successively extruding in image wise manner a second portion upon previously extruded portion, such that the second portion due to gravitational force slides over the first portion to form a large contact surface between the first extruded portion and the second extruded portion and wherein a large contact surface contributes to strength of a bond between the first and second portions.

US Pat. No. 10,167,405

AQUEOUS COLORING AGENT DISPERSION FOR INKJET, INK COMPOSITION, INKJET RECORDING METHOD, AND COLORED BODY

NIPPON KAYAKU KABUSHIKI K...

1. An aqueous coloring agent dispersion for inkjet comprising at least a coloring agent (I), a liquid medium (II), and a polymer dispersion agent (III),wherein the polymer dispersion agent (III) is an A-B block polymer obtained by copolymerizing, via a living radical polymerization method, y using as a polymerization initiator any one of a mixture of an organic tellurium compound and an organic ditellurium compound, and a mixture of the organic tellurium compound, an azo-based polymerization initiator, and the organic ditellurium compound,
wherein the organic tellurium compound is represented by the following formula (1):

wherein, R1 represents a C1-C8 alkyl group, an aryl group, a substituted aryl group, or an aromatic heterocyclic group; R2 and R3 represent a hydrogen atom or a C1-C8 alkyl group; and R4 represents an aryl group, a substituted aryl group, an aromatic heterocyclic group, an acyl group, an amide group, an oxycarbonyl group, or a cyano group, and
the organic ditellurium compound is represented by the following formula (2):
(R1Te)2  (2)
wherein, R1 has the same meaning as in the above formula (1),
wherein A and B are polymers obtained by polymerizing different monomers, and
the monomer for configuring the A block is two kinds of monomers represented by the following formula (3) in which R5 is a hydrogen atom and R6 is a methyl group and a monomer in which R5 is an n-butyl group and R6 is a methyl group:
and the monomer for configuring the B block is benzyl methacrylate,wherein a mass ratio of the polymer dispersion agent (III) to the coloring agent (I) is 0.1 to 1.0, and
wherein a mass average molecular weight of the B block to that of the polymer dispersion agent (III) is 50 to 74%.

US Pat. No. 10,167,404

FIXABLE, UV CURABLE INK

Hewlett-Packard Developme...

1. A fixable, ultraviolet (UV) curable ink, consisting of:an aqueous ink vehicle including water and a co-solvent;
a pigment;
a dispersant;
a polyurethane polymer dispersion suspended as droplets within the aqueous ink vehicle, the polyurethane polymer dispersion including a polyurethane polymer selected from the group consisting of a polyether-based polyurethane, a polyester-based polyurethane, a polycarbonate-based polyurethane, and mixtures thereof, and the polyurethane polymer having i) an acid number ranging from 0 mg/g to less than 20 mg/g and ii) a glass transition temperature of less than 0° C.;
a water soluble or water dispersible photoinitiator;
optionally a base in an amount sufficient to adjust a pH of the UV curable ink so that it ranges from 7.5 to 9.5; and
optionally an additive selected from the group consisting of a biocide, a non-ionic surfactant, an anti-kogation agent, a buffer, and combinations thereof.

US Pat. No. 10,167,403

INK, INK CONTAINER, AND METHOD FOR PRODUCING FUNCTIONAL ELEMENT

SEIKO EPSON CORPORATION, ...

1. An ink for forming a light emitting layer in an organic electroluminescence (EL) device, ejected as a droplet from a nozzle of an inkjet head, the ink comprising:a light emitting material; and
an aromatic solvent, wherein
the ejection amount of the droplet is 9.5 ng or more and 11 ng or less,
the length of the droplet when the droplet is ejected from the nozzle having a diameter size of 27 ?m at an ejection velocity of 6 m/sec or more and 9 m/sec or less is 250 ?m or less, and
the light emitting material is a fluorescent material or a phosphorescent material.

US Pat. No. 10,167,402

ELECTRO-OPTICAL SECURITY ELEMENT FOR SECURTIY AND/OR VALUABLE DOCUMENT

BUNDESDRUCKEREI GMBH, Be...

1. A security element for a security and/or valuable document, comprising a matrix based on an organic polymeric material, wherein at least one electrically conductive pigment is dispersed in the matrix, and at least one organic light-emitting semiconductor dispersed in the matrix, which semiconductor is capable of non-contact excitation of light emission, in the presence of the conductive pigment, and wherein the particle size of the conductive pigment is less than 200 nm, and the organic light-emitting semiconductor is not encapsulated, and is directly surrounded by the matrix and is embedded therein, wherein properties of the security element depend on an interaction of the organic polymeric material and the at least one organic light-emitting semiconductor in the matrix that differs depending on a type of excitation.

US Pat. No. 10,167,401

IMAGE FORMING METHOD

KONICA MINOLTA, INC., To...

1. An image forming method, comprising:preparing an actinic radiation-curable inkjet ink containing a radical polymerizable compound, a photopolymerization initiator, a gelling agent, and a nucleating agent;
discharging, from a nozzle of an inkjet head, a droplet of the actinic radiation-curable inkjet ink to cause the droplet to land on a surface of a recording medium; and
curing the droplet by irradiating the droplet having been caused to land on the recording medium with actinic radiation, wherein the gelling agent contains, in a molecular structure thereof, a polar group, and a C15-26 alkyl group,
the nucleating agent is a (poly)glycerin fatty acid ester, and
an oxygen concentration in an atmosphere where irradiation with the actinic radiation is conducted is less than 20 vol %.

US Pat. No. 10,167,400

WHITE INKS

Hewlett Packard Developme...

1. A white ink, comprising:an aqueous ink vehicle;
from 5 wt % to 50 wt % of a white metal oxide pigment having an average particulate size from 100 nm to 2,000 nm, and being dispersed by a non-ionic or predominantly non-ionic dispersant having an acid number not higher than 100 mg KOH/g based on dry polymer weight;
from 0.02 wt % to 2 wt % of an anionic low molecular weight polymer having a weight average molecular weight of 3,000 Mw to 50,000 Mw and an acid number higher than 100 mg KOH/g based on dry polymer weight; and
from 2 wt % to 30 wt % of latex particulates having a glass transition temperature from 0° C. to 130° C.

US Pat. No. 10,167,397

METHOD TO DETERMINE CONNECTOR METAL WEAR VIA FLUORESCENCE

International Business Ma...

1. A method of processing an electrical component, comprising:applying a UV-responsive indicator active for Pd, Ni, or Cu to a connector on an electrical component;
irradiating the UV-responsive indicator applied to the connector with UV radiation;
detecting a response to the UV radiation; and
determining a quality of the connector based on the response to the UV radiation comprising:
determining a ratio of intensity of emitted fluorescent light to intensity of the UV radiation;
comparing the ratio to a threshold value; and
registering failure of the connector if the ratio is above the threshold value.

US Pat. No. 10,167,396

LOW SMOKE FIRE-RESISTANT OPTICAL RIBBON

Corning Incorporated, Co...

1. An optical fiber ribbon cable, comprising:a cable jacket having an interior surface defining a central bore;
at least one buffer tube located in the central bore of the cable jacket;
at least one optical fiber ribbon disposed within the at least one buffer tube, the at least one optical fiber ribbon comprising:
a plurality of optical fibers;
a polymer matrix surrounding the plurality of optical fibers; and
a low-smoke, flame retardant (LSFR) coating surrounding the polymer matrix;
wherein the LSFR coating includes from 25 to 65% by weight of an inorganic, halogen-free flame retardant filler dispersed in a curable acrylate medium; and
wherein the inorganic, halogen-free flame retardant filler is comprised of particles that have, on average, a maximum outer dimension of 5 microns.

US Pat. No. 10,167,394

CORROSION-INHIBITING SOL-GEL COATING SYSTEMS AND METHODS

The Boeing Company, Chic...

1. A corrosion-inhibiting coating material bonded to a metal substrate, the coating material comprising:a corrosion-inhibiting compound that is insoluble in water and is a polymer of 2,5-dimercapto-1,3,4-thiadiazole, wherein the polymer of 2,5-dimercapto-1,3,4-thiadiazole includes at least one disulfide group; and
a zirconium-based sol-gel bonded to the metal substrate, wherein the zirconium-based sol-gel is formed from an aqueous sol solution containing an emulsion of the corrosion-inhibiting compound;
wherein the corrosion-inhibiting compound is contained within the zirconium-based sol-gel.

US Pat. No. 10,167,392

COMPOSITIONS OF COATED DIAMOND NANOPARTICLES, METHODS OF FORMING COATED DIAMOND NANOPARTICLES, AND METHODS OF FORMING COATINGS

Baker Hughes Incorporated...

1. A composition, comprising:a plurality of coated diamond nanoparticles dispersed in water, each diamond nanoparticle having at least one silane functional group covalently bonded directly to a surface thereof, the at least one silane functional group selected from the group consisting of halogen-substituted silanes and alkoxysilanes.

US Pat. No. 10,167,391

AZO COMPOUND, USE THEREOF AND METHOD FOR PREPARING SAME

BIONEER CORPORATION, Dae...

1. A quencher comprising a compound represented by the following formula 1:A1-N?N-A2-N?N-A3  Formula 1
wherein
A1 has a structure of the following formula 2;
A2 has a structure of the following formula 4; and
A3 has a structure of the following formula 5,

wherein
Z1 to Z4 are CR1
R1 is hydrogen or a nitro group;
X1 is CH2, NH, sulfur or oxygen; and
X2 is CH or nitrogen,

wherein
Z10 to Z13 are CR3;
R3 is hydrogen, a hydroxyl group, a C1-C10 alkoxy group NR11R12, or a C1-C10 alkyl group, with the proviso that all CR3 are not simultaneously hydrogen;

wherein,
Z14 to Z17 are CR4;
R4 is hydrogen or a C1-C10 alkyl group;
Z18 is CH or nitrogen; and
L1 and L2 are each independently hydrogen, a C1-C30 alkyl group, a hydroxy-substituted C1-C30 alkyl group, a C1-C30 carboxyl group or a C1-C30 carbonyloxy-substituted C1-C30 alkyl group,
or
A1 has a structure of the following formula 3;
A2 has a structure of the following formula 4; and
A3 has a structure of the following formula 5,

wherein
Z5 is nitrogen and Z6 to Z9 are each independently CR2;
R2 is hydrogen

wherein
Z10 to Z13 are CR3;
R3 is hydrogen, a hydroxyl group or a C1-C10 alkoxy group or a C1-C10 alkyl group

wherein,
Z14 to Z17 are CR4;
R4 is hydrogen or a C1-C10 alkyl group
Z18 is CH or nitrogen; and
L1 and L2 are each independently hydrogen, a C1-C30 alkyl group a hydroxy-substituted C1-C30 alkyl group, a C1-C30 carboxyl group or a C1-C30 carbonyloxy-substituted C1-C30 alkyl group.

US Pat. No. 10,167,388

BLOCK COPOLYMERS, SYNTHESIS AND APPLICATION AS DEHYDRATING AND DESALTING OF HEAVY CRUDES

INSTITUTO MEXICANO DEL PE...

1. Block copolymers ?,?-di-aryl or alkyl sulfonates of poly(ethylene oxide)w-poly(propylene oxide)-poly(ethylene oxide)w of bis-ammonium characterized by having following structural general formulas (1) to (5):where R isand R represents triblock copolymers with molecular weights in the range from 1000 to 4000 Daltons, of poly(ethylene oxide)w-poly(propylene oxide)-poly(ethylene oxide)w type, obtained by the use of ethylene glycol as an initiator,w and y are whole numbers consistent with the molecular weight,
R1, R2 and R3 radicals are independently selected from the group consisting of —CH2(CH2)AB; -CEGJ; —CH2CHLM; —CH2(CH2)QM;

where A is a number between 1 and 9, B is H,
E, G and J are a radical independently selected from the group consisting of: —H, methyl, ethyl, n-propyl, iso-propyl, sec-butyl, iso-butyl, tert-butyl, n-butyl, phenyl, cyclohexyl, and cyclopentyl,
L is a radical represented by methyl or ethyl, and M is a hydroxyl group,
Q is a number between 1 and 5, T is represented by groups E, G and J, NO2, Cl, F and Br,
R4 is a radical independently selected from the group consisting of —(CH2)AB; —OU; —CH(C6H5)2; and —C(C6H5)3, where A is a number between 1 and 9; B is H, U is a radical independently selected from the group consisting of methyl, ethyl and benzyl,
R5 is a radical independently selected from the group consisting of -(2-methyl-phenyl), -(4-methyl-phenyl), and -(4-phenyl-phenyl);
R6 is a radical independently selected from the group consisting of -(4-methoxy-phenyl), -(4-piperazinyl), and NO2;
R7 is a radical independently selected from the group consisting of Br, (phenyl-sulfanyl), and (methyl-sulfanyl);
R8 is a radical independently selected from the group consisting of NO2 and Br;
R9 is Br;
R10 is (octyloxy);
R11 is Br;
R12 is a radical selected from the group consisting of -methyl, -(4-methyl-phenyl), and -(2-methoxy-phenyl);
R13 is a radical selected from the group consisting of NO2, -(4-methyl-phenyl), -(3-methyl-phenyl), -(2-methoxy-phenyl), and -(3-methoxy-phenyl);
R14 radical represented by -methyl, -(2-phenoxy-ethoxy), -(4-nitro-phenoxy), -(4-phenoxy-butoxy), and
Z is a radical independently selected from the group consisting of methanesulfonate, benzenesulfonate and para-toluenesulfonate.

US Pat. No. 10,167,387

SYNTHETIC POLYMERIC MATERIALS AND DEVICES THEREOF

Colorado State University...

1. A polymeric material, comprising:a polymer host comprising a silicone-based polymer; and
a guest molecule comprising hyaluronic acid or derivatives thereof;
wherein the guest molecule is disposed within the polymer host, and
wherein the guest molecule is covalently bonded to at least one other guest molecule, such that the covalently bonded guest molecules interpenetrate the polymer host molecules.

US Pat. No. 10,167,386

ACRYLIC POLYVINYL ACETAL FILMS AND COMPOSITION

3M Innovative Properties ...

1. A film comprising at least one layer formed from a film composition comprising:a (meth)acrylic polymer and polyvinyl acetal resin comprising polymerized units having the following formula

wherein R1 is hydrogen or a C1-C7 alkyl group; and
at least 10 wt-% of polymerized units of monofunctional alkyl (meth)acrylate monomer having a glass transition temperature (Tg) of less than 0° C.;
wherein the film has a single phase and a glass transition temperature (Tg) in the range of 30° C. to 60° C.

US Pat. No. 10,167,377

PHOSPHORUS CONTAINING EPOXY COMPOUNDS AND COMPOSITIONS THEREFROM

FRX POLYMERS, INC., Chel...

1. A compound of Formula I:wherein:R is C1 to C20 alkyl, C1 to C20 alkenyl, C1 to C20 alkynyl, substituted C1 to C20 alkyl, substituted C1 to C20 alkenyl, substituted C1 to C20 alkynyl, C3 to C20 cycloalkyl, substituted C3 to C20 cycloalkyl, C6 to C20 aryl, C6 to C20 heteroaryl, substituted C6 to C20 aryl, or substituted C6 to C20 heteroaryl;
X is C1 to C20 alkylene, C1 to C20 alkenylene, C1 to C20 alkynylene, substituted C1 to C20 alkylene, substituted C1 to C20 alkenylene, substituted C1 to C20 alkynylene, C3 to C20 cycloalkylene, substituted C3 to C20 cycloalkylene, C6 to C20 arylene, C6 to C20 heteroarylene, or substituted C6 to C20 heteroarylene;
Y is X—OH or X—O—Z-epoxy, C6 to C20 arylene, C6 to C20 heteroarylene, substituted C6 to C20 arylene, substituted C6 to C20 heteroarylene, carboxyl, amine, vinyl, or isocyanate;
Z is C1 to C20 alkylene, C1 to C20 alkenylene, C1 to C20 alkynylene, substituted C1 to C20 alkylene, substituted C1 to C20 alkenylene, or substituted C1 to C20 alkynylene; and
n is an integer from 2 to 1000; and
wherein the compound has a weight average molecular weight of from about 5,000 g/mole to about 10,000 g/mole as determined by gel permeation chromatography based on polystyrene calibration.

US Pat. No. 10,167,374

METHOD FOR RECOVERING ORGANIC FIBERS FROM A COMPOSITE MATERIAL

UNIVERSITY DE BORDEAUX, ...

1. A method for recovering organic fibers from a composite material comprising a polymer matrix and organic fibers, the method comprising the following steps:providing a solution comprising a mixture of water and alcohol;
disposing the composite material inside a reactor;
placing the mixture in contact with said composite material in order to carry out a solvolysis reaction of said polymer matrix of said composite material;
recovering said organic fibers;
wherein said organic fibers are selected from aramid fibers, plant fibers and any mixture thereof;
wherein the pressure and temperature in said reactor are adjusted so as to fall within the homogeneous subcritical region of the phase diagram, within the supercritical region, or within 50° C. of the critical temperature and within 50 bar of the critical pressure;
wherein said temperature is below the degradation temperature of the organic fibers and is set to at most 300° C.; and
wherein said mixture of water and alcohol has a water/alcohol volume ratio of between 50:50 and 75:25.

US Pat. No. 10,167,372

MANUFACTURE OF POLYLACTIC ACID FOAMS USING LIQUID CARBON DIOXIDE

BIOPOLYMER NETWORK LIMITE...

1. A method of producing polylactic acid foam, the method comprising(a) providing a crystallisable polylactic acid resin, the crystallisable polylactic acid resin comprising a polylactic acid resin that has been prepared in an amorphous state and that has been impregnated with liquid CO2 at a temperature of ?57° C. to 0° C., the resin comprising less than 5% crystallinity as determined by differential scanning calorimetry and at least 92% by weight L- or D-lactic acid, and
(b) expanding the impregnated resin to produce a foam having a crystallinity of at least 15% by weight and a density of 5 to about 150 g/L.

US Pat. No. 10,167,370

FILM, METHOD FOR PRODUCING SAME, TRANSPARENT CONDUCTIVE FILM, AND TOUCH PANEL

FUJIFILM Corporation, To...

1. A film comprising:a substrate including a cyclic olefin-based resin; and
an easily adhesive layer that is laminated adjacent to the substrate,
wherein the content of a fluorine-containing polymer in the easily adhesive layer is greater than 20 mass % with respect to the total mass of the easily adhesive layer, and
the water content of the easily adhesive layer is 0.3% to 2.5%.

US Pat. No. 10,167,368

THERMAL INTERFACE MATERIALS INCLUDING POLYMERIC PHASE-CHANGE MATERIALS

International Business Ma...

1. A method of forming a material for thermal management comprising:forming one or more vinyl-terminated fatty acids from a bio-renewable material comprising castor oil;
forming a mixture comprising one or more vinyl-terminated fatty acids and one or more glycols;
polymerizing the mixture to form a diene;
polymerizing the diene to form a polymeric phase-change material; and
forming a thermal interface material that includes the polymeric phase-change material.

US Pat. No. 10,167,365

POLYMER AND COMPOSITION

DSM IP ASSETS B.V., Heer...

1. A polyester resin comprising an alkyd resin and/or a saturated polyester resin, wherein said polyester resin is obtained by reacting the following components A to E in a process (I):(A) Component A comprises one or more cyclic imides of Formula 1;

wherein R? represents a divalent optionally substituted saturated aliphatic C1-30 organo moiety; and
R represents H or a monovalent optionally substituted saturated C1-30 organo moiety;
(A?) Component A? comprises a saturated dicarboxylic acid and/or a saturated hydroxy acid, wherein component A? is optional only if component A comprises a dicarboxylic acid or a hydroxy acid;
(B) Component B comprises at least one saturated polyhydric alcohol;
(C) Optional Component C comprises naturally occurring rosin, the rosin comprising from 40 to 80 parts per hundred by weight of rosin of an unsaturated mono carboxylic acid comprising at least one C15-25 cyclohydrocarbo moiety capable of undergoing a Diels Alder or Ene reaction;
(D) Optional Component D comprises at least one linear C12-60 hydrocarbo carboxylic acid optionally comprising at least two linoleically unsaturated double bonds;
(E) Optional Component E other than any of Components A to D, wherein Component E is selected from the group consisting of monocarboxylic acids, amines, isocyanates, (poly)ethers, (poly)siloxanes (poly)amides and (poly)acrylates.

US Pat. No. 10,167,362

DOPING-INDUCED CARRIER DENSITY MODULATION IN POLYMER FIELD-EFFECT TRANSISTORS

THE REGENTS OF THE UNIVER...

1. A method of fabricating an organic field effect transistor (OFET), comprising:forming a source contact and a drain contact to a channel comprising semiconducting polymers;
providing a dielectric between the semiconducting polymers and a gate;
doping the semiconducting polymers that interface with the source contact;
doping the semiconducting polymers that interface with the drain contact; and
wherein the doping of the semiconducting polymers that interface with the source contact and the doping of the semiconducting polymers that interface with the drain contact dopes the semiconducting polymers with one or more doping concentrations that:
increase linearity of the OFET's current-voltage (IV) curve, for voltages applied between the source contact and the drain contact in a range of 0 and +/?5 V, and
do not change the channel's resistance, defined as Rs/W, to within 4% as compared to before the doping, where Rs is the channel's series resistance and W is the channel's width.

US Pat. No. 10,167,358

PROCESS FOR MODIFYING ISOCYANATES WITH USE OF CYCLIC AMMONIUM SALTS AS CATALYST

COVESTRO DEUTSCHLAND AG, ...

1. A process for modifying isocyanates, in which at least one organic isocyanate having an NCO functionality of >1 is oligomerized in the presence of at least one catalyst, characterized in that the catalyst comprises at least one cyclic ammonium salt having a cation of the formula I as catalysts for the isocyanate modification,wherein the N-substituents R1 and R2 are mutually independently identical or different aliphatic, cycloaliphatic, aromatic or araliphatic C1-C20 radicals, which are saturated or unsaturated, linear or branched, optionally substituted and/or interrupted by heteroatoms from the group of oxygen, sulfur and nitrogen and Y is a substituted or unsubstituted, linear or branched C2-C20 segment optionally interrupted by heteroatoms from the group of oxygen, sulfur, nitrogen and also by aromatic rings, and optionally comprising further rings.

US Pat. No. 10,167,357

MULTI-BASE MATERIAL ADAPTIVITY PULLING REMOVAL TYPE BINDER PRODUCT, BINDER COMPOSITION AND ASSEMBLY

3M INNOVATIVE PROPERTIES ...

1. A binder composition, comprising:an acrylic acid copolymer, comprising a (methyl)acrylate monomer unit and a vinyl carboxylic acid comonomer unit;
a flexibilizer, wherein the flexibilizer comprises the combination of hydroxy-terminated polybutadiene and SBS rubber;
a tackifying resin, comprising a high-Tg tackifying resin with a Tg of at least 20° C. and a low-Tg tackifying resin with a Tg of not more than 0° C.; and
an isocyanate curing agent.

US Pat. No. 10,167,355

CATALYST SYSTEM FOR PRODUCING POLYETHYLENE COPOLYMERS IN A HIGH TEMPERATURE SOLUTION POLYMERIZATION PROCESS

BOREALIS AG, Vienna (AT)...

1. A catalyst system comprising:(i) a metallocene complex of formula (I)
whereinM is Zr;
each X is independently chlorine or a methyl radical;
L is a bridge of the formula —SiR82—, wherein both R8 are the same C1-C10-hydrocarbyl or C6-C10 aryl group;
n is 1 or 2;
R1 and R1? are the same or are different and are a linear or branched C1-C6-alkyl group;
R2 and R2? are the same or are different and are a CH2-R9 group, with R9 being H or linear or branched C1-C6-alkyl group;
R5 is H or a linear or branched C1-C6-alkyl group or an OR group, wherein R is a C1-C6-alkyl group;
R5? is a linear or branched C1-C6-alkyl group or an OR group, wherein R is a C1-C6-alkyl group;
R6 and R6? are the same or are different and are H or a C(R10)3 group, with R10 being the same or different and R10 is H or a linear or branched C1-C6-alkyl group;
or R5 and R6 and/or R5? and R6? taken together form an unsubstituted 4-7 membered ring condensed to the benzene ring of the indenyl moiety;
with the proviso that at least one of R5 and R6 or R5? and R6? together form an unsubstituted 4-7 membered ring condensed to a benzene ring of the indenyl moiety;
with the proviso that when R5 and R6 as well as R5? and R6? taken together form an unsubstituted 5 membered ring condensed to the benzene ring of the indenyl moiety then R2 and R2? are not a C1-alkyl group; and
R7 and R7? are the same or are different and are H or a linear or branched C1-C6-alkyl group;
(ii) an aluminoxane cocatalyst, wherein the aluminoxane cocatalyst is methyl aluminoxane; and
(iii) a boron containing cocatalyst comprising an anion of formula:
(Z)4B?  (III)
where Z is an optionally substituted phenyl derivative, said substituent being a halo-C1-6-alkyl or halo group.

US Pat. No. 10,167,354

HIGH PRESSURE RADIAL POLYMERISATION PROCESS FOR A COPOLYMER OF ETHYLENE SILANE GROUPS CONTAINING COMONOMER

BOREALIS AG, Vienna (AT)...

1. A copolymer of ethylene with silane groups containing comonomer that is produced in a high pressure radical polymerisation process comprising the steps of:(a) compressing ethylene together with the silane groups containing comonomer under pressure in a compressor, wherein a compressor lubricant is used for lubrication,
(b) polymerising ethylene together with the silane groups containing comonomer in a polymerisation zone,
(c) separating the obtained ethylene copolymer from the unreacted products and recovering the separated ethylene copolymer in a recovery zone,
wherein in step (a) the compressor lubricant comprises a mineral oil and the ethylene copolymer has a silane groups containing comonomer content of 0.5 to 3 wt % and an MFR2 of 0.3 to 10 g/10 min; and
wherein the copolymer has a hot set elongation percentage y satisfying:
y

US Pat. No. 10,167,351

METHODS OF CONTROLLING POLYOLEFIN MELT INDEX WHILE INCREASING CATALYST PRODUCTIVITY

Univation Technologies, L...

1. A method comprising:contacting in a fluidized bed gas phase reactor an olefin monomer with a catalyst system in the presence of an induced condensing agent (ICA) to produce a first polyolefin having a first melt index, the catalyst system comprising a metallocene catalyst;
increasing a partial pressure of the ICA in the reactor to produce a second polyolefin having a second melt index;
wherein increasing the partial pressure of the ICA results in a higher catalyst productivity for producing the second polyolefin when compared to the catalyst productivity for producing the first polyolefin.

US Pat. No. 10,167,348

SOLUTION POLYMERS FORMED FROM METHYLENE MALONATE MONOMERS, POLYMERIZATION, AND SOLUTION POLYMER PRODUCTS

Sirrus, Inc., Loveland, ...

1. A process comprising the steps of:i) mixing at least one monomer with a solvent;
ii) adding an initiator to the solvent or the mixture of the solvent and the at least one monomer, wherein the molar ratio of the one or more monomers to the initiator is about 50:1 or more;
iii) anionically polymerizing the at least one monomer to form a polymer having a weight average molecular weight of about 3000 daltons or more, wherein the at least one monomer includes a 1,1-disubstituted alkene compound in solution, wherein the resulting polymer is substantially free of a melting temperature and is substantially free of a glass transition temperature of about 15° C. or more.

US Pat. No. 10,167,333

NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUS SURFACE ANTIGEN

1. An antibody or fragment thereof capable of specifically binding to the Hepatitis B surface antigen (HBsAg) and having Hepatitis B Virus (HBV) neutralizing activity, wherein said antibody or fragment thereof comprises a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO: 5, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO: 6, a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO: 7, a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO: 8, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO: 9 and a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO: 10.

US Pat. No. 10,167,319

CAGED CELL PENETRATING PEPTIDE-POLYMER CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS

1. A caged cell penetrating peptide (cCPP)-macromolecular carrier conjugate of formula 1:
wherein
x, y, u, and z are independently percentages of the respective element composition of the conjugate, wherein x is present from 0.05%-50%, y is present from 0-50%, u is present from 0-50% and z is present from 0-50%;
P is a caged cell penetrating peptide, wherein the amino acid sequence of the cell penetrating peptide comprises the amino acid sequence KRRMKWKK;
M is a macromolecular carrier molecule consisting of underivatized monomers selected from the group consisting of N (2-hydroxypropyl)methacrylamide (HPMA), N-methylacrylamide, N,N-dialkylacrylamides, acrylic acid, polyethylene glycol, methacrylic acid, polyamino acids, polysaccharides, polyvinyl pyrrolidone-maleic anhydride polymers, polylactic-co-glycolic acid, and combinations thereof;
D is a detectable agent or a therapeutic agent, or a combination thereof, wherein said detectable agent is fluorescent, radioactive, luminescent or electron dense, and wherein said therapeutic agent is a toxin, a chemotherapeutic agent, D(KLAKLAK)2, KLAK, a radioisotope, an antimetabolite, a microtubule inhibitor, or a combination thereof; and
J and K are spacer molecules.

US Pat. No. 10,167,314

METHODS OF TREATING DEPRESSION AND OTHER RELATED DISEASES

Northwestern University, ...

1. A method for treating a patient suffering from postpartum depression comprising administering to said patient an effective amount of a GLYX-13 peptide represented by formula:or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,167,313

SELECTIVE CASPASE INHIBITORS AND USES THEREOF

Genesis Technologies Limi...

1. A method for inhibiting a caspase in a subject in need thereof, comprising administering to said subject an effective amount of a compound of Formula 1:whereina is 0 or 1;
b is 0 or 1 provided that when b is 0, a is 0;
A is
1) H,
2) C1-C6 alkyl,
3) aryl,
4) heteroaryl,
5) heterocyclyl,
6) R3—C(O)—,
7) R3—OC(O)—,
8) R3—C(O)O—,
9) R3—S(O)2—, or
10) PhCH2OC(O)—;
P2, P3, P5, when present, and PX, when present, are any (D) or (L) amino acid residue or a non-natural amino acid residue;
P4 is any (D) or (L) amino acid selected from the group consisting of Ala, Arg, Asp, Asn, Cys, Glu, Gln, Gly, Ile, His, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, and Val, or non-natural amino acid residue;
the line “-” when located between P2, P3, P4, P5 or PX represents a peptide bond or a peptidomimetic bond;
the wavy line represents either cis or trans orientation of R1and R2;
R1 is
1) aryl,
2) heteroaryl,
3) heterocyclyl,
4) C2-C6alkene-R20,
5) S2R5,
6) SO3R5,
7) SOR5,
8) SONHR5,
9) SO2NHR5,
10) CN,
11) CO2R5,
12) COR5,
13) PO3R5,
14) PO(OR5)2, or
15) PO(OR5),
wherein the aryl, the heteroaryl, or the heterocyclyl are optionally substituted with one or more R30;
R2 is
1)R1,
2) H,
3) halogen,
4) haloalkyl,
5) C1-C6 alkyl,
6) C2-C6 alkene,
7) C3-C7 cycloalkyl,
8) OR9;
9) OCOR6,
10) OCO2R6,
11) NR7R8,
12) NHSO2R6,
13) NHCOR6,
14) aryl,
15) heteroaryl, or
16) heterocyclyl;
R3 is
1) C1-C6 alkyl,
2) aryl,
3) heteroaryl, or
4) heterocyclyl;
R4 is
1) H, or
2) C1-C6 alkyl;
R5 is
1) H,
2) C1-C6 alkyl,
3) C2-C6 alkene,
4) C3-C7 cycloalkyl,
5) aryl,
6) heteroaryl,
7) heterocyclyl, or
8) any optionally protected (D) or (L) amino acid residue;
R6 is
1) any (D) or (L) amino acid residue,
2) C1-C6 alkyl,
3) C3-C7 cycloalkyl,
4) aryl,
5) heteroaryl, or
6) heterocyclyl,
in which the alkyl or the cycloalkyl are optionally substituted with one or more R10 substituents; and in which the aryl, heteroaryl or heterocyclyl are optionally substituted with one or more R20 substituents;
R7 and R8 are independently selected from:
1) H,
2) C1-C6 alkyl,
3) C3-C7 cycloalkyl,
4) haloalkyl,
5) aryl,
6) heteroaryl, or
7) heterocyclyl,
wherein the alkyl and the cycloalkyl are optionally substituted with one or more R10 substituents, and the aryl, the heteroaryl and the heterocyclyl are optionally substituted with one or more R20 substituents;
R9 is
1) H,
2) C1-C6 alkyl,
3) C3-C7 cycloalkyl,
4) aryl,
5) heteroaryl, or
6) heterocyclyl,
in which the alkyl or the cycloalkyl are optionally substituted with one or more R10 substituents; and in which the aryl, heteroaryl or heterocyclyl are optionally substituted with one or more R20 substituents;
R10 is independently selected from:
1) halogen,
2) C1-C6 alkyl,
3) C3-C7 cycloalkyl,
4) haloalkyl,
5) aryl,
6) heteroaryl,
7) heterocyclyl,
8) OR9,
9) S(O)mR9,
10) NR7R8 ,
11) COR9,
12) C(O)OR9,
13) OC(O)R9,
14) SC(O)R9,
15) CONR7R8, or
16) S(O)2NR7R8;
R20 is independently selected from:
1) halogen,
2) NO2,
3) CN,
4) C1-C6 alkyl,
5) haloalkyl,
6) C3-C7 cycloalkyl,
7) OR7,
8) NR7R8,
9) SR7,
10) aryl,
11) heteroaryl,
12) heterocyclyl,
13) SO2R5,
14) SO3R5,
15) SOR5,
16) SONHR5,
17) SO2NHR5,
18) PO3R5,
19) PO(OR5)2,
20) PO(OR5),
21) COR7,
22) CO2R7,
23) S(O)mR7,
24) CONR7R8, or
25) S(O)2NR7R8,
wherein the alkyl and the cycloalkyl are optionally substituted with one or more R6 substituents; and wherein the aryl, the heteroaryl, or the heterocyclyl are optionally substituted with one or more R30;
R30 is
1) NO2,
2) C2-C6 alkene-R20,
3) SO2R5,
4) SOR5,
5) SONHR5,
6) SO2NHR5,
7) CN,
8) CO2R5,
9) CORS,
10) PO3R5,
11) PO(OR5)2, or
12) PO(OR5); and
wherein m is an integer of 0, 1, or 2;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,167,311

BORONIC ACID ESTERS AND PHARMACEUTICAL FORMULATIONS THEREOF

Ohio State Innovation Fou...

1. A compound defined by Formula IA
wherein
Z, together with O1 and O2, represent a moiety derived from a polyol, wherein the polyol comprises a sugar;
L is absent, or is a linking group; and
A comprises a lipid moiety chosen from a fatty acid, a glycerolipid, a phospholipid, a sphingolipid, a sterol, or a prenol.

US Pat. No. 10,167,310

SYSTEM AND METHOD FOR PRODUCING INTERLEUKIN RECEPTOR ANTAGONIST (IRA)

ESTAR TECHNOLOGIES LTD, ...

1. A system for preparing autologous IL-1RA cytokine comprising:a. a blood collection tube;
b. a tube cover adapted to be received over an open end of the blood collection tube for maintaining said tube closed;
c. a portion of separation gel in the blood collection tube;
d. an anticoagulant portion in the blood collection tube;
e. a plasma collection syringe comprising a sharp needle configured to be inserted into the blood collection tube;
f. a buffy coat collection syringe configured to be inserted into the blood collection tube; and
g. an incubation tube separate from said blood collection tube with a cover, said incubation tube comprising washed and pretreated borosilicate glass beads in a size range of about 0.5-5 mm and adapted to receive contents of the buffy coat collection syringe removed from the blood collection tube;
wherein said blood collection tube is a vacuum tube; said separation gel and said anticoagulant are in said vacuum tube; said separation gel is adapted as a barrier and as a separating element between separation tractions;
further wherein said blood collection tube is adapted such that, when containing whole blood, after centrifugation yields separation fractions comprising, a first fraction of red blood cells sediment, a second fraction of said separation gel, a third fraction comprising white blood cells and platelets, and a fourth fraction of plasma solution.

US Pat. No. 10,167,309

ASYMMETRIC AUXILIARY GROUP

WAVE LIFE SCIENCES LTD., ...

1. A chiral reagent or a salt thereof, wherein the chiral reagent has the structure of the following chemical formula (I?):
wherein G1 is a hydrogen atom, a nitro group, a halogen atom, a cyano group, or a group of formula (II), (III) or (V), G2 is a nitro group, a cyano group, or a group of formula (III) or (V), or both G1 and G2 are taken together to form a group of formula (IV),

wherein G21 to G23 are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C1-3 alkyl group,

wherein G31 to G33 are independently C1-4 alkyl group, C1-4 alkoxy group, C6-14 aryl group, C7-14 aralkyl group, C1-4 alkyl C6-14 aryl group, C1-4 alkoxy C6-14 aryl group, or C6-14 aryl C1-4 alkyl group,

wherein G41 to G46 are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C1-3 alkyl group,

wherein G51 to G53 are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, C1-3 alkyl group or C1-3 alkyloxy group.

US Pat. No. 10,167,308

HIGHLY EFFICIENT SYNTHESIS OF LONG RNA USING REVERSE DIRECTION APPROACH

ChemGenes Corporation, W...

1. A process of synthesizing an RNA oligonucleotide of the following formula:
wherein:
B is a member selected from the group consisting of adenine, cytosine, guanine, uracil, 6-oxopurine, 5-methyl-cytosine, 5-methyl-uracil, 5-fluro-uracil, 7-deaza-adenine, 7-deaze-adenine and 5-fluro-cytosine;
n is an integer from 100 to about 200;
L is a nucleoside, or a non-nucleoside ligand wherein the non-nucleoside ligand is a member selected from the group consisting of cholesterol with a linker or a spacer, biotin, ethyleneglycol, glycerol, a polyethyelenglycol, a hexaehtyleneglycol, an amino linker, a disulfide linker, a peptide linker, a polypeptide linker, a protein, a flurophore, a quencher dye, one or more 2?,5?-linked deoxynucleoside unit, one or more 2?,5?-linked ribonucleoside unit, and one or more 2?,5?-linked deoxyribose unit,
wherein L is attached at the 3?-end of the RNA nucleotide through an intervening phosphate; and
the process of synthesizing the RNA oligonucleotide is in a direction from the 5?-end to the 3?-end of the RNA nucleotide, and the process comprises the steps of:
(a) taking a nucleoside solid support represented by Formula 2:

wherein:
M is a linker represented by the formula Y—C(O) and optionally connected to a solid support suitable for oligonucleotide synthesis,
wherein Y is a hydrocarbon diradical moiety having a length between 2 carbons and 20 carbons, and Y is selected from the group consisting of alkyl, alkenyl, cycloalkyl, aryl, and aralkyl, and the hydrocarbon diradical moiety optionally comprises intervening —O—, —S—, —S(O)2— —C(O)— and —NR6— where R6 is a hydrogen radical, or a substituted C1 to C20 alkyl or a substituted aralkyl;
W is selected from the group consisting of an oxygen diradical, an N—H diradical, and a fluorine radical, and R is selected so that:
if W is an oxygen diradical, then R is tert butyl dimethyl silyl (TBDMS) or triisopropylsilyl oxymethylene (TOM); and
if W is an N—H diradical, then R is of the form R5x, where x is selected from the group consisting of fluorenylmethyloxycarbonyl (Fmoc), trifluoroacetyl, acetyl, alkanoyl and aroyl; and
if W is a fluorine radical, then R is not present;
B is selected from the group consisting of nucleoside base radicals consisting of 9-(N6-benzoyladeninyl)-, 9-(N6-acetyladeninyl)-, 9-(N6-tert-butyl phenoxyacetyladeninyl)-, 9-(N6-phenoxyacetyladeninyl)-, 9-(N6-isopropyl phenoxyacetyladeninyl)-, 1-(N6—(N,N-dimethylformamidinyl)adeninyl), 1-(N4-benzoylcytosinyl)-, 1-(N4-acetylcytosinyl)-, 1-(N4—(N,N-dimethylformamidinyl)cytosinyl)-, 1-(N4-phenoxyacetylcytosinyl)-, 1-(N4-tert-butylphenoxyacetylcytosinyl)-, 1-(N4-isopropyl phenoxyacetylcytosinyl)-, 9-(N2-isobutylguaninyl)-, 9-(N2-tert butyl phenoxyacetylguaninyl)-, 9-(N2-isopropyl phenoxyacetylguaninyl)-, 1-(N4-phenoxyacetylcytosinyl)-, 1-(N4-tert butyl phenoxyacetylcytosinyl)-, 1-(N4-isopropyl phenoxyacetylcytosinyl)-, and 1-uracilyl-; or
B is a modified nucleoside base radical selected from the consisting of 1-(N4-benzoyl-5-methylcytosinyl)-, 1-(N4-—(N,N-dimethylformamidinyl)-5-methylcytosinyl)-, 1-(N4-acetyl-5-methylcytosinyl)-, 1-(5-methyl-uracilyl)-, 1-(5-fluoro-uracilyl)-, 1-(N4-benzoyl-5-fluorocytosinyl)-, 9-(N6-benzoyl-7-deazaadeninyl)-, 9-(N6—(N,N-dimethylformamidinyl)-7-deazaadenyl)-, 9-(N2-isobutyl-7-deazaguaninyl)-, and 9-(N2—(N,N-dimethylformamidinyl)-7-deazaguaninyl)-;
Z is a member selected from the group consisting of dimethoxy triphenyl (DMT), monomethoxy triphenyl (MMT) and trimethoxy triphenyl (TMT);
(b) placing a phosphoramidite represented by Formula 1 on a oligonucleotide synthesizer;

wherein
Y is an oxygen atom or a sulfur atom;
W is selected from the group consisting of an oxygen diradical, an N—H diradical, and a fluorine radical; and R4 is selected so that:
if W is an oxygen diradical, then R4 is tert butyl dimethyl silyl (TBDMS) or triisopropylsilyl oxymethylene (TOM); and
if W is an N—H diradical, then R4 is of the form R5X, where x is selected from the group consisting of fluorenylmethyloxycarbonyl (Fmoc), trifluoroacetyl, acetyl, alkanoyl and aroyl; and
if W is a fluorine radical, then R4 is not present;
B is selected from the group consisting of nucleoside base radicals consisting of 9-(N6-benzoyladeninyl)-, 9-(N6-acetyladeninyl)-, 9-(N6-tert-butyl phenoxyacetyladeninyl)-, 9-(N6-phenoxyacetyladeninyl)-, 9-(N6-isopropyl phenoxyacetyladeninyl)-, 1-(N6—(N,N-dimethylformamidinyl)adeninyl), 1-(N4-benzoylcytosinyl)-, 1-(N4-acetylcytosinyl)-, 1-(N4—(N,N-dimethylformamidinyl)cytosinyl)-, 1-(N4-phenoxyacetylcytosinyl)-, 1-(N4-tert-butylphenoxyacetylcytosinyl)-, 1-(N4-isopropyl phenoxyacetylcytosinyl)-, 9-(N2-isobutylguaninyl)-, 9-(N2-tert butyl phenoxyacetylguaninyl)-, 9-(N2-isopropyl phenoxyacetylguaninyl)-, 1-(N4-phenoxyacetylcytosinyl)-, 1-(N4-tert butyl phenoxyacetylcytosinyl)-, 1-(N4-isopropyl phenoxyacetylcytosinyl)-, and 1-uracilyl-; or
B is a modified nucleoside base radical selected from the consisting of 1-(N4-benzoyl-5-methylcytosinyl)-, 1-(N4—(N,N-dimethylformamidinyl)-5-methylcytosinyl)-, 1-(N4-acetyl-5-methylcytosinyl)-, 1-(5-methyl-uracilyl)-, 1-(5-fluoro-uracilyl)-, 1-(N4-benzoyl-5-fluorocytosinyl)-, 9-(N6-benzoyl-7-deazaadeninyl)-, 9-(N6—(N,N-dimethylformamidinyl)-7-deazaadenyl)-, 9-(N2-isobutyl-7-deazaguaninyl)-, and 9-(N2—(N,N-dimethylformamidinyl)-7-deazaguaninyl)-;
Z is a member selected from the group consisting of dimethoxy triphenyl (DMT), monomethoxy triphenyl (MMT) and trimethoxy triphenyl (TMT);
R1 is an alkyl or aryl radical;
R2 is an alkyl or aryl radical; and
R3 is cyanoethyl, alkyl or aryl radical;
B is hydrogen or a nucleobase that is optionally functionalized at each primary amine with an amine protecting group;
(c) removing the protecting group Z from the nucleoside solid support represented by Formula 2;
(d) performing the process of RNA synthesis by coupling the nucleoside of Formula 2 and the phosphoramidite of Formula 1 in the oligonucleotide synthesizer using a mixture of ancillary regents to result in an oligonucleotide having at least one protecting group;
(e) providing a phosphoramidite with the L group;
(f) adding the phosphoramidite with the L group at the end of the oligonucleotide to result in an oligonucleotide having the L group;
(g) detaching the oligonucleotide having the L group from the solid support;
(h) removing the at least one protecting group from the oligonucleotide;
(i) removing a silyl protecting group to result in the oligonucleotide;
(j) participating the oligonucleotide; and
(k) analyzing the oligonucleotide for purity determination,
wherein the mixture of ancillary reagent in step (d) comprises phenoxy acetic anhydride/tetrahydrofuran/pyridine), 10% N-methylimidazole/tetrohydrofuran), 3% trichloroacetic acid in toluene, 0.05 M iodine/pyridine/water/tetrahyrofuran and 5-ethylthio-1-H-tetrazole at 0.35 M in acetonitrile.

US Pat. No. 10,167,305

ALLYL COMPLEXES FOR USE IN COUPLING REACTIONS

Johnson Matthey Public Li...

1. A complex of formula (1):
wherein:
M is palladium or nickel;
R1 and R2 are, independently, C1-C20 straight-chain alkyl, C1-C20 branched-chain alkyl, C3-C15 cycloalkyl, C5-C20 aryl, or C3-C20 heteroaryl;
R3 is:
(a) dimethylaminophenyl; or
(b) a substituted metallocenyl of formula (2):

wherein:
R10 is C1-C20 alkyl, C6-C20 aryl, (C1-C20 alkyl)HN—, (C1-C20 dialkyl)N—, (C1-C20 dialkyl)amino-C1-C20-alkyl or C1-C20 alkoxy-C1-C20-alkyl;
R11 is C1-C20 alkyl or C6-C20 aryl;
p is 0, 1, 2, 3 or 4, wherein when p is 2, 3 or 4, each R10 is the same or different;
q is 2, 3, 4 or 5, wherein each R11 is the same or different,
R4 is C1-C20 straight-chain alkyl, C1-C20 branched-chain alkyl, C3-C15 cycloalkyl, C6-C20 aryl, or C5-C20 heteroaryl,
n is 0, 1, 2, 3, 4 or 5; and
X is a halo group,
each alkyl, alkoxy, heteroalkyl, aryl or heteroaryl is optionally substituted with one or more halo, C(halo)3, Ra, ?O, ?S, ORa, SRa, NRaRb, ?NRa, ?N—ORa, CN, SCN, NCS, NO2, C(O)Ra, C(O)ORa, C(S)Ra, C(S)ORa, S(O)2OH, S(O)2Ra, S(O)2NRaRb, OS(O)Ra, or C(O)NRaRb, wherein:
Ra and Rb are, independently, H, C1-20 alkyl, C6-20 aryl, C6-20 aryl-(C1-20alkyl), or C1-20 heteroalkyl, C6-20 heteroaryl, or together with the atom to which they are attached form a C3-15 heterocycloalkyl; and
the heteroatoms in the heteroaryl, heteroalkyl or heterocycloalkyl are sulfur, oxygen, or nitrogen.

US Pat. No. 10,167,304

RUTHENIUM COMPOUND, MATERIAL FOR THIN FILM FORMATION, AND PROCESS FOR THIN FILM FORMATION

ADEKA CORPORATION, Tokyo...

1. A ruthenium compound represented by general formula (I):
wherein R1, R2, and R3 each independently represent a straight or branched chain alkyl group having 1 to 5 carbon atoms, provided that the total number of the carbon atoms of R1 and R2 is 3 to 10.

US Pat. No. 10,167,303

IRIDIUM ORGANOMETALLIC COMPLEX CONTAINING A SUBSTITUTED DIBENZO[F,H]QUINOXALINE AND AN ELECTRONIC DEVICE HAVING AN EMITTING LAYER CONTAINING THE IRIDIUM COMPLEX

UDC IRELAND LIMITED, Dub...

1. A compound of formula:wherein:each La is independently:

wherein:
a) R1 is H, C1-C8 alkyl or C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl may optionally be substituted by C1-C8 alkyl or C1-C8 perfluoroalkyl;
R2 is H or C1-C8 alkyl;
R3 is C1-C8 alkyl, Si(C1-C8 alkyl)3 or C3-C8 cycloalkyl; and
R8 is C1-C8 alkyl, Si(C1-C8 alkyl)3 or C3-C8 cycloalkyl; or
b) R1 is a group of formula:

wherein:
R4 is C1-C8 alkyl, CF3 or NR7R9;
R4? is C1-C8 alkyl or CF3;
R4?is C1-C8 alkyl or CF3;
R7 is phenyl, 1-naphthyl or 2-naphthyl; and
R9 is phenyl, 1-napthyl or 2-naphthyl; or
R7 and R9, together with the nitrogen atom to which they are bonded, form a group of formula:

wherein:
each R10 is independently H or C1-C8 alkyl; and
R2 is H;
R3 is C1-C8 alkyl, Si(C1-C8 alkyl)3 or C3-C8 cycloalkyl; and
R8 is C1-C8 alkyl, Si(C1-C8 alkyl)3 or C3-C8 cycloalkyl; or
c) R1 and R2 together form a —(CH2)3— ring or —(CH2)4— ring, wherein the —(CH2)3— ring or —(CH2)4— ring may optionally be substituted by one or two C1-C8 alkyl and/or by one or two C1-C8 perfluoroalkyl;
R3 is C1-C8 alkyl, Si(C1-C8 alkyl)3 or C3-C8 cycloalkyl; and
R8 is C1-C8 alkyl, Si(C1-C8 alkyl)3 or C3-C8 cycloalkyl.

US Pat. No. 10,167,302

PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES

UNIVERSITY COLLEGE CORK, ...

1. A compound of formula (I), or a pharmaceutically acceptable salt, or prodrug thereof selected from a phosphoramidate derivative, a SATE (S-acyl-2-thioethyl) ester derivative, a pivaloyloxymethyl (POM) derivative, an isopropyloxymethylcarbonyl (POC) derivative, a cyclo-saligenyl (cycloSal) derivative and an alkyloxyalkyl derivative,
wherein:
X is selected from O and NR11;
Y is selected from O, S and NR12;
A is selected from —(CR1R2)n-, —(CR9R10)—, —(CR9R10)—(CR1R2)n-, —(CR1R3)—(CR2R4)—(CR1R2)n-, —CR3?CR4—(CR1R2)n- and —C?C—(CR1R2)n-;
R1 and R2 are independently selected from H, alkyl, hydroxyl, hydroxymethyl and halogen;
R3 and R4 are independently selected from H and alkyl, or R3 and R4 together with the carbon atoms to which they are attached form a mono or bicyclic ring system selected from cycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl and heteroaryl;
R5 is selected from H, P(?O)(OH)2 and P(?O)(OH)—O—P(?O)(OH)2;
R6 is selected from H and alkyl;
R7 and R8 are independently selected from H, alkyl, halogen and hydroxymethyl
R9 and R10 together with the carbon atom to which they are attached form a mono or bicyclic ring system selected from cycloalkyl, cycloalkenyl, heterocycloalkyl and heterocycloalkenyl;
R11 is selected from H and alkyl;R12 is selected from H and alkyl;
m is 0, 1, 2 or 3;
n is 1, 2 or 3;
p is 0 or 1;
q is 0, 1, 2 or 3;
r is 0, 1, 2, 3, 4 or 5;
s is 0 or 1;
Base is a natural or non-natural nucleobase; and
wherein each alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl and heteroaryl may be optionally substituted.

US Pat. No. 10,167,300

METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES

Dow AgroSciences LLC, In...

1. A compound of Formula I, or salt thereof, wherein:
Z is optionally substituted 5-pyrimidinyl, optionally substituted 4-pyrimidinyl, optionally substituted oxazolyl, optionally substituted 3-pyridinyl, optionally substituted 4-pyridinyl, or tetrazolyl;
n is 0 or 1;
R1 is alkyl, alkynyl, haloalkyl, aryl, or heteroaryl, each optionally substituted with 0, 1, 2 or 3 independent R4;
R2 is aryl, heteroaryl aryloxy, heteroaryloxy, arylalkynyl, heteroarylalkynyl, arylalkyl, heteroarylalkyl, arylalkoxy, heteroarylalkoxy, aryloxyalkyl, or heteroaryloxyalkyl wherein each aryl or heteroaryl is optionally substituted with 0, 1, 2 or 3 independent R4;
R3 is independently H, alkyl, aryl, substituted aryl, heteroaryl, arylalkyl, or heteroarylalkyl, —C(O)alkyl, —C(O)aryl, —Si(alkyl)3, each optionally substituted with 0, 1, 2 or 3 independent R4;
R4 is independently aryl, heteroaryl, alkyl, thioalkyl, cyano, haloalkyl, cyanoalkyl, hydroxy, alkoxy, halo, haloalkoxy, —C(O)alkyl, —C(O)OH, —C(O)Oalkyl, —SCF3, —SF5, —SCN, or SO2(alkyl), —Si(alkyl)3, or oxime; and
R5-R7 are independently selected from the group consisting of H, alkyl, alkoxy, halo, and haloalkyl.

US Pat. No. 10,167,299

1-(3-AMINOPROPYL) SUBSTITUTED CYCLIC AMINE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

SHANGHAI INSTITUTE OF MAT...

1. A compound of formula I, a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof,
wherein,
W is absent or —CH2CH2—;
X is N or CR6;
R1 is selected from a 5 to 7-membered heteroaryl unsubstituted or substituted with 1-3 substituents, wherein said heteroaryl contains 1 to 3 heteroatoms selected from oxygen, sulfur or nitrogen and each of said substituents is independently selected from a halogen, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched alkyloxy, a C1-C4 straight or branched chain haloalkoxy, —NR10R11, —C(?O)R12, a C1-C4 straight or branched alkanoyloxy, a cyano, a nitro and a hydroxy, or two adjacent R1 substituents with the atoms to which each is attached are combined to form a fused 5-7 membered ring;
each of R10 and R11 is independently selected from a group consisting of H, a C1-C4 straight or branched alkyl and —C(?O)R13;
R12 is selected from a group consisting of a C1-C4 straight or branched alkyl, a C1-C4 straight or branched alkyloxy, a hydroxyl, an amino (NH2) and a C1-C4 straight or branched alkylamino;
R13 is selected from a group consisting of H and a C1-C4 straight or branched alkyl;
R2 is selected from the following groups unsubstituted or substituted with 1-3 substituents: a C1-C6 straight or branched alkyl, a C3-C7 cycloalkyl, a 4 to 7-membered heterocyclic group, a C6-C12 aryl or a 5-7 membered heteroaryl; wherein, said substituent is selected from a group consisting of a halogen, a hydroxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched alkyloxy, a C1-C4 straight or branched alkyl carbonyl, a C1-C4 straight or branched haloalkoxy, a C1-C4 straight or branched alkylsulfonyl group, a C1-C4 straight or branched alkylsulfonylcarbamoyl, a tetrazolyl, a cyano, a nitro, an amino, a carboxy, a phenyl, a halophenyl, a phenoxy, and a halophenoxy;
each of R3, R4 and R5 is independently selected from a group consisting of H, a C1-C6 straight or branched alkyl and a C3-C7 cycloalkyl;
R6 is selected from a group consisting of H and a C1-C6 straight or branched alkyl; alternatively, R5 and R6 may bind together with

 to form

R7 is selected from a group consisting of H, C(?O)R8, C(?O)OR8, C(?O)NR8R9, SO2R8 and the following groups substituted by 1-3 substituents a C1-C6 straight or branched alkyl, a C3-C7 cycloalkyl, a 4 to 7-membered heterocyclic group, a benzyl, a C6-C12 aryl and a 5-7 membered heteroaryl; wherein said substituent is selected from a halogen, a hydroxy, a C1-C4 straight or branched alkyloxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched haloalkoxy, a cyano, a nitro, an amino and a carboxyl;
each of R8 and R9 is independently selected from a group consisting of a hydrogen and the following groups unsubstituted or substituted with 1-3 substituents: a C1-C6 straight or branched alkyl, a C3-C7 cycloalkyl, a 4-7 membered heterocyclic group, a benzyl, a C6-C12 aryl and a 5-7 membered heteroaryl; wherein said substituent is selected from a group consisting of a halogen, a hydroxy, a C1-C4 straight or branched alkoxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched haloalkoxy, a cyano, a nitro, an amino, and a carboxyl.

US Pat. No. 10,167,298

PSEUDOPOLYMORPHS OF AN HCV NS5A INHIBITOR AND USES THEREOF

1. A crystalline form of the compound having the structure:
wherein said crystalline form is selected from the following forms: Form A (methanolate), Form B (ethanolate), Form C (1-propanolate), Form D (2-propanolate), Form E (acetonate), Form F (1-butanolate), Form G (ethylene glycolate), Form H (propylene glycolate), Form I (methyl isobutyl ketone/propylene glycol mixed solvate), Form J (hydrate) and Form K (1,5-naphthalene disulfonic acid salt).

US Pat. No. 10,167,297

SUBSTITUTED PYRIDINE COMPOUNDS HAVING HERBICIDAL ACTIVITY

BASF SE, Ludwigshafen (D...

1. A compound of the formula I
wherein
R is hydroxyl or O—RA where RA is C1-C-8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C1-C8-alkylcarbonyl-, C3-C6-cycloalkylcarbonyl-, C1-C8-alkoxycarbonyl-, C1-C8-alkylthiocarbonyl-, C1-C8-alkoxycarbonyloxy-C1-C3-alkyl-, C1-C8-alkylcarbonyloxy-C1-C3-alkyl-, tri(C1-C4-alkyl)silyl-, C1-C8-alkyl-S(O)n—, aryl-S(O)n—, aryl-C1-C4-alkyl- or arylcarbonyl-, where the aryl moiety is unsubstituted or substituted by one to five Ra and each Ra is independently halogen, nitro, cyano, C1-C8-alkyl, C1-C6-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, or C1-C4-alkyl-S(O)n—;
R1 and R2 independently of one another are halogen, cyano, nitro, C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkoxy-C1-C4-alkyl-, C1-C6-haloalkoxy-C1-C4-alkyl-, C3-C6-cycloalkyl-C1-C3-alkyl-, C3-C6-cycloakyl-C1-C3-alkoxy-, C1-C6-alkoxy-C2-C6-alkoxy-, C1-C6-alkoxy-C2-C6-alkoxy-C1-C3-alkyl-, C1-C6-alkylthio-, C1-C6-haloalkylthio-, C1-C6-alkylsulfonyl-, C1-C6-haloalkylsulfonyl-, C1-C3-alkylaminosulfonyl-, C1-C3-dialkylaminosulfonyl-, C1-C3-alkylamino-sulfonyl-C1-C3-alkyl-, C1-C3-dialkylamino-sulfonyl-C1-C3-alkyl-, C1-C3-alkylcarbonylamino-, N—C1-C3-alkyl-N—C1-C3-alkylcarbonylamino-, C1-C3-alkylsulfonylamino-, N—C1-C3-alkyl-N—C1-C3-alkylsulfonylamino-, C1-C3-alkylsulfonylamino-C1-C3-alkyl-, C1-C3-alkylaminocarbonyl-C1-C3-alkyl-, C1-C3-dialkylaminocarbonyl-C1-C3-alkyl-, N—C1-C3-alkylcarbonyl-N—C1-C3-alkylamino-C1-C3-alkyl-, N—C1-C3-alkylsulfonyl-N—C1-C3-alkylamino-C1-C3-alkyl-, C1-C3-alkylcarbonylamino-C1-C3-alkyl-, Z-heterocyclyl or Z-heterocyclyloxy wherein said heterocyclyls are 5- or 6-membered heterocyclyls containing 1, 2 or 3 heteroatoms selected from the group consisting of O, N and S, and are unsubstituted or partially or fully substituted by substituents selected from the group consisting of halogen, C1-C3-alkyl, C3-C6-cycloalkyl, C1-C3-haloalkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, C1-C6-alkyl-S(O)n—, cyano, nitro and phenyl;
R3 is hydrogen;
R4 is hydrogen or halogen;
R5, R6, and R7 independently of one another are hydrogen, halogen or C1-C4-alkyl;
Rx, Ry independently of one another are hydrogen, C1-C5-alkyl, C2-C5-alkenyl, C2-C5-alkynyl, C1-C5-haloalkyl, C1-C2-alkoxy-C1-C2-alkyl- or halogen; or
Rx and Ry are together a C2-C5-alkylene or C2-C5-alkenylene chain and form a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or fully unsaturated monocyclic ring together with the carbon atom they are bonded to, wherein 1 or 2 of any of the CH2 or CH groups in the C2-C5-alkylene or C2-C5-alkenylene chain may be replaced by 1 or 2 heteroatoms independently selected from O or S;
R8 is H, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C6-cycloalkyl or C2-C6-alkenyl;
R9 is C1-C4-alkyl, C1-C4-haloalkyl, C1-C6-alkoxy-, hydroxy-C1-C4-alkyl, C1-C6-haloalkoxy, C1-C6-alkoxy-C1-C4-alkyl-, C1-C6-alkoxy-C2-C6-alkoxy-, C1-C6-alkoxy-C2-C6-alkoxy-C1-C3-alkyl-, C3-C6-cycloalkyl, C1-C3-alkyl-C3-C6-cycloalkyl-, C3-C6-cycloalkyl-C1-C3-alkyl-, C3-C6-cycloalkyloxy-, C3-C6-cycloakyl-C1-C3-alkoxy-, C2-C6-alkenyl, C2-C6-alkenyloxy-, amino, C1-C4-alkylamino-, C2-C6-alkenylamino, C1-C4-dialkylamino-, C3-C6-cycloalkylamino-, or aryl being unsubstituted or substituted by one to five Ra and each Ra being independently selected from the group consisting of halogen, nitro, cyano, C1-C8-alkyl, C1-C6-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy and C1-C4-alkyl-S(O)n—; or R9 is a nitrogen-containing ring selected from the group consisting of aziridine, azetidine, pyrrolidine and piperidine, wherein each of said nitrogen-containing rings is bonded via its nitrogen atom to the carbon atom of the N—C?O group;
or R8 and R9 form together with the N—C?O group to which they are attached a heterocyclic ring of the formula (A1) or (A2)

wherein
each # denotes the bonding site to the remainder of the formula I;
X1, X3, X4, X5 and X7 are independently from one another O or CR10R11 with the proviso that only one of X1 and X3 in the formula (A1) and only one of X4, X5 and X7 in the formula (A2) is O;
X2 and X6 are CR10R11, and wherein R10 and R11 in each of the aforementioned groups CR10R11 are independently of one another hydrogen or C1-C4-alkyl;
Z is independently a covalent bond or C1-C4-alkylene;
n is independently 0, 1 or 2;
or an agriculturally suitable salt or N-oxide thereof.

US Pat. No. 10,167,296

SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

EVOTEC INTERNATIONAL GMBH...

1. A compound of formula (I)
wherein
Ar is selected from the group consisting of:

wherein X is CH or N;
R5 is H, halogen or CN; and
R4 is selected from the group consisting of C1-6-alkyl, C3-7-cycloalkyl, heterocyclyl, —(CH2)1-3—C(?O)—NH—(C1-5-alkyl) and —(CH2)1-3—C(?O)—N(CH3)—(C1-5-alkyl);
wherein each alkyl or cycloalkyl group of R4 is optionally substituted with one or more F or one CN, OH or CF3;
wherein each heterocyclyl is optionally substituted with one or more F and/or one OH or —O—(C1-3-alkyl); or
R4 is selected from the group consisting of:

R1 is halogen, C1-3-alkyl or —O—(C1-3-alkyl);
R2 is selected from the group consisting of OH, —O—(C1-6-alkyl), —O—(CH2)1-3—(C3-7-cycloalkyl), —O—(CH2)1-3—O—(C1-3-alkyl), —O-heterocyclyl and —O—(CH2)2-4-heterocyclyl,
wherein in the definition of R2, each heterocyclyl is optionally substituted with one C1-3-alkyl group, and wherein one CH2 group of said heterocyclyl of R2 may be replaced with a carbonyl group;
R3 is selected from the group consisting of:

wherein R6 is C1-2-alkyl;
R7 is C1-5-alkyl, C3-7-cycloalkyl or heterocyclyl,
wherein the alkyl group of R7 is optionally substituted with one or more F or with one OH or —O—(C1-3-alkyl), and
wherein the heterocyclyl group of R7 is tetrahydropyranyl; and
or wherein R6 and R7 together with the sulfur atom to which they are attached form a 4- to 7-membered saturated or partly unsaturated heterocycle that may be substituted in any position not adjacent to the sulfur atom by one or two F, OH or —O—(C1-3-alkyl) or by one or two C1-3-alkyl and that further to the sulfur atom may contain one additional heteroatom selected from the group consisting of O, S and NRN,
wherein RN is H or C1-3-alkyl,
wherein, if not otherwise specified, each alkyl group in the above definitions is linear or branched and may be substituted with one to three F;or a salt thereof.

US Pat. No. 10,167,295

ANALGESIC COMPOUNDS AND METHODS OF USE

The Regents of the Univer...

1. A method of producing sexually dimorphic analgesia in a male subject in need thereof, the method comprising administering to the male subject a therapeutically effective amount of a compound having the formula:
or a pharmaceutically acceptable salt thereof; wherein R4 is hydrogen or methyl; R5 is —C(O)-L1-R3; L1 is a bond, —CH2—, —CH2CH2—, or —CH2CH2CH2—; and R3 is (i) an unsubstituted 5-membered heterocyloalkyl; (ii) an unsubstituted 6-membered heterocycloalkyl; (iii) a 5-membered heterocyloalkyl substituted with one or two substituents selected from the group consisting of ?O, halogen, —OH, —NH2, —SH, —C(O)OH, —C(O)NH2, —CF3, —CCl3, —CN, —N3, an unsubstituted C1-C8 alkyl, and benzyl; or (iv) a 6-membered heterocycloalkyl.

US Pat. No. 10,167,294

FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE

Akarna Therapeutics, Ltd....

1. A compound according to Formula (IV), or a pharmaceutically acceptable salt or solvate thereof:
wherein:
R1 is selected from the group consisting of hydrogen, optionally substituted C1-C6alkyl, optionally substituted C2-C6alkenyl, optionally substituted C2-C6alkynyl, optionally substituted C3-C8cycloalkyl, optionally substituted aryl, optionally substituted —(C1-C2alkylene)-(aryl), optionally substituted C2-C9heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted —(C1-C2alkylene)-(heteroaryl);
R2 is selected from the group consisting of —CN, —C(O)OR25, —C(O)N(R25)R26,

 or R1 and R2 together with the carbon atoms to which they are attached, form an optionally substituted C2-C9heterocycloalkyl ring or an optionally substituted heteroaryl ring;
R4 and R5 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C1-C6alkoxy, optionally substituted C1-C6alkyl, optionally substituted C2-C6alkenyl, and optionally substituted C2-C6alkynyl; or R4 and R5 together with the carbon atom to which they are attached, form an optionally substituted C3-C6cycloalkyl ring or an optionally substituted C2-C7heterocycloalkyl ring;
R6 is selected from the group consisting of hydrogen, halogen, optionally substituted C1-C6alkyl, optionally substituted C2-C6alkenyl, optionally substituted C2-C6alkynyl, and —C(O)N(R27)R28;
R7 is selected from the group consisting of hydrogen, halogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6alkoxy, optionally substituted C2-C6alkenyl, and optionally substituted C2-C6alkynyl;
R8 is selected from the group consisting of hydrogen, optionally substituted C1-C6alkyl, optionally substituted C3-C8cycloalkyl, optionally substituted aryl, optionally substituted —(C1-C2alkylene)-(aryl), optionally substituted heteroaryl, optionally substituted C2-C9heterocycloalkyl, and optionally substituted —(C1-C2alkylene)-(heteroaryl);
each R12 is independently selected from the group consisting of hydrogen and C1-C6alkyl;
each R13 and R14 are each independently selected from the group consisting of hydrogen and C1-C6alkyl; or R13 and R14 together with the nitrogen atom to which they are attached, form an optionally substituted C2-C9heterocycloalkyl ring;
each R15 is independently selected from the group consisting of halogen, —OH, —CN, —NO2, —NH2, optionally substituted C1-C6alkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6alkylamine, optionally substituted C3-C8cycloalkyl, optionally substituted C2-C9heterocycloalkyl, aryl, heteroaryl, —C(O)OR12, —C(O)N(R13)R14, —OC(O)OR12, —OC(O)N(R13)R14, —N(R13)C(O)OR12, and —N(R13)C(O)N(R13)R14;
R25 and R26 are each independently selected from the group consisting of hydrogen, optionally substituted C1-C6alkyl, optionally substituted C3-C8cycloalkyl, optionally substituted aryl, optionally substituted —(C1-C2alkylene)-(aryl), optionally substituted C2-C9heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted —(C1-C2alkylene)-(heteroaryl);
R27 and R28 are each independently selected from the group consisting of hydrogen, optionally substituted C1-C6alkyl, optionally substituted C3-C8cycloalkyl, optionally substituted aryl, optionally substituted —(C1-C2alkylene)-(aryl), optionally substituted C2-C9heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted —(C1-C2alkylene)-(heteroaryl); or R27 and R28 together with the nitrogen atom to which they are attached, form an optionally substituted C2-C9heterocycloalkyl ring;
R30 is halogen, —OH, —CN, —NO2, —NH2, optionally substituted C1-C6alkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6alkylamine, optionally substituted C3-C8cycloalkyl, optionally substituted C2-C9heterocycloalkyl, aryl, heteroaryl,

each R31 is independently halogen, —OH, —CN, —NO2, —NH2, optionally substituted C1-C6alkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6alkylamine, optionally substituted C3-C8cycloalkyl, optionally substituted C2-C9heterocycloalkyl, aryl, or heteroaryl;
each R32 and R33 are each independently selected from the group consisting of hydrogen, halogen, and C1-C6alkyl;
R34 and R35 are each independently selected from the group consisting of hydrogen, optionally substituted C1-C6alkyl, optionally substituted C3-C8cycloalkyl, and optionally substituted C2-C9heterocycloalkyl; or R34 and R35 together with the nitrogen atom to which they are attached, form an optionally substituted C2-C9heterocycloalkyl ring;
n is 0, 1, 2, or 3
p is 0, 1, 2, 3, or 4;
r is 0, 1, 2, 3, or 4; and
t is 2, 3, or 4.

US Pat. No. 10,167,293

[8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES

BAYER PHARMA AKTIENGESELL...

1. A compound of general formula (I):in which:R1 represents hydrogen, halogen, C1-C3-alkyl, C1-C3-haloalkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, nitro or cyano;
R2 represents hydrogen, halogen, C1-C3-alkyl, C1-C3-haloalkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, nitro, cyano or SF5;
R3 represents hydrogen, halogen, C1-C3-alkyl, C1-C3-haloalkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, nitro or hydroxy;
R4 represents hydrogen, halogen, C1-C3-alkyl, C1-C3-haloalkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, nitro, cyano or SF5;
R5 represents hydrogen, halogen, C1-C3-alkyl, C1-C3-haloalkyl, C1-C3-alkoxy, C1-C3-haloalkoxy, nitro or cyano;wherein R1 and R2 or R2 and R3 are optionally linked to one another in such a way that they jointly form a methylenedioxy, ethylenedioxy, ethyleneoxy, trimethyleneoxy or a group selected from:or a stereoisomer, a tautomer, an N-oxide, or a salt thereof, or a mixture of same.

US Pat. No. 10,167,292

BENZODIAZEPINES AS BROMODOMAIN INHIBITORS

Catalyst Therapeutics Pty...

1. A compound of Formula I or a pharmaceutically acceptable derivative, polymorph, salt or prodrug thereof
wherein:
R1 is selected from the group consisting of H, C1-4alkyl, CF3, CF2H, C1-4alkylXH, C1-4alkylOCOR5; wherein X?O, S;
R2 is 0-3 substituents independently selected from the group consisting of C1-4alkyl, CN, Cl, Br, I, C3-10heterocyclyl, OC1-4alkyl, C5-10heteroaryl, C1-4alkylC6-10aryl, C1-4alkylC5-10heteroaryl, hydroxyl, nitro, COR6, CO2R6, CONR5R6, CONHSO2R5, SO2NHCOR5, CONR5OR6, C1-4alkylNR5R6, C1-4alkylOR6, NR5R6, NR5COR6, NR7CONR5R6 and NR5CO2R6;
R3 is selected from the group consisting of C1-4alkyl, C3-10cycloalkyl, C3-10heterocyclyl, C6-10aryl, C1-4alkylC6-10 aryl;
R4 is 1 to 2 groups on the same or adjacent carbons selected from oxo, C1-4alkyl, C1-4alkylOH, C1-4alkylOCOR5, C1-4alkylCONR5R6, C1-4alkylC6-10aryl, C1-4alkylC5-10heteroaryl;
R5 and R6 are independently selected from the group consisting of hydrogen, C1-4alkyl, C3-10cycloalkyl, C3-10heterocyclyl, C6-10aryl, C5-10heteroaryl, C1-4alkylC6-10aryl and C1-4alkylC5-10heteroaryl;
alternatively R5 and R6 are bound to the same atom and form an optionally substituted ring that is 4 to 10 carbon atoms in size wherein optionally one or more carbon atoms are replaced with O, S, S(O), SO2, or NR7; and
R7 is selected from the group consisting of hydrogen and C1-4alkyl
and further wherein, unless otherwise stated, each alkyl, cycloalkyl, heterocycyl, heteroaryl, and aryl is optionally substituted.

US Pat. No. 10,167,290

SUBSTITUTED PYRAZINO[2,3-B]PYRAZINES AS MTOR KINASE INHIBITORS

Signal Pharmaceuticals, L...

1. A method for preparing a compound of formula (II):
the method comprising contacting a compound of formula (VI):

with R1—Y in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base,
wherein Y is B(OR+)2 or Sn(R++)3;
R1 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;
R2 is H, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl;
R3 is H, or a substituted or unsubstituted C1-8 alkyl; and
each R+ is hydrogen, or each R+, together with the boron atom and the atoms to which they are attached, form a cyclic boronate;
each R++ is independently C1-3 alkyl;
the palladium catalyst is bis(dibenzylideneacetone)palladium(0)/tri-o-tolylphosphine, or palladium (II) acetate/4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; and
substituted means substituted with a substituent selected from the group consisting of chloro; iodo; bromo; fluoro; alkyl; hydroxy; alkoxy; alkoxyalkyl; amino; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonato; phosphine; thiocarbonyl; alkylsulfonyl; sulfonamide; acyl; ester; urea; urethane; oxime; hydroxylamine; alkoxyamine; aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxo; B(OH)2, O(alkyl)aminocarbonyl; cycloalkyl, which may be monocyclic or fused or non-fused polycyclic, or a heterocyclyl, which may be monocyclic or fused or non-fused polycyclic; monocyclic or fused or non-fused polycyclic aryl or heteroaryl; aryloxy; aralkyloxy; heterocyclyloxy; and heterocyclylalkoxy.

US Pat. No. 10,167,289

PYRAZOLOPYRIMIDINE COMPOUNDS

University Health Network...

1. A method for treating cancer, the method comprising administering to a subject in need thereof an effective amount of a compound represented by the following structural formula:or a pharmaceutically acceptable salt thereof, wherein the cancer is pancreatic cancer, prostate cancer, lung cancer, melanoma, colon cancer, ovarian cancer, hepatocellular carcinoma, mesothelioma, leukemia, lymphoma or glioblastoma multiform.

US Pat. No. 10,167,288

SUBSTITUTED PYRAZOLYLPYRAZOLE DERIVATIVE AND USE OF SAME AS HERBICIDE

KYOYU AGRI CO., LTD., Ka...

1. A compound represented by the following formula (I):wherein,R1 represents a chlorine atom or bromine atom,
R2 represents a cyano group,
R3 represents a hydrogen atom or C1-C6 alkyl group which may be optionally substituted with one or more halogen atoms,
R4 represents a C1-C6 alkyl group which may be optionally substituted with one or more halogen atoms, a C3-C6 alkenyl group which may be optionally substituted with one or more halogen atoms, or a C3-C6 alkynyl group which may be optionally substituted with one or more halogen atoms,
a represents 3 to 5, and
X represents an oxygen atom or sulfur atom.

US Pat. No. 10,167,287

SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE

Duquesne University of th...

1. A method of treating a patient having cancer selected from the group consisting of Malignant Pleural Mesothelioma and Non-Small Cell Lung Cancer, comprising administering to the patient an effective amount of a compound of a formula:
wherein X is O and n is three, and optionally comprising a pharmaceutically acceptable salt, hydrate, or solvate thereof, and including optionally administering an effective amount of said salt, hydrate, or solvate of said compound to said patient.

US Pat. No. 10,167,286

COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

Mitokinin, Inc., New Yor...

1. A compound comprising the following formula or pharmaceutically acceptable salt thereof:
wherein X is independently selected from a C—H, C—CH3, C—CH2CH3, C—CH2CH2CH3, or CR3, wherein R3 is independently selected from a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
L1 is a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;
R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R4 is hydrogen, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 is N;
R5 is CH, CCH3, or CC6H5; and
R6 is N;
wherein the compound does not comprise kinetin or cytokinin.

US Pat. No. 10,167,285

SMALL-MOLECULE HSP90 INHIBITORS

Memorial Sloan Kettering ...

1. A compound of the formula:or a salt thereof,wherein the right side aryl ring optionally comprises one or more heteroatoms which are N or O, R is an amino alkyl moiety, optionally substituted on the amino nitrogen with one or two carbon-containing substituents selected independently from the group consisting of alkyl, alkenyl and alkynyl substituents, wherein the total number of carbons in the amino alkyl moiety is from 1 to 9;
X4 is hydrogen or halogen, wherein the halogen is F or Cl, or Br;
X3 is CH2, CF2, S, SO, SO2, O, NH, or NR2, wherein R2 is alkyl; and
X2 is halogen, alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, alkylamido, dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, SO2-alkyl, COO-alkyl, NH2, OH, or CN;
X1 has the formula —O—(CH2)n—O—, wherein n is 1 or 2, and one of the oxygens is bonded at the 5?-position of the aryl ring and the other at the 4?-position of the aryl ring; and
the compound comprises a radiolabeled atom.

US Pat. No. 10,167,284

SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR

Heptares Therapeutics Lim...

1. A compound of the formula (1):
or a salt thereof, wherein:
p is 0, 1 or 2;
q is 1 or 2;
r is 1 or 2;
s is 1 or 2, where the total of r and s is 2 or 3;
X is C or N;
Z is CH2, N, O or S;
Y is NH, O, S or CH2;
R1 can be H, halo, CN, OH, C1-3 alkoxy, NH2, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-6 cycloalkyl, optionally substituted C3-6 cycloalkenyl, W or CH2—W where W is an optionally substituted 5 or 6 membered cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring, NR5R6, COOR5, CONR5R6, NR7CONR5R6, NR7COOR5, OCONR5R6, SR5, SOR5, SO2R5 or SO3R5;
R2 can be independently H, halo, CN, OH, C1-3 alkoxy, NH2, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-6 cycloalkyl, optionally substituted C3-6 cycloalkenyl, W or CH2—W where W is an optionally substituted 5 or 6 membered cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring, NR5R6, COOR5, CONR5R6, NR7CONR5R6, NR7COOR5, OCONR5R6, SR5, SOR5 or SO2R5; or R1 and R2 together form an optionally substituted cycloalkyl or heterocycloalkyl ring;
R3 can be independently H, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-6 cycloalkyl, optionally substituted C3-6 cycloalkenyl, W or CH2—W where W is an optionally substituted 5 or 6 membered cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring; or R3 and R2 together form an optionally substituted cycloalkyl or heterocycloalkyl ring;
R4 can be H, optionally substituted C1-5 alkyl, optionally substituted C2-5 alkenyl, optionally substituted C2-5 alkynyl, optionally substituted C3-6 cycloalkyl or optionally substituted C3-6 cycloalkenyl; and
R5, R6 and R7 can be independently H or C1-6 alkyl.

US Pat. No. 10,167,283

?-LACTAMASE INHIBITORS AND USES THEREOF

SUANZHU PHARMA CO., LTD.,...

1. A compound of Formula (I), a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof:
wherein,
R1 is —SO3M, —OSO3M, —SO2NH2, —PO3M, —OPO3M, —CH2CO2M, —CF2CO2M or CF3;
M is selected from H or a pharmaceutically acceptable cation;
Ring A is selected from the group consisting of 5- to 15-membered bridged cyclyl, 5- to 15-membered spiro cyclyl, 5- to 15-membered bridged heterocyclyl or 5- to 15-membered spiro heterocyclyl, which is optionally substituted with substituent(s) selected from the group consisting of halogen, amino, carboxyl, hydroxyl, cyano, C1-6 alkyl, halo C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino or C1-6 alkylcarbonyl;
R2 is selected from the group consisting of hydrogen atom, halogen, amino, carboxyl, hydroxyl, C1-6 alkyl, halo C1-6 alkyl, hydroxylC1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyC1-6 alkyl, halo C1-6 alkoxy, halo C1-6 alkoxyC1-6 alkyl, C1-6 alkylamino, di(C1-6 alkyl)amino, C1-6 alkylaminoC1-6 alkyl, C1-6 alkylcarbonyl, halo C1-6 alkylcarbonyl, halo C1-6 alkylcarbonylC1-6 alkyl, C1-6 alkylcarbonyloxy, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxyC1-6 alkyl, C1-6 alkylacylamino, C1-6 alkylaminocarbonyl, di(C1-6 alkyl)aminocarbonyl, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C1-6 alkylsulfonylC1-6 alkyl, C1-6 alkylsulfonylamino, C1-6 alkylsulfonyloxy, C2-6 alkenyl, C2-6 alkynyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkyl-C1-6 alkyl, 6- to 8-membered aryl, 6- to 15-membered fused aryl, 4- to 15-membered fused cyclyl, 5- to 15-membered bridged cyclyl, 5- to 15-membered Spiro cyclyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyl-C1-6 alkyl, 5- to 8-membered heteroaryl, 5- to 15-membered fused heteroaryl, 4- to 15-membered fused heterocyclyl, 5- to 15-membered bridged heterocyclyl or 5- to 15-membered Spiro heterocyclyl.

US Pat. No. 10,167,282

1-(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO [2, 3-B]PYRAZIN- 8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER

CANCER RESEARCH TECHNOLOG...

1. A method of treating a disorder comprising administering to a subject in need of treatment thereof a therapeutically-effective amount of a compound selected from compounds of the following formulae and pharmaceutically acceptable salts and N-oxides thereof:
wherein the disorder is:
malignant melanoma; colorectal carcinoma; metastatic colorectal carcinoma; follicular thyroid cancer; insular thyroid cancer; papillary thyroid cancer; ovarian carcinoma; low grade ovarian carcinoma; non-small cell lung cancer; hairy cell leukemia; cholangiocarcinoma; pediatric low-grade glioma; pilocytic astrocytoma; ganglioglioma; pleomorphic xanthoastrocytoma; multiple myeloma; medullary carcinoma of the pancreas; pancreatic ductal adenocarcinoma; pancreatic cancer; non-small cell lung cancer; ovarian neoplasms; peritoneal neoplasms; fallopian tube neoplasms; lung cancer and associated pleural effusion; recurrent or metastatic squamous cell cancer of the head and neck; locally advanced nasopharyngeal carcinoma; glioblastoma; glioblastoma multiforme; giant cell glioblastoma; gliosarcoma; diffuse intrinsic pontine glioma; HIV-related kaposi sarcoma; multiple myeloma; renal cell carcinoma; metastatic gastric adenocarcinoma; acute myeloid leukemia; hepatocellular carcinoma; dermatofibrosarcoma; medullary thyroid cancer; papillary thyroid cancer; follicular thyroid cancer; myelodysplastic syndrome; neurofibromatosis type 1; plexiform neurofibroma; spinal cord neurofibroma; breast cancer; biliary tract neoplasms; cervical cancer; prostate cancer; melanoma; bladder carcinoma; urethra carcinoma; ureter carcinoma; renal carcinoma; pelvis carcinoma; sarcoma; liposarcoma; colon cancer; osteosarcoma; synovial carcinoma; neuroblastoma; or rhabdomyosarcoma.

US Pat. No. 10,167,281

SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS

Axxam S.P.A., Bresso (MI...

1. A method of treating conditions or diseases selected from Alzheimer's Disease, Lewy body dementia, fronto-temporal dementia, taupathies, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's Disease and parkinsonian syndromes, Huntington's disease, Charcot-Marie-Tooth disease; head trauma, cerebral ischemia, meningitis, cognitive psychiatric disorders; sleep disorders; neuropathic and inflammatory pain, chronic pain, migraine, multiple sclerosis pain, HIV-related neuropathy, HIV-induced neuroinflammation and CNS damage, epilepsy and status epilepticus, inflammatory processes of the musculoskeletal system, liver fibrosis, gastrointestinal tract disorders genito-urinary tract disorders, ophthalmic diseases, chronic obstructive pulmonary disease (COPD), autoimmune diseases nephritis, in a mammal in need thereof:said method comprising:
administering a therapeutically effective amount of a compound of the following Formula (I) or a pharmaceutically acceptable salt thereof:

including any stereochemically isomeric form thereof, wherein
n is 1 or 2;
Y represents oxygen or sulfur;
each of R1 and R2 is independently selected from the group consisting of hydrogen, deuterium, halogen, C1-C4 alkyl, optionally substituded with hydroxy or halogen, such as hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, C3-C6 cycloalkyl, optionally substituded with hydroxy or halogen, or C1-C4 alkyloxy; each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-C4 alkyl, difluoromethyl, trifluoromethyl, C1-C4 alkyloxy, NR9R10, wherein R9 and R10 independently are hydrogen or C1-C4 alkyl, or 2-thiazolidin-1,1-dione; or the two R3 groups or the R3 and R4 groups taken together form a six membered heterocyclic ring containing a nitrogen atom;
R5 is selected from hydrogen, halogen, or is an heterocyclic ring selected from pyrimidin-2-yl, pyridin-2-yl or pyrazin-2-yl, optionally substituted with halogen, C1-C4 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl or C1-C4 alkyloxy;
R7 is hydrogen or C1-C4 alkyl;
the radical

represents an optionally substituted azetidine, pyrrolidine, piperidine, morpholine, oxazepane or 1,2,3,4-tetrahydroisoquinoline ring, wherein each of R6 is independently selected from the group consisting of hydrogen, halogen, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 spirocycloalkyl difluoromethyl, trifluoromethyl, C1-C4 alkyloxy, aryl, heteroaryl, C1-C4 aryloxy or C1-C4 arylalkoxy wherein the aryl group or heteroaryl group is optionally substituted with halogen C1-C4 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl or C1-C4 alkyloxy,
to said mammal; and
treating said conditions or diseases in a mammal in need thereof.

US Pat. No. 10,167,280

SUBSTITUTED OXOPYRIDINE DERIVATIVES

BAYER PHARMA AKTIENGESELL...

1. A compound of the formula
in which
R1 is a group of the formula

where * is the attachment point to the oxopyridine ring,
R6 is chlorine,
R7 is fluorine, cyano, difluoromethyl, or difluoromethoxy,
R8 is hydrogen,
R2 is chlorine, cyano, methoxy, or difluoromethoxy,
R3 is methyl, ethyl, n-propyl, or n-butyl,
where methyl may be substituted by a substituent selected from the group consisting of cyclopropyl, cyclobutyl, cyclohexyl, tetrahydro-2H-pyranyl, oxazolyl, and pyridyl,
in which cyclobutyl and cyclohexyl may be substituted by 1 to 2 substituents selected independently from the group consisting of hydroxyl and methoxy,
and
in which oxazolyl may be substituted by a methyl substituent,
and
where ethyl, n-propyl, and n-butyl may be substituted by a substituent selected from the group consisting of methoxy and trifluoromethoxy,
R4 is hydrogen,
R5 is a group of the formula

where # is the attachment point to the nitrogen atom,
R12 is hydrogen or fluorine,
R13 is hydroxyl or —NHR14,
in which
R14 is hydrogen, methyl, or ethyl,or a salt thereof, a solvate thereof, or a solvate of the salt thereof.

US Pat. No. 10,167,279

COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS

Novartis AG, Basel (CH)

1. A compound, or a pharmaceutically acceptable salt thereof, of formula I or II:in which:L is selected from NHC(O)— and —C(O)NH—;
Y1 is selected from N and CH;
Y2 is selected from N and CH;
Y3 is selected from N and CH;
Y4 is selected from N and CR8; wherein R8 is selected from H, hydroxy-ethoxy, 3-hydroxyoxetan-3-yl, 2,3-dihydroxypropoxy, bis(hydroxy-ethyl)-amino, 4-hydroxy-piperidin1-yl, hydroxy-ethyl-amino, 4-amino-4-methylpiperidin-1-yl, 2-oxooxazolidin-3-yl, methoxy and methyl;
Y5 is selected from N and CR1;
or R1 and the nitrogen of Y4 form a 5 member unsaturated ring containing and additional heteroatom selected from N, O and S;
or R1 and R8 together with the ring to which they are both attached form 2H-benzo[b][1,4]oxazin-3(4H)-one substituted with one to two R20 groups independently selected from methyl and hydroxy-ethyl;
or R8 and Y3 together with the ring to which they are both attached form 1H-benzo[d]imidazole substituted with methyl;
R1 is selected from H, ethoxy, isopropoxy, methoxy-ethyl-amino, (2-hydroxyethyl)(methyl)amino, (1-hydroxypropan-2-yl)amino, methoxy-ethoxy, hydroxy-ethoxy, methoxy, (2-hydroxypropyl)amino, (tetrahydro-2H-pyran-4-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, (1-ethylpiperidin-4-yl)oxy and pyrazolyl; wherein said pyrazolyl can be unsubstituted or substituted with 1 to 2 methyl groups; each
R2a is independently selected from hydrogen and OH;
R2b is selected from H, methyl, halo, fluoro-methyl, hydroxy, hydroxymethyl, difluoromethyl, formyl, methoxy and cyano;
R3 is selected from:
whereinindicates the point of attachment with L;R4 is selected from H, methyl, hydroxy-ethyl, hydroxy-propyl and 2,3-dihydroxypropyl;
R15 is selected from —CF3, methoxy, —C(CH3)2F, —CF2CH2F, —C(CH3)2CN, —C(CH3)F2, —CHF2, —C(CH3)2OH, t-butyl, 1-cyanocyclopropyl, 2-(trifluoromethyl)cyclopropyl, —C(F2)C2H5, methyl-sulfonyl, 4-ethylpiperazin-1-yl, —C(CH3)2NH2 and dimethyl-amino-methyl;
R16 is selected from H, halo, hydroxy, dimethyl-amino, hydroxy-methyl, amino-methyl, —C(CH3)2NH2 and —CF3; or a pharmaceutically acceptable salt thereof; with the proviso that a compound of formula II is not 2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-6-oxo-5-(tetrahydro-2H-pyran-4-yl)-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide or 2-(2-fluoropropan-2-yl)-N-(4-methyl-3-(1-methyl-6-oxo-5-(tetrahydro-2H-pyran-4-yl)-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide.

US Pat. No. 10,167,278

CYCLOPROPANECARBOXAMIDE MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

Auspex Pharmaceuticals, I...

1. A compound of Formula I:
or a salt thereof, wherein:
R1-R3 and R6-R23 are, independently, hydrogen or deuterium;
R4-R5 are, independently, —CH3, —CH2D, —CD2H, or —CD3;
at least one of R1-R23 is deuterium or contains deuterium; and
at least one of R1-R23 independently has deuterium enrichment of no less than about 10%.

US Pat. No. 10,167,277

ACTIVATORS OF CLASS I HISTONE DEACETLYASES (HDACS) AND USES THEREOF

Massachusetts Institute o...

1. A compound of Formula (B):or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein:each of XB1, XB3, and XB4 is independently oxygen, sulfur, NRB4a, or C(RB4b)2, wherein RB4a is hydrogen, a nitrogen protecting group, or optionally substituted C1-6 alkyl, and each occurrence of RB4b is independently hydrogen, halogen, or optionally substituted C1-6 alkyl, or two RB4b groups are joined to form an optionally substituted, carbocyclic or heterocyclic ring;
XB2 is nitrogen or CRB2a, wherein RB2a is hydrogen, halogen, or optionally substituted C1-6 alkyl;
each instance of RB1 is independently halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —ORB1a, —N(RB1a)2, —SRB1a, —C(?O)RB1a, —C(?O)ORB1a, —C(?O)SRB1a, —C(?O)N(RB1b)2, —OC(?O)RB1a, OC(?O)ORB1a, —OC(?O)SRB1a, —OC(?O)N(RB1b)2, —NRB1bC(?O)RB1b, —NRB1bC(?O)ORB1a, —NRB1bC(?O)SRB1a, —NRB1bC(?O)N(RB1b)2, —SC(?O)RB1a, —SC(?O)ORB1a, —SC(?O)SRB1aSC(?O)N(RB1b)2, —C(?NRB1b)RB1a, —C(?NRB1b)ORB1a, —C(?NRB1b)SRB1a, —C(?NRB1b)N(RB1b)2, —OC(?NRBb)RB1a, —OC(?NRB1b)ORB1a, —OC(?NRB1b)SRB1a, —OC(?NRB1b)N(RB1b)2, —NRB1bC(?NRB1b)RB1b, —NRB1bC(?NRB1b)ORB1a, —NRB1bC(?NRB1b)SRB1a, NRB1bC(?NRB1b)N(RB1b)2, —SC(?NRB1b)RB1a, —SC(?NRB1b)ORB1a, —SC(?NRB1b)SRB1a SC(?NRB1b)N(RB1b)2, —C(?S)RB1a, —C(?S)ORB1a, —C(?S)SRB1a, —C(?S)N(RB1b)2, —OC(?S)RB1a, OC(?S)ORB1a, —OC(?S)SRB1a, —OC(?S)N(RB1b)2, —NRB1bC(?S)RB1b, —NRB1bC(?S)ORB1a, —NRB1bC(?S)SRB1a, —NRB1bC(?S)N(RB1b)2, —SC(?S)RB1a, —SC(?S)ORB1a, —SC(?S)SRB1a, SC(?S)N(RB1b)2, —S(?O)RB1a, —SO2RB1a, —NRB1bSO2RB1a, —SO2N(RB1b)2, —CN, —SCN, or —NO2, wherein each occurrence of RB1a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, and each occurrence of RB1b is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group when attached to a nitrogen atom, or two RB1b groups are joined to form an optionally substituted heterocyclic ring;
each of RB2, RB3, RB4, and RB5 is independently hydrogen, halogen, or optionally substituted C1-6 alkyl;
RB6 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —N(RB6b)2, or —SRB6a, wherein RB6a is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, and each occurrence of RB6b is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group, or two RB6b groups are joined to form an optionally substituted heterocyclic ring; and
p is 0, 1, 2, 3, or 4;
provided that the compound is not of the formula:

US Pat. No. 10,167,276

COMPOUNDS AND METHODS FOR INHIBITING JAK

Dizal (Jiangsu) Pharmaceu...

5. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable diluent, excipient or carrier.

US Pat. No. 10,167,275

AZD9291 INTERMEDIATE AND PREPARATION METHOD THEREFOR

SUZHOU MIRACPHARMA TECHNO...

1. A compound N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-formamidine]phenyl-2-propenamide as shown in formula II

US Pat. No. 10,167,273

SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES

Takeda Pharmaceutical Com...

1. A compound of formula (Ia) or a pharmaceutically acceptable salt thereof,wherein
R1 is;
q is 0 or 1;
each R12 independently represents halogen, cyano, carboxyl, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 alkoxycarbonyl, C1-C6 alkoxyC1-C6 alkyl or a 5- to 9-membered heterocyclic ring system;
R13 represents CHF; and
R14 represents a substituted phenyl, wherein the substituted phenyl includes at least one substituent selected from halogen, cyano, methyl, trifluoromethyl, methoxy and trifluoromethoxy.

US Pat. No. 10,167,272

MUSCARINIC AGONISTS

Heptares Therapeutics Lim...

1. A compound of the formula (1):
or a pharmaceutically acceptable salt thereof, wherein
p is 1 or 2;
q is 0, 1 or 2;
r is 1 or 2;
s is 0 or 1, where the total of r and s is 1 or 2;
wherein the moiety:

is selected from groups A to KKK as follows:

R3 is H; and
R4 is a hydrogen or a C1-6 non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and wherein one or two, but not all, carbon atoms of the hydrocarbon group may optionally be replaced by a heteroatom selected from O, N and S and oxidised forms thereof.

US Pat. No. 10,167,271

FLUOROQUINOLONE CARBOXYLIC ACID COMPOUNDS AND USE THEREOF FOR THE PREPARATION OF BESIFLOXACIN HYDROCHLORIDE

MANKIND PHARMA LTD, (IN)...

1. Fluoroquinolone carboxylic acid compounds of Formula-I, and salts thereof:
wherein, R is hydrogen or a halogen.

US Pat. No. 10,167,270

SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY

Northwestern University, ...

1. A compound or a salt or solvate thereof having a formula:
wherein:
R1 is hydrogen or C1-C10 alkyl;
n is 0, 1, 2, 3, or 4;
R8 is hydrogen, C1-C8 alkyoxy, C1-C8 alkyl, halo, or R8 has a formula selected from
p is 1-10 and R9 is amino or R9 has a formula selected fromwherein R10 is H, C1-C6 straight chain or branched alkyl, or a succinimidyl group;R3 is pyridinyl, phenyl, thiophenyl, halo, furanyl, or pyrimidinyl, and R3 optionally is substituted at one or more positions with C1-C8 alkyl, halo, or amino, or R3 has a formula,
wherein R4 is amino, or R4 has a formulawherein R5 is CH2— or O—CH2—CH2—, and m is 0-4,R6 is H or R6 has a formula
wherein R7 is H, —OH, C1-C8 alkyl, or C1-C8 alkoxy.

US Pat. No. 10,167,269

COCKROACH ATTRACTION-AGGREGATION SUBSTANCE, COCKROACH AGGREGATION ATTRACTANT AND COCKROACH CONTROLLING AGENT

Kyoto University, Kyoto ...

1. A cockroach attraction-aggregation compound, the compound being represented by general formula:
wherein R1 to R4 are each independently selected from the group consisting of a hydrogen atom, a halogen atom,
an optionally substituted (C1-C6)alkyl group,
an optionally substituted (C3-C6)cycloalkyl group,
an optionally substituted (C2-C6)alkenyl group, and
an optionally substituted (C2-C6)alkynyl group;
wherein R5 is an unsubstituted methyl group,
wherein two of R2, R3 and R4 are hydrogen atoms and the other is selected from the group consisting of an optionally substituted (C1-C6)alkyl group, an optionally substituted (C3-C6)cycloalkyl group, an optionally substituted (C2-C6)alkenyl group, and an optionally substituted (C2-C6)alkynyl group, and
provided that in the case where R1 is methyl, R2 is a hydrogen atom, and R3 and R4 are each independently a hydrogen atom or methyl is excluded, in the case where R1 is ethyl or 2-hydroxyl-1-propyl, R2, R3 and R4 are each a hydrogen atom is excluded, in the case where R1 is ethyl, R2 and R4 are each a hydrogen atom, and R3 is methyl is excluded, in the case where R1 is ethyl, R2 and R3 are each a hydrogen atom, and R4 is methyl is excluded, and in the case where R1 is hydrogen atom, and R2, R3 and R4 are each independently a methyl is excluded, or
a salt thereof.

US Pat. No. 10,167,268

PROCESS FOR PURIFYING A CRUDE COMPOSITION OF DIALKYL ESTER OF 2,5-FURANDICARBOXYLIC ACID

Synvina C.V., Amsterdam ...

1. A process for purifying an ester composition comprising at least 90% wt of the dialkyl ester of 2,5-furandicarboxylic acid as starting dialkyl ester concentration and up to 5% wt of the monoalkyl ester of 2,5-furandicarboxylic acid as starting monoalkyl ester concentration, the percentages being based on the weight of the ester composition, which process comprises subjecting the ester composition to melt crystallization to yield a purified dialkyl ester composition containing a dialkyl concentration higher than the starting dialkyl ester concentration and a melt residue containing a monoalkyl ester concentration higher than the starting monoalkyl ester concentration,wherein the melt residue is subject to conversion into a monoalkyl ester-rich intermediate product containing a momoalkyl ester concentration of at least 10% wt, based on the weight of the intermediate product, and
wherein the monoalkyl ester-rich intermediate product that is subjected to melt crystallization has a temperature in the range of 180 to 250° C.

US Pat. No. 10,167,267

CONVERSION AND PURIFICATION OF BIOMASS

AGENCY FOR SCIENCE, TECHN...

1. A method for synthesizing an optionally substituted furoic acid, comprising:converting a biomass to an optionally substituted furan, wherein said furan is unsubstituted or substituted by at least one —C1-C10-alkyl-OH group, via a dehydration reaction in the presence of an organic solvent;
purifying the optionally substituted furan by first evaporating the organic solvent from the optionally substituted furan produced from said dehydration reaction to obtain a solid residue or an aqueous slurry, followed by adding water to the residue or aqueous slurry for extraction of the optionally substituted furan with water, collecting the supernatant separately from the residue; and
oxidizing the extracted optionally substituted furan to form the optionally substituted furoic acid.

US Pat. No. 10,167,266

SODIUM CHANNEL BLOCKERS

Parion Sciences, Inc., D...

1. A pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and an osmotically active agent:wherein:X is halogen;
Y is —N(R2)2;
R1 is hydrogen or lower alkyl;
each R2 is independently —R7;
R3 is hydrogen or lower alkyl;
R4 is a group represented by formula (A):
and wherein:each RL is independently —R7, —(CH2)n—OR8, —O—(CH2)m—OR8, —(CH2)n—NR7R10, —O—(CH2)m—NR7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —O—(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —O—(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(?O)NR7R10, —O—(CH2)m—C(?O)NR7R10, —(CH2)n—(Z)g—R7, —O—(CH2)m—(Z)g—R7, —(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)n—CO2R7, —O—(CH2)m—CO2R7, —OSO3H, —O-glucuronide, —O-glucose,

each o is independently an integer from 0 to 10;
each p is an integer from 0 to 10;with the proviso that the sum of o and p in each contiguous chain is from 1 to 10;each x is, independently, O, NR10, C(?O), CHOH, C(?N—R10), CHNR7R10, or a single bond;
each R5 is independently —(CH2)m—OR8, —O—(CH2)m—OR8, —(CH2)n—NR7R10, —O—(CH2)m—NR7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —O—(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —O—(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(?O)NR7R10, —O—(CH2)m—C(?O)NR7R10, —(CH2)n—(Z)g—R7, —O—(CH2)m—(Z)g—R7, —(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)n—CO2R7, —O—(CH2)m—CO2R7, —OSO3H, —O-glucuronide, —O-glucose,

each R6 is independently —R7, —OR11, —N(R7)2, —(CH2)m—OR8, —O—(CH2)m—OR8, —(CH2)n—NR7R10, —O—(CH2)m—NR7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —O—(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —O—(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(?O)NR7R10, —O—(CH2)m—C(?O)NR7R10, —(CH2)n—(Z)g—R7, —O—(CH2)m—(Z)g—R7, —(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)n—CO2R7, —O—(CH2)m—CO2R7, —OSO3H, —O-glucuronide, —O-glucose,wherein when two R6 are —OR11 and are located adjacent to each other on a phenyl ring, the alkyl moieties of the two R6 may be bonded together to form a methylenedioxy group,
each R7 is independently hydrogen or lower alkyl;
each R8 is independently hydrogen, lower alkyl, —C(?O)—R11, glucuronide, 2-tetrahydropyranyl, or

each R9 is independently —CO2R7, —CON(R7)2, —SO2CH3, or —C(?O)R7;
each R10 is independently —H, —SO2CH3, —CO2R7, —C(?O)NR7R9, —C(?O)R7, or —CH2—(CHOH)n—CH2OH;
each Z is independently CHOH, C(?O), CHNR7R10, C?NR10, or NR10;
each R11 is independently lower alkyl;
each g is independently an integer from 1 to 6;
each m is independently an integer from 1 to 7;
each n is independently an integer from 0 to 7; and
each Q is independently C—R5 or C—R6, wherein one Q is C—R5.

US Pat. No. 10,167,265

TREATMENT OF PULMONARY AND OTHER CONDITIONS

The United States of Amer...

1. A method for treating a pulmonary disease in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:
wherein represents a single bond;
A is CH(S—R5), wherein R5 is an acylamino-substituted carboxylalkyl, a sulfonate-substituted alkyl, or an acylamino-substituted amido; and
X1 and X2 are each independently an optionally-substituted N-heterocycle wherein the pulmonary disease is pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, acute lung injury (ALI), acute respiratory distress syndrome, pulmonary hypertension, lung cancer, or pulmonary manifestations of cystic fibrosis.

US Pat. No. 10,167,264

SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS

Jiangsu Medolution Ltd, ...

1. A compound according to Formula I:
or a pharmaceutically acceptable salt, solvate, stereoisomer or tautomer thereof, wherein
R1 is hydrogen, C1-C6 alkoxy, F, Cl, or CF3;
R2 is C1-C6 alkyl or C(O)R3; and
R3 is C1-C6 alkyl;
with the proviso that when R1 is C1-C6 alkoxy, R2 is not C(O)R3.

US Pat. No. 10,167,263

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

NORTHWESTERN UNIVERSITY, ...

1. A compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is H;
R2 is H and
R3 is —R10, —OR10, —SR10, —S(O)R10, —SO2R10, —OSO2R10, —C(O)R10, —C(O)OR10, —OC(O)R10, —OC(O)OR10, —C(O)N(R10)2, —OC(O)N(R10)2, a suitable amino protecting group, or an optionally substituted 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, or sulfur;
wherein R10 is hydrogen, halogen, optionally substituted C1-20 alkyl, optionally substituted phenyl, optionally substituted arylalkyl or monocyclic aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and wherein R10 optionally is substituted with substituents selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, nitro, hydroxy, amino, C1-6 alkylamino, cyano, isocyano, isocyanato, and isothiocyanato substituents,
providing that R3 is not benzimidazolyl and
providing that R3 is not benzothiazolyl;
m is 0-5;
each R4 is independently —R11, —SR11, —CN, —S(O)R11, —SO2R11, —OSO2R11, —N(R11)2, —NR11C(O)R11, —NR11C(O)(CO)R11, —NR11C(O)N(R11)2, —NR11C(O)OR11, —N(R11)S(O)R11, —N(R11)SO2R11, —N(R11)SO2OR11, —C(O)R11, —C(O)OR11, —OC(O)R11, —OC(O)OR11, —C(O)N(R11)2, —OC(O)N(R11)2, or a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur,
wherein R11 is halogen, optionally substituted C1-20 alkyl, optionally substituted phenyl, optionally substituted aryl, optionally substituted arylalkyl or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and wherein RH optionally is substituted with substituents selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, nitro, hydroxy, amino, C1-6 alkylamino, cyano, isocyano, isocyanato, and isothiocyanato substituents; and,
providing where R3 is H and m=1 or 2, R4 is —R12, —OR12, —SR12, CN, —S(O)R12, —SO2R12, —OSO2R12, N(R12)2, —NR12C(O)R12, —NR12C(O)(CO)R12, —NR12C(O)N(R12)2, —NR12C(O)OR12, —N(R12)S(O)R12, —N(R12)SO2R12, —N(R12)SO2OR12, —C(O)R12, —C(O)OR12, —OC(O)R12, —OC(O)OR12, —C(O)N(R12)2, —OC(O)N(R12)2, or a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
wherein R12 is halogen, optionally substituted C5-20 alkyl, optionally substituted phenyl, optionally substituted aryl, optionally substituted arylalkyl or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and wherein R12 optionally is substituted with substituents selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, nitro, hydroxy, amino, C1-6 alkylamino, cyano, isocyano, isocyanato, and isothiocyanato substituents,
providing where R3 is H, m=2 and at least one R4 is halogen, the at least one R4 that is halogen is mew or ortho to the C—O bond; and
providing where R3 is H, m=1, and R4 is bromine, R4 is meta to the C—O bond.

US Pat. No. 10,167,261

2-OXO-3,4-DIHYDROQUINOLIN-6-YL SULPHONAMIDE CPDS AND THEIR USE AS PLANT GROWTH REGULATORS

THE REGENTS OF THE UNIVER...

1. A compound of Formula (I):
wherein:
R1 is selected from hydrogen, alkyl, cyano-alkyl, haloalkyl, alkoxy-alkyl, haloalkoxy-alkyl, cycloalkyl-alkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, and heterocycloalkyl; or
R1 is selected from alkyl-aryl, cycloalkyl, phenyl and heteroaryl, each optionally substituted with one to three Rx;
each Rx is independently selected from halogen, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfanyl, haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl and cycloalkyl;
R2a, R2b, R3a, R3b, R4, R5 and R6 are independently selected from hydrogen, halogen, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy and cycloalkyl;
R2a and R2b, or R2a and R3a, together with the atom to which they are attached, are optionally joined to form a cycloalkyl;
L is selected from alkyl, alkenyl, alkoxy and alkoxy-alkyl, each optionally substituted with one to three moieties independently selected from halogen, cyano, alkyl and alkoxy;
A is cycloalkyl optionally substituted with one to four Ry;
each Ry is independently selected from halogen, cyano, nitro, alkyl, haloalkyl, —OH, alkoxy, haloalkoxy, alkylsulfanyl, haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, cycloalkyl, ?O, ?N—OH, —N?OMe, COOH, COOR9, CONHR9, CONR9aR9 and NHCOR9,
with the proviso that when one or more Ry is ?O, ?N—OH or —N?OMe, A is not C3 cycloalkyl;
R9 and R9a are independently alkyl;
each R8 is independently selected from hydrogen, halogen, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfanyl, haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl and alkoxy-alkyl;
n is selected from 1, 2, and 3;
or salts or N-oxides thereof.

US Pat. No. 10,167,260

2-AMINOPYRIDINE-BASED SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS

Northwestern University, ...

1. A compound selected from compounds of a formulawherein X is selected from N and CH; L is selected from (OCH2)n and CH2NH(CH2)n moieties, and n is an integer selected from 1-3; and R1 is selected from amino, pyridin-2-yl, pyridin-4-yl, piperidin-4-yl, phenyl, fluorophenyl and chlorophenyl moieties, and salts thereof.

US Pat. No. 10,167,259

ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF

The Board of Regents of t...

1. A compound of the formula:wherein:A1 is

wherein:
A2 is —O—;
A3 is alkanediyl(C?6), alkenediyl(C?6), or a substituted version of either of these groups;
R2 is

wherein:
Y1, Y5, Y6, Y7, Y8, and Y9 are each independently hydrogen, hydroxy, phosphate, halo, alkyl(C?12), alkoxy(C?12), acyloxy(C?12), heteroaryl(C?12), acyl(C?12), alkylamino(C?12), dialkylamino(C?12), or a substituted version of any of these groups, and Y2 and Y4 are alkoxy(C?12) or substituted alkoxy(C?12), and Y3 is alkoxy(C<12);
R3 is hydrogen, alkyl(C?8), or a substituted alkyl(C?8); and
R1 is

wherein:
X6 is hydrogen or hydroxy;
X7 is O, NH, or C(R5)2;
X8 is hydrogen, hydroxy, phosphate, halo, alkyl(C?6), alkoxy(C?6), acyloxy(C?6), heteroaryl(C?12), acyl(C?6), alkylamino(C?6), dialkylamino(C?6), or a substituted version of any of these groups;
X9, X10, X11, and R5 are each independently hydrogen, hydroxy, phosphate, halo, alkyl(C?12), alkoxy(C?12), acyloxy(C?12), heteroaryl(C?12), acyl(C?12), alkylamino(C?12), dialkylamino(C?12), or a substituted version of any of these groups.

US Pat. No. 10,167,258

INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF

The Board of Regents of t...

1. A compound of the formula:
wherein:
X1 is hydrogen, halogen, hydroxy, amino, cyano, nitro, or oxo, or alkyl(C?12), alkenyl(C?12), alkynyl(C?12), aryl(C?18), aralkyl(C?18), heterocycloalkyl(C?12), heteroaryl(C?12), acyl(C?12), —C(O)-alkoxy(C?12), alkoxy(C?12), alkenyloxy(C?12), alkynyloxy(C?12), aryloxy(C?18), aralkyloxy(C?18), heterocycloalkyloxy(C?12), heteroaryloxy(C?12), acyloxy(C?12), alkylamino(C?12), dialkylamino(C?12), alkenylamino(C?12), alkynylamino(C?12), arylamino(C?18), aralkylamino(C?18), heterocycloalkylamino(C?12), heteroarylamino(C?12), amido(C?12), -arenediyl(C?6)-heteroaryl(C?12), or a substituted version of any of these groups, or is taken together with X6 as defined below;
X2 and X5 are each independently hydrogen, hydroxy, nitro, cyano, or amino, or
alkyl(C?12), alkenyl(C?12), alkynyl(C?12), aryl(C?18), aralkyl(C?18), heterocycloalkyl(C?12), heteroaryl(C?12), acyl(C?12), alkoxy(C?12), alkenyloxy(C?12), alkynyloxy(C?12), aryloxy(C?18), aralkyloxy(C?18), heterocycloalkyloxy(C?12), heteroaryloxy(C?12), acyloxy(C?12), alkylthio(C?12), alkenylthio(C?12), alkynylthio(C?12), arylthio(C?18), aralkylthio(C?18), heterocycloalkylthio(C?12), heteroarylthio(C?12), acylthio(C?12), alkylamino(C?12), dialkylamino(C?12), alkenylamino(C?12), alkynylamino(C?12), arylamino(C?18), aralkylamino(C?18), heterocycloalkylamino(C?12), heteroarylamino(C?12), amido(C?12), -alkanediyl(C?6)-heterocycloalkyl(C?12), or a substituted version of any of these groups; or

wherein:
R is hydrogen; or
alkyl(C?12), alkenyl(C?12), acyl(C?12), aryl(C?12), aralkyl(C?12), or a substituted version of any of these groups;
X3 and X4 are each independently hydrogen, hydroxy, or amino, or
alkoxy(C?12), alkenyloxy(C?12), alkynyloxy(C?12), aryloxy(C?18), aralkyloxy(C?18), heterocycloalkyloxy(C?12), heteroaryloxy(C?12), acyloxy(C?12), alkylamino(C?12), dialkylamino(C?12), alkenylamino(C?12), alkynylamino(C?12), arylamino(C?18), aralkylamino(C?18), heterocycloalkylamino(C?12), heteroarylamino(C?12), amido(C?12), -alkanediyl(C?6)-heterocycloalkyl(C?12), or a substituted version of any of these groups; or

wherein:
R is hydrogen; or
alkyl(C?12), alkenyl(C?12), acyl(C?12), aryl(C?12), aralkyl(C?12), or a substituted version of any of these groups;
X6 is hydrogen, halogen, hydroxy, amino, nitro, or cyano, or
alkyl(C?12), alkenyl(C?12), alkynyl(C?12), aryl(C?18), aralkyl(C?18), heterocycloalkyl(C?12), heteroaryl(C?12), acyl(C?12), alkoxy(C?12), alkenyloxy(C?12), alkynyloxy(C?12), aryloxy(C?18), aralkyloxy(C?18), heterocycloalkyloxy(C?12), heteroaryloxy(C?12), acyloxy(C?12), alkylamino(C?12), dialkylamino(C?12), alkenylamino(C?12), alkynylamino(C?12), arylamino(C?18), aralkylamino(C?18), heterocycloalkylamino(C?12), heteroarylamino(C?12), or amido(C?12), or a substituted version of any of these groups, or is taken together with X1 as defined below;
Y1, Y2, Y3, Y4, and Y5 are each independently hydrogen, amino, cyano, halo, hydroxy, or nitro, or
alkyl(C?12), alkenyl(C?12), alkynyl(C?12), aryl(C?12), aralkyl(C?12), heteroaryl(C?12), heterocycloalkyl(C?12), acyl(C?12), or a substituted version of any of these groups;
X1 and X6 when taken together have the formula:

wherein:
X1? and X6? are each independently hydrogen, hydroxy, halo, or amino;
alkyl(C?12), alkenyl(C?12), alkynyl(C?12), aryl(C?12), aralkyl(C?12), heteroaryl(C?12), acyl(C?12), or a substituted version of any of these groups;
provided that at least one of Y1, Y2, Y3, Y4, or Y5 are hydroxy or alkoxy(C?12) and that X2, X3, X4, and X5 are not all hydrogen, or that when X1 is oxo then X6 is not aryl(C?8);
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,167,257

INDOLE DERIVATIVES FOR USE IN MEDICINE

Iomet Pharma Ltd., Midlo...

1. A compound of the following formula, or a pharmaceutically acceptable salt thereof:wherein:each of R1, R2, R3 and R4 is independently selected from H, halogen, —CN, C1-C6 alkyl, C1-C6 halogenated alkyl, —OH, C1-C7 alkoxy, —O—CF3, —C(O)—NH2, —C(O)—NHMe, NH—SO2Me, NH—SO2Et, —NH—SO2Pr, and —NH—SO2iPr;
R5 is H;
R7 is selected from H and C1-C6 alkyl;
R61 is selected from H and C1-C6 alkyl;
R65 is a heterocyclic group selected from pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, tetrazol-1-yl, tetrazol-2-yl, and tetrazol-5-yl; each of which is optionally substituted with one to three substituents independently selected from halogen, methyl, ethyl, propyl, —C(O)-methyl, —S(O)2-methyl and phenyl; and
R63 and R64 together form a 3-6 membered carbocyclic or heterocyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, tetrahydrofuranyl and tetrahydropyranyl.

US Pat. No. 10,167,256

PSYCHOTROPHIC AGENTS AND USES THEREOF

LB PHARMACEUTICALS INC., ...

1. A compound of Formula I:
including pharmaceutically acceptable salts and stereoisomers thereof, wherein:
R1 is

 and
X and Z are the same or different and independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroarylalkyl, and heteroaryl, optionally the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroarylalkyl, and heteroaryl groups are further substituted with one or more substitution groups selected from the group consisting of halogens, chlorine, bromine, fluorine, amines, hydroxy groups, carboxylic acids, nitro groups, carbonyl and other alkyl and aryl groups as defined herein; with the proviso that at least one of X and Z is not hydrogen.

US Pat. No. 10,167,255

PROCESS FOR PREPARING AMINES

STUDIENGESELLSCHAFT KOHLE...

1. A process for preparing an amine of formula I comprising reductive amination of a carbonyl compound of the formula II with an amine compound of the formula III and carbon monoxide as reductant in the presence of a catalyst and without introducing hydrogen (H2) from an external hydrogen source to yield said amine of formula I:
wherein:
R1 and R2 are each independently hydrogen or a substituent selected from the group consisting of C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, aryl, C1-C20 carboxylate, C1-C20 alkoxy, C2-C20 alkenyloxy, C2-C20 alkynyloxy, aryloxy, C2-C20 alkoxycarbonyl, C1-C20 alkylthiol, arylthiol, C1-C20 alkylsulfonyl, and C1-C20 alkylsulfinyl, each of which is optionally substituted with one or more moieties selected from the group consisting of C1-C10 alkyl, C1-C10 alkoxy, aryl, and one or more functional groups selected from the group consisting of hydroxyl, thiol, thioether, ketone, aldehyde, ester, ether, amine, imine, amide, nitro, carboxylic acid, disulfide, carbonate, isocyanate, carbodiimide, carboalkoxy, carbamate, and halogen, wherein at least one of R1 and R2 is not hydrogen; and
R3 and R4 are each independently hydrogen or a substituent selected from the group consisting of C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, aryl, C1-C20 carboxylate, C1-C20 alkoxy, C2-C20 alkenyloxy, C2-C20 alkynyloxy, aryloxy, C2-C20 alkoxycarbonyl, C1-C20 alkylthiol, arylthiol, C1-C20 alkylsulfonyl, and C1-C20 alkylsulfinyl, each of which is optionally substituted with one or more moieties selected from the group consisting of C1-C10 alkyl, C1-C10 alkoxy, aryl, and one or more functional groups selected from the group consisting of hydroxyl, thiol, thioether, ketone, aldehyde, ester, ether, amine, imine, amide, nitro, carboxylic acid, disulfide, carbonate, isocyanate, carbodiimide, carboalkoxy, carbamate, and halogen, wherein at least one of R3 and R4 is not hydrogen.

US Pat. No. 10,167,254

IDO INHIBITORS

Bristol-Myers Squibb Comp...

1. A method for treating a cancer that is melanoma, lung cancer, head cancer, neck cancer, renal cell carcinoma, or bladder cancer in a human in need of such treatment comprising administering to said human a therapeutically effective amount of a compound according to formula (I)
wherein:
Y is N, CH or CF;
V is N, CH or CF;
R1 is —COOH, —COOC1-C6 alkyl, —CONH2, —CN, optionally substituted 5 or 6 membered heterocyclyl having 1-4 ring vertices independently selected from O, N, S, 5 or 6 membered optionally substituted heteroaryl having 1-4 ring vertices independently selected from O, N, S, —NHCONHR13, —CONHSO2R14, —CONHCOR13, —SO2NHCOR13, —CONR13, —CONHSO2NR13R14, —SO2NHR13, —NHCONHSO2R13, —CHCF3OH, —COCF3, —CR2R3OH, or —NHSO2R13;
R13 is H, optionally substituted C1-C10 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, optionally substituted 5-6 membered heterocyclyl having 1-4 ring vertices independently selected from O, N, S, optionally substituted phenyl, or optionally substituted 5-6 membered heteroaryl having 1-4 ring vertices independently selected from O, N, S;
R14 is H, optionally substituted C1-C10 alkyl, phenyl, or C3-8 cycloalkyl;
R2 and R3 are independently -hydrogen, optionally substituted C1-C10 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted phenyl; or
R2 and R3 are taken together with the carbon to which they are attached to form an optionally substituted 3- to 6-membered carbocyclic or heterocyclic ring;
R4 and R5 are independently H, optionally substituted C1-C10 alkyl, optionally substituted C1-C10-alkoxy-C1-C10-alkyl, optionally substituted C1-C10 alkoxy, optionally substituted aryl, optionally substituted aryl-C1-C10-alkyl, optionally substituted 5- to 8-membered heteroaryl containing 0-3 heteroatoms selected form N, S and O, optionally substituted C3-C8 cycloalkyl or optionally substituted heterocyclyl containing 0-3 heteroatoms selected form N, S and O; or
R4 and R5 are taken together with the nitrogen to which they are attached to form a 4- to 8-membered optionally substituted heterocyclic ring containing 0-3 additional heteroatoms selected from —N—, —S— and —O—; or
R4 and R5 are taken together with the nitrogen to which they are attached to form a 6- to 10-membered optionally substituted heterobicyclic ring containing 0-3 additional heteroatoms selected from —N—, —S—, and —O—;
R6 is optionally substituted 5 or 6 membered aryl, optionally substituted 5 or 6 membered heteroaryl having 1 to 4 ring vertices independently selected from O, N, S, optionally substituted C3-C8 cycloalkyl optionally substituted 9 to 10 membered fused bicyclic heterocyclyl having 1 to 4 ring vertices independently selected from O, N, S, 9 to 10 membered fused bicyclic heteroaryl having 1 to 4 ring vertices independently selected from O, N, S or —COR7;
R7 is optionally substituted —CR2R3-5 or 6 membered aryl, optionally substituted —CR2R3-5 or 6 membered heteroaryl, —CR2R3-3 to 6 membered heterocyclyl, optionally substituted 5 or 6 membered aryl, optionally substituted 5 or 6 membered heteroaryl, optionally substituted C3-C8 cycloalkyl, or optionally substituted 3 to 6 membered heterocyclyl; and
Rx and Ry are each independently H, optionally substituted C1-C10 alkyl, optionally substituted C1-C10 alkoxy, or optionally substituted C3-C8 cycloalkyl; or
Rx and Ry are taken together with the carbon to which they are attached to form a 3- to 7-membered heterocyclic ring containing 0-3 additional heteroatoms selected from —N—, —S— and —O—;
and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,167,253

IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF

Nitto Denko Corporation, ...

1. A compound comprising the structure shown in Formula I
wherein R1 and R2 are
R1=CH2(CH2)nOC(?O)R4
R2=CH2(CH2)mOC(?O)R5
wherein n and m are each independently from 1 to 2; and R4 and R5 are independently for each occurrence a C(12-20) alkyl group, or a C(12-20) alkenyl group;
wherein R3 is selected from

wherein
each R6 is independently selected from H, alkyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkoxy, and aminoalkyl;
each R7 is independently selected from H, alkyl, hydroxyalkyl, and aminoalkyl;
Q is O or NR7.

US Pat. No. 10,167,252

COMPOUNDS AND MIXTURES WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SUCH COMPOUNDS

Eastman Chemical Company,...

1. An antidegradant compound represented by formula I:
wherein each X is independently selected from the group consisting of ethyl, methyl, or hydrogen.

US Pat. No. 10,167,250

PROCESS FOR THE PREPARATION OF 2-(TRIHALOMETHYL) BENZAMIDE

SRF Limited, Gurgaon (IN...

1. A process for the preparation of 2-(trihalomethyl) benzamide of Formula I,
wherein X is selected from the group consisting of fluorine, chlorine, bromine and iodine; and R is hydrogen or substituted/unsubstituted C1-C7 alkyl group, said process comprising:
a) reacting a reaction mixture consisting of a compound of Formula II with a compound of Formula III in iso-propanol to obtain the compound of Formula I; and

wherein X is selected from the group consisting of fluorine, chlorine, bromine and iodine; and R is hydrogen or substituted/unsubstituted C1-C7 alkyl group,
b) isolating the compound of Formula I formed in (a).

US Pat. No. 10,167,249

AMINO AND IMINO PROPIONIC ACIDS, PROCESS OF PREPARATION AND USE

INSTITUTO MEXICANO DEL PE...

1. A corrosion inhibiting composition including a corrosion inhibiting compound consisting of N-alkenyl amine or imino propionic acid of structural formula:where R is a linear or branched alkenyl chain having 1 to 30 carbon atoms, R1 is a radical represented by —H or —CH3 and R2 is —H.

US Pat. No. 10,167,246

PREPARATIVE METHOD FOR CARBOXYLIC ACIDS

ZHEJIANG ZHUJI UNITED CHE...

1. A preparative method for carboxylic acids, wherein compounds (II) are reacted in the presence of hydrogen peroxide and base to produce target products (I), the reaction scheme is shown as below:
wherein R1 is an aryl, a pyridyl, a pyrimidyl, a pyridazinyl, a pyrazinyl, a benzothienyl, a benzofuranyl, a quinolinyl, an isoquinolinyl, a thiadiazolyl, a C1-6 alkyl, a C3-6 cycloalkyl, a C2-6 alkenyl, or C2-6 alkynyl; R2 is an alkoxycarbonyl, an alkylaminocarbonyl, an aminocarbonyl, an alkylthiolcarbonyl, a cyano, a sulfonyl, a sulfinyl, an aldehyde, or a nitro, R3 is an alkoxycarbonyl, an alkyl amido carbonyl, an aminocarbonyl, a cyano, a sulfonyl, a sulfinyl, or a nitro.

US Pat. No. 10,167,245

METHOD FOR HYDROFORMYLATING CYCLOOCTADIENE USING 4-([1,1?:3?,1?-TERPHENYL]-2?-YLOXY)-S-DINAPHTHO[2,1-D:1?,2?-F][1,3,2]DIOXAPHOSPHEPINE

EVONIK DEGUSSA GMBH, Ess...

1. A method for hydroformylating cyclooctadiene, comprising the method steps of:a) initially charging cyclooctadiene;
b) adding a complex comprising:
a metal atom selected from: Rh, Ru, Co, Ir, and
a ligand having the structure (1):

or
adding a precursor complex comprising a metal atom selected from: Rh, Ru, Co, lr, and a compound having the structure (1):

c) feeding in H2 and CO,
d) heating the reaction mixture, wherein the cyclooctadiene is converted to an aldehyde.

US Pat. No. 10,167,244

METHOD FOR HYDROFORMYLATING CYCLOOCTADIENE USING 2-(ANTHRACEN-9-YLOXY)-4,4,5,5-TETRAMETHYL-1,3,2-DIOXAPHOSPHOLANE

EVONIK DEGUSSA GMBH, Ess...

1. A method for hydroformylating cyclooctadiene, comprising the method steps of:a) initially charging cyclooctadiene;
b) adding a complex comprising:
a metal atom selected from: Rh, Ru, Co, Ir, and
a ligand having the structure (1):

or
adding a precursor complex comprising a metal atom selected from: Rh, Ru, Co, Ir, and a compound having the structure (1):

c) feeding in H2 and CO,
d) heating the reaction mixture, wherein the cyclooctadiene is converted to an aldehyde.

US Pat. No. 10,167,243

BIOMASS CONVERSION PROCESS TO HYDROCARBONS

SHELL OIL COMPANY, Houst...

1. A process for the production of a higher hydrocarbon from solid biomass, said process comprising:a. providing a biomass solid containing cellulose, hemicellulose, and lignin;
b. digesting and hydrodeoxygenating the biomass solid in a liquid digestive solvent in the presence of a hydrothermal hydrocatalytic catalyst and hydrogen at a temperature in a range of 110° C. to less than 300° C. and at a pressure in a range of from 20 bar to 200 bar, said liquid digestive solvent containing a solvent mixture having a boiling point of at least 40° C., to form a stable oxygenated hydrocarbon intermediate product having a viscosity of less than 100 centipoise (at 50° C.), a diol content of at least 2 wt. %, less than 2 wt. % of sugar, and less than 2 wt. % acid (based on acetic acid equivalent), based on the stable oxygenated hydrocarbon intermediate product, and at least 60% of carbon in the stable oxygenated hydrocarbon intermediate product exists in molecules having 9 carbon atoms or less;
c. separating the stable oxygenated hydrocarbon intermediate product to an organic rich phase and an aqueous rich phase;
d. reacting at least a portion of the aqueous rich phase with an acidic amorphous silica alumina catalyst at a temperature in a range from 300° C. to 400° C. to convert diol in the aqueous rich phase into monooxygenate compounds thereby producing monooxygenate-containing stream comprising water, organic monooxygenates, and unsaturated aliphatic hydrocarbons;
e. contacting at least a portion of the monooxygenate-containing stream with a solid acid condensation catalyst at a temperature in a range from 275° C. to about 425° C. thereby producing a first higher hydrocarbons stream; and
f. contacting at least a portion of the organic rich phase with a solid acid condensation catalyst at a temperature in a range from 275° C. to about 425° C. thereby producing a second higher hydrocarbons stream.

US Pat. No. 10,167,242

PROCESS FOR PREPARING A C3-C7 (HYDRO) FLUOROALKENE BY DEHYDROHALOGENATION

Mexichem Amanco Holding S...

1. A process for preparing a C3-7 (hydro)fluoroalkene comprising dehydrohalogenating a C3-7 hydro(halo)fluoroalkane in the presence of a catalyst consisting of a metal oxide supported on alumina, wherein the catalyst has a sodium content of less than about 800 ppm, wherein the metal of the metal oxide is a transition metal selected from the group consisting of Cr, Nb, Ta, V, Mo, or Co and optionally wherein the catalyst further contains at least one additional metal selected from the group consisting of Zn, Cr, In, Co and mixtures thereof.

US Pat. No. 10,167,241

TWO-BED PARAFFIN TO OLEFIN ENHANCEMENT PROCESS

UOP LLC, Des Plaines, IL...

1. A process for the removal of heavy aromatics from an olefins stream comprising:passing an olefins feed stream to a first adsorbent unit in two unit adsorbent system to generate a first adsorbent effluent stream with reduced heavy aromatics content;
running the first adsorbent unit until breakthrough;
equalizing pressure in a second adsorbent unit to the pressure of the first adsorbent unit;
passing the olefins feed stream to the second adsorbent unit to generate a second adsorbent unit effluent stream with reduced heavy aromatics content;
passing the second adsorbent unit effluent stream to the first adsorbent unit, displacing the fluid in the first adsorbent unit;
discontinuing the first adsorbent unit displacement and moving the first adsorbent unit off-line and the second adsorbent unit on-line;
performing a trim displacement of the first adsorption unit following the first adsorption unit displacement;
passing regenerant to the first adsorbent unit to regenerate the first adsorbent unit, wherein the regenerant flows in a co-current direction relative to the olefin feed stream through the first adsorbent unit;
equalizing the in the first adsorbent unit to the pressure of the second adsorbent unit;
passing the olefins feed stream to the first adsorbent unit to generate the first adsorbent unit effluent stream;
passing the first adsorbent unit effluent stream to the second adsorbent unit, displacing the fluid in the second adsorbent unit;
discontinuing the second adsorbent unit displacement and moving the second adsorbent unit off-line and the first adsorbent unit on-line;
performing a trim displacement of the second adsorption unit following the second adsorption unit displacement; and
passing regenerant to the second adsorbent unit to regenerate the second adsorbent unit, wherein the regenerant flows in a co-current direction relative to the olefin feed stream through the first adsorbent unit.

US Pat. No. 10,167,240

METHOD AND APPARATUS FOR SOLUBILIZING HUMIC ACID GRANULES

Humic Growth Solutions, I...

1. A method of reconstituting humic acid in solid form as an aqueous solution, comprising the steps of:forming a mixture comprising water and naturally occurring, solid humic acid in a fixed-dimension tank having inlet structure and an outlet, a fixed volume of at least about 300 gallons, and a lower section with said outlet being adjacent the bottom of the lower section,
said mixture-forming step comprising the steps of introducing solid, naturally occurring humic acid in the form of granules and/or powders through said inlet structure and into the confines of said tank, and also introducing water through the inlet structure into the confines of said tank;
forming said aqueous solution by continuously recirculating said mixture from said outlet and to said inlet structure using a recirculation assembly, and agitating said mixture using a motor-driven mixing shaft extending into the confines of the tank, said recirculation assembly including a pump equipped with an impeller and capable of recirculating said mixture at a rate of at least about 125 gallons per minute from said outlet to said inlet structure, and
allowing said mixture to reside within said tank for a residence time of at least about 2 minutes during said recirculation step; and
recovering a solution of humic acid which resists undue sedimentation for at least about 3 days.

US Pat. No. 10,167,239

PELLETED FEATHER MEAL AND SOYBEAN MEAL BASED ORGANIC FERTILIZER

True Organic Products, In...

1. A pelleted feather meal, soybean meal, and meat and bone meal based organic fertilizer product, wherein the pelleted feather meal, soybean meal, and meat and bone meal based organic fertilizer product is produced from a process including:obtaining a quantity of feather meal;
obtaining a quantity of soybean meal;
obtaining a quantity of meat and bone meal;
combining at least part of the quantity of the feather meal, at least part of the quantity of the soybean meal, and at least part of the quantity of meat and bone meal to create a combination of feather meal, soybean meal, and meat and bone meal, where the combination of feather meal and soybean meal is at least 70% of the entire combination; and
processing the combination of feather meal, soybean meal, and meat and bone meal to create a pelletized blend feather meal and soybean meal based organic fertilizer product.

US Pat. No. 10,167,237

PROCESS AND A PLANT FOR OXIDATIVE BIOSTABILIZATION OF CITRUS PULP

12. A system for oxidative biostabilization of citrus pulp, said system comprising:a mixer having a configuration capable of mixing a mass of fresh pulp with a mass of active biostabilized pulp to obtain a reaction mixture;
a first open-chamber reactor having a configuration capable of oxidative biostabilization in air of the reaction mixture, said first reactor being provided with a first inlet end in communication with said mixer and a second end for outlet of active biostabilized pulp;
a mechanical blade turner associated within said reactor, said turner having a configuration capable of feeding the reaction mixture along said reactor between said first end and said second end;
a blower having a configuration capable of blowing air into said first reactor from beneath; and
a mechanical movement device having a configuration capable of transferring a partial mass of the active biostabilized pulp from an intermediate area of said first reactor or an area downstream of said second end, to an area upstream of said mixer.

US Pat. No. 10,167,236

METHOD FOR PROVIDING AN INORGANIC COATING TO AMMONIUM NITRATE-BASED PARTICLES

YARA INTERNATIONAL ASA, ...

20. A method for reducing caking of an ammonium nitrate-based fertilizer, the method comprising applying the inorganic coating according to 13 on a particulate ammonium nitrate-based fertilizer.

US Pat. No. 10,167,235

JOINED BODY AND METHOD FOR PRODUCING THE SAME

NGK Insulators, Ltd., Na...

1. A joined body, comprising:a porous ceramic;
a metal member; and
a joint of an oxide ceramic that penetrates into pores of the porous ceramic and joins the porous ceramic to the metal member,
wherein a penetration depth of the oxide ceramic into the ores of the porous ceramic is 10 ?m or more.

US Pat. No. 10,167,234

METHOD OF MAKING AN ALUMINA-SILICATE OXYNITRIDE AND CUBIC BORON NITRIDE CERAMIC COMPOSITE

King Fahd University of P...

1. A method for producing a composite of cubic boron nitride (cBN) dispersed in a SiAlON ceramic, the method comprising:mixing
silicon nitride nanoparticles,
aluminum nitride nanoparticles,
silica nanoparticles,
calcium oxide nanoparticles, and
cubic boron nitride (cBN) microparticles to produce a mixture, and
sintering the mixture to produce the composite.

US Pat. No. 10,167,226

ANTI-STATIC AGENT FOR GLASS FIBER INSULATION

Johns Manville, Denver, ...

1. A composition comprising:ground glass fiber trimmings, wherein the ground glass fiber trimmings are formed from trimming edges of a batt or roll formed from glass fibers;
a polyether antistatic agent, wherein the polyether antistatic agent has a molecular weight of less than about 2000; and
a dedusting agent, wherein the dedusting agent comprises less than 0.3% by weight of the composition.

US Pat. No. 10,167,225

SUBSTRATE PROVIDED WITH A STACK HAVING THERMAL PROPERTIES AND A SUBSTOICHIOMETRIC INTERMEDIATE LAYER

SAINT-GOBAIN GLASS FRANCE...

1. A substrate coated on one face with a thin-films stack having reflection properties in the infrared and/or in solar radiation comprising a single metallic functional layer and two antireflection coatings, said coatings each comprising at least one dielectric layer, said functional layer being positioned between the two antireflection coatings wherein at least one of said antireflection coatings comprises an intermediate layer, which is an absorbent layer comprising zinc tin oxide SnxZnyOz with a ratio of 0.1?x/y?2.4 with 0.75(2x+y)?z?0.95(2x+y), and having a physical thickness of between 2 nm and 25 nm.

US Pat. No. 10,167,223

PREPARATION METHOD OF DOPED VANADIUM DIOXIDE POWDER

SHANGHAI INSTITUTE OF CER...

1. A hydrothermal method for preparing a doped vanadium dioxide powder, the method comprising:a step of titrating a quadrivalent vanadium aqueous solution having a V4+ ion concentration between 0.005 and 0.5 mol/L with a basic reagent selected from the group consisting of ammonia, sodium hydroxide, potassium hydroxide, soda ash, sodium bicarbonate, potassium carbonate solution, potassium bicarbonate and combinations thereof, and at a mole ratio of the basic reagent to the quadrivalent vanadium ion V4+ aqueous solution from 1:50 to 10:1, to obtain a precursor suspension having a chemical composition of V4H6O10;
a step of mixing the precursor suspension with a doping agent in a hydrothermal reactor; and
a step of a hydrothermal reaction to obtain the doped vanadium oxide powder, wherein:
the doped vanadium oxide powder has a chemical composition of V1-xMxO2, 0 the doped vanadium oxide powder is in particle form of particles that have an aspect ratio of 1:1-10:1, and
the particles have a particle size of no more than 100 nm in at least one dimension.

US Pat. No. 10,167,221

PREFINING APPARATUS FOR CONDITIONING GLASSES

Corning Incorporated, Co...

1. A glass prefiner comprising:a molten glass holding chamber having a top portion, a bottom portion, and an enclosing sidewall;
a foam breaker having a head and a stein, the head configured to engage glass foam within the chamber; and
an exit conduit having a first opening, a second opening, and an intermediate passage, the first opening positioned in a lower section of the chamber to be immersed in molten glass below the glass foam and the second opening positioned in an upper section of the chamber to be above the glass foam, the exit conduit defining a space above the second opening between the exit conduit and the top portion of the chamber;
wherein the top portion of the chamber includes a third opening configured to accommodate the stem of the foam breaker, the stem of the foam breaker inserted in the third opening to provide foam-breaking movement to the head of the foam breaker within the chamber;
wherein the sidewall includes an inlet configured to receive molten glass from a molten glass source and an outlet configured to discharge prefined molten glass; and
wherein the exit conduit is in fluid communication with the outlet such that only prefined molten glass passing through the exit conduit at the first opening may be discharged through the outlet.

US Pat. No. 10,167,220

METHOD AND APPARATUS FOR ADDING THERMAL ENERGY TO A GLASS MELT

Corning Incorporated, Co...

1. A method for fining molten glass comprising:introducing a gas into an apparatus for generating a thermal plasma by a radio frequency (RF) electromagnetic field, the apparatus comprising:
an electrode,
a grounded electrode,
a dielectric plasma confinement vessel extending between the electrode and the grounded electrode,
a magnetic field generator extending around the dielectric plasma confinement vessel,
an inlet for delivering a gas into the dielectric plasma confinement vessel,
an RF current source to create the RF electromagnetic field for converting the gas into a thermal plasma, and
an outlet for delivering the thermal plasma,
introducing molten glass into a fining vessel; and
contacting the molten glass with the thermal plasma.

US Pat. No. 10,167,219

ECOLOGICAL BIOWATER PURIFICATION SYSTEM

1. An ecological biowater purification system comprising at least one water purification tank that comprises:a water inlet that admits a water flow into each water purification tank of the at least one water purification tank;
a water outlet that discharges the water flow from each water purification tank of the at least one water purification tank;
a water purification device comprising a plurality of water purification pools that communicate with one another and that include:
a sedimentation pool that communicates with the water inlet;
an anaerobic pool that communicates with the sedimentation pool;
an anoxic pool that communicates with the anaerobic pool;
a level-1 biological filter pool that communicates with the anoxic pool; and
a level-2 biological filter pool that communicates with the level-1 biological filter and that communicates with the water outlet, each pair of adjacent water purification pools of the plurality of water purification pools having a baffle board and communication hole combination to facilitate communication with one another, each water purification pool of the water purification pools being provided with a carrier that contains a stuffing material for water purification and that is configured to be replaceable;
a suction device that comprises a plurality of suction nozzles, each suction nozzle of the plurality of suction nozzles being disposed on a respective bottom of each water purification pool; and a plurality of suction pipes, each suction pipe of the plurality of suction pipes being connected to one suction nozzle of the plurality of suction nozzles so as to discharge precipitates out of a respective water purification pool of the at least one water purification pools;
a first backflow device including a water pump connected between the level-2 biological filter pool and the sedimentation pool to cause a portion of water contained in the level-2 biological filter pool to flow back to the sedimentation pool; and
a second backflow device including a water pump connected between (1) the level-1 biological filter pool and the level-2 biological filter pool and (2) the anaerobic pool to cause a portion of water contained in the level-1 biological filter pool and in the level-2 biological filter pool to flow back to the anaerobic pool,
wherein, when the at least one water purification tank comprises more than one water purification tank, the outlet of one water purification tank is connected to the inlet of another water purification tank.

US Pat. No. 10,167,218

PRODUCTION OF ULTRA-HIGH-DENSITY BRINES

Gradiant Corporation, Wo...

1. A method for forming concentrated brine, comprising:supplying a saline water input stream comprising an amount of suspended solids to a suspended solids removal apparatus;
removing, within the suspended solids removal apparatus, at least a portion of the suspended solids from the saline water input stream to produce a suspended-solids-diminished stream having a lower amount of suspended solids relative to the saline water input stream and a suspended-solids-enriched stream having a higher amount of suspended solids relative to the saline water input stream;
supplying at least a portion of the suspended-solids-enriched stream to a filtration apparatus and removing at least a portion of liquid within the suspended-solids-enriched stream to form a filter cake; and
adding an acid to the filter cake to form a brine solution comprising a dissolved salt and having a density of at least 9 pounds/gallon.

US Pat. No. 10,167,217

PROCESS FOR INDUSTRIAL PRODUCTION OF SEA WATER BASICALLY SUITABLE FOR FOOD USE

STERALMAR SRL, Bisceglie...

1. A process for industrial production of sea water suitable for alimentary use, comprising the following steps:A) drawing sea water and decanting the sea water to obtain decanted sea water;
B) filtering the decanted sea water to obtain a filtered sea water;
C) sterilizing the filtered sea water to obtain a purified sea water;
D) abating boron content in the purified sea water to obtain a sea water with a boron content of less than one milligram per liter;
E) filtering the sea water with a boron content of less than one milligram per liter to obtain a filtered sea water with a boron content of less than one milligram per liter;
F) sterilizing the filtered sea water with a boron content of less than one milligram per liter to obtain a sea water suitable for alimentary use;
G) continuously analysing, examining, and checking of the purified sea water obtained in step C), the sea water with a boron content of less than one milligram per liter in step D), and the sea water suitable for alimentary use in step F), to guarantee that the obtained sea water suitable for alimentary use is purified, filtered, and, hence, free from any pathogenic agent; and
H) storing in tanks or bottling the sea water suitable for alimentary use.

US Pat. No. 10,167,216

HIGH EFFICIENCY WASTEWATER TREATMENT SYSTEM

Gregory D. Graves, Milan...

1. A wastewater treatment plant comprising:a wastewater treatment tank including a top wall, a bottom wall, a front wall, a back wall, a left side wall and a right side wall, the front wall, the back wall, the left side wall and the right side wall being connected together along respective sides and at respective top ends around a bottom side perimeter of the top wall and at respective bottom ends to a top side perimeter of the bottom wall, and having a plurality of interior walls extending between the top, bottom, left side and right side walls and defining a plurality of chambers within the wastewater treatment tank, the plurality of chambers including
a pretreatment chamber having an inlet formed in and extending through a front wall of the pretreatment chamber and the inlet being positioned adjacent to a first side wall and a top end of the front wall of the pretreatment chamber, a pretreatment chamber outlet formed in and extending through a back wall of the pretreatment chamber and adjacent to an opposite side wall and a top end of the back wall of the pretreatment chamber, and a pretreatment chamber access opening formed in and extending through a top wall of the pretreatment chamber;
an anoxic chamber including an anoxic chamber inlet sealingly coupled to and configured for fluid communication with the pretreatment chamber via the pretreatment chamber outlet, an anoxic chamber outlet formed in and extending through a back wall of the anoxic chamber, the back wall being opposite the back wall of the pretreatment chamber;
an aeration chamber including an aeration chamber inlet sealingly coupled to and configured for fluid communication with the anoxic chamber via the anoxic chamber outlet, an aeration chamber outlet opening formed in and near a bottom of a back wall of the aeration chamber opposite the aeration chamber inlet, an aeration chamber access opening formed in and extending through a top wall of the aeration chamber, an aeration chamber riser mounted on the top wall of the aeration chamber and surrounding and covering the aeration chamber access opening, an air pump positioned above the aeration chamber access opening, and a diffusion bar positioned near a bottom of the aeration chamber and attached to and configured for fluid communication with the air pump; and
a clarification chamber including a clarification chamber inlet sealingly coupled to and configured for fluid communication with the aeration chamber via the aeration chamber outlet opening, a clarification chamber outlet opening formed in a back wall of the clarification chamber, a clarification chamber access opening being formed in and extending through a top wall of the clarification chamber, a pump located near the aeration chamber outlet and sealingly coupled to and configured for fluid communication with the anoxic chamber via a piping component; and
a first piping section connected to the pump at a first end and extending upwardly and away from the pump and connecting at a second end to a check valve, which in turn connects to a first end of a second piping section that extends upwardly and through the clarification chamber access opening and is connected at a second end to a first end of a third piping section that extends laterally across the top wall of the clarification chamber and connects at a second end to a first end of a fourth piping section that extends toward the anoxic chamber and is connected at a second end to a first end of a fifth piping section that extends into and toward a bottom of the anoxic chamber and is connected at a second end to an outlet section located near the bottom of the anoxic chamber and that has a plurality of openings defined in the outlet section and that each is configured for fluid communication from an inside of the outlet section to the anoxic chamber.

US Pat. No. 10,167,214

SYSTEM AND METHOD FOR GAS-DISPERSION-RETURN-SLUDGE-BASED WASTEWATER TREATMENT

1. A system for gas-dispersion-return sludge-based wastewater treatment, comprising:a sedimentation vessel into which wastewater comprising inorganic solids and solid organic materials is pumped and in which at least some of the inorganic solids settle from the wastewater;
an adjustment vessel into which the wastewater from the sedimentation vessel is pumped and which comprises anaerobic organisms that solubilize at least some of the solid organic materials within the wastewater;
an aerobic reaction vessel into which the wastewater from the adjustment vessel is pumped and in which the wastewater pumped from the adjustment vessel mixes with a gas-dispersion return sludge to form a mixed liquor, the gas-dispersion return sludge comprising at least one reactive gas a portion of which is dissolved and a portion of which is in a state of ultra-fine bubbles, the gas-dispersion return sludge further comprising aerobic microorganisms that immobilize the solubilized organic materials within the mixed liquor as activated sludge using the at least one dissolved reactive gas, wherein at least some of the ultra-fine bubbles dissolve within the mixed liquor upon a consumption of the dissolved portion of the reactive gases by the aerobic microorganisms;
a sludge sedimentation vessel into which the mixed liquor is pumped from the aerobic reaction vessel and in which the mixed liquor is separated into a supernatant and the activated sludge;
a sludge storage vessel into which the activated sludge from the sludge sedimentation vessel is pumped, wherein at least some of the activated sludge from the sludge collection vessel is pumped to a line atomizer as a return sludge;
a gas generator configured to generate the at least one reactive gas;
the line atomizer configured to form the gas-dispersion return sludge by rendering at least a portion of the at least one reactive gas generated by the gas generator into the ultra-fine bubbles within the return sludge, wherein a portion of the ultra-fine bubbles dissolves within the return sludge, the line atomizer further configured to pump the gas-dispersion return sludge solely into the aerobic reaction vessel; and
a controller interfaced to the sludge storage vessel, the line atomizer, and the gas generator, the controller configured to receive data comprising at least one of a desired degree of purification of the wastewater, a desired speed of purification of the wastewater, and an amount of the wastewater to be purified, and to control the amount of the gas-dispersion return sludge pumped into the aerobic reaction vessel based on the received data.

US Pat. No. 10,167,213

AERATION CONTROL VALVE SYSTEM WITH BYPASS GAS RELEASE PASSAGE FOR WATER TREATMENT SYSTEM AND METHODS FOR USING SAME

R.E. Proscott Co, Inc., ...

1. An aeration control valve system for use with a water treatment tank, the aeration control valve system comprising:a supply water inlet passage configured to receive water from a water supply;
a service water outlet passage configured to direct water to a service water system;
first and second tank passages configured to direct water in to or out of the water treatment tank;
a gas passage fluidly coupled to the first tank passage and configured to allow gas to pass to the water treatment tank;
a drain outlet passage configured to direct water from the water treatment tank to a drain;
a valve cycle actuator configured to provide fluid connections between the passages based on different positions of the valve cycle actuator during different operation cycles; and
a bypass gas release passage extending from a point beyond a flow region of water flowing from the supply water inlet passage and configured to allow gas to be released from the water treatment tank to the gas passage or to the drain outlet passage, during a gas release cycle, while bypassing the water flowing from the supply water inlet passage through the first tank passage.

US Pat. No. 10,167,212

CONTINUOUS FLOW DECONTAMINATION OF AN MTBE-CONTAMINATED AQUEOUS LIQUID

King Fahd University of P...

1. A continuous process for filtering and decontaminating a contaminated aqueous liquid comprising methyl-tert-butyl ether (MTBE), comprising:flowing the contaminated aqueous liquid through at least one selected from the group consisting of a submicron filter, a carbon filter, and an oil filter, to remove particulate matter and long-chain fatty organic molecules, then
flowing the filtered contaminated aqueous liquid while pretreating the contaminated aqueous liquid with chlorine and/or a hypochlorous acid salt to form a chlorinated aqueous liquid comprising 10-50 ppm of chlorine and/or the hypochlorous acid salt, relative to the total mass of the chlorinated aqueous liquid; and
irradiating the chlorinated aqueous liquid with light having a wavelength of about 254 nm from a monochromatic light source that generates a 254 nm wavelength of light or with a polychromatic light source having wavelengths between 200 nm and 370 nm to produce a radical molecular species that degrades the MTBE into at least one degradation byproduct selected from the group consisting of tert-butyl formate (TBF), tert-butyl alcohol (TBA), acetone, carbon dioxide and water and foil is a decontaminated aqueous liquid;
wherein a concentration of MTBE in the contaminated aqueous liquid is higher than a concentration of MTBE in the decontaminated aqueous liquid.

US Pat. No. 10,167,211

FLUID FILTRATION SYSTEM

Green Age Technologies LL...

1. A method of filtering a fluid, comprising:flowing a fluid into a filter assembly in an initial feed flow direction, the fluid containing suspended solids and dissolved impurities, wherein the filter assembly comprises:
a vessel defining a pressure chamber; and
a filter screen with apertures disposed within the vessel, the screen
dividing the pressure chamber into a first subchamber and a second subchamber,
a first pump configured to induce fluid flow from the first subchamber to the second subchamber;
flowing the fluid from the first subchamber to the second subchamber in the feed flow direction;
accumulating at least a portion of the suspended solids in the apertures on the filter screen thereby reducing the effective diameter of the apertures and causing a pressure differential across the filter screen and inducing fluid cavitation in the feed flow direction;
controlling a first pressure of the first subchamber relative to a second pressure of the second subchamber to maintain the fluid cavitation in the fluid flowing in the feed flow direction; and
precipitating out dissolved impurities within the fluid in said first subchamber during the controlled and maintained fluid cavitation.

US Pat. No. 10,167,210

METHODS FOR CONSERVING RESOURCES BY TREATING LIQUIDS WITH ELECTROMAGNETIC FIELDS

Reverse Ionizer Systems, ...

1. A method for conserving resources comprising:receiving data, representative of one or more resources of a transport system or reference system affected by treatment of unwanted material in a liquid, at a user control system or an agent control system (collectively “control system”),
computing an indication of the difference between an amount of resources currently being used by the transport system or the reference system based on the received data and a threshold amount of resources at the control system; and
wherein the treatment of the unwanted material in the liquid comprises generating and applying a magnetic field that includes a modulation signal corresponding to an ionic cyclotron frequency of the unwanted material to treat the unwanted material in the liquid using at least two immersible radial coils configured in a Helmholtz coil arrangement, and at least two axial coils.

US Pat. No. 10,167,209

SYSTEM AND METHOD FOR DISINFECTION AND FOULING PREVENTION IN THE TREATMENT OF WATER

DREXEL UNIVERISITY, Phil...

1. A treatment system comprising:a chamber having an inlet and an outlet;
a cathode and an anode located within the chamber for applying a plasma spark discharge to contents of the chamber; and
at least two electrodes located in the chamber for applying an RF oscillating energy field within the chamber.

US Pat. No. 10,167,208

STERILIZATION SYSTEM

LG Electronics Inc., Seo...

1. A sterilization system comprising:a water supply apparatus provided with a filter unit, the filter unit having a plurality of filters configured to purify water supplied from a water supply unit, a water cock through which water purified by the filter unit is dispensed, and connection passages connecting the filter unit and the water cock to each other; and
a sterilizer configured to sterilize the water supply apparatus,
wherein the sterilizer comprises:
a sterilizing water generator that has electrodes and that is configured to generate sterilized water by using the electrodes to electrolyze water filtered by the filter unit;
a circulation pump configured to pump purified water discharged from the water supply apparatus such that the purified water circulates to the sterilizing water generator and returns to the water supply apparatus;
a circulation passage connected to the water cock to define a closed loop for circulation of purified water and sterilized water such that purified water or sterilized water is discharged from the water supply apparatus and circulates back to the water supply apparatus via the circulation pump and the sterilizing water generator; and
a rinsing water supply passage configured to supply water supplied from the water supply unit to the water supply apparatus to wash out the water supply apparatus,
wherein the water supply apparatus comprises a second water tank configured to heat purified water,
wherein the circulation passage extends from the water cock to the circulation pump,
wherein the sterilizer further comprises a first drain passage that is branched out from the circulation passage, the first drain passage having a first side connected to the circulation passage between the water cock and the circulation pump and a second side connected to an outside of the sterilizer, and
wherein the first drain passage is configured to drain out hot water discharged from the second water tank to the outside of the sterilizer based on the second water tank being sterilized.

US Pat. No. 10,167,207

ELECTROLYTIC APPARATUS WITH CIRCULATOR, REVERSE OSMOSIS FILTER, AND COOLER, FOR PRODUCING REDUCING WATER

SAMSUNG ELECTRONICS CO., ...

1. An apparatus for producing reducing water comprising:an electrolytic bath comprising a cathode chamber provided with a cathode, an anode chamber provided with an anode, and an intermediate chamber interposed between the cathode chamber and the anode chamber, wherein the intermediate chamber comprises a cation exchange resin that dissociates hydrogen ions when the cation exchange resin reacts with water; and
a circulator to supply water to the intermediate chamber and supply water discharged through the cation exchange resin to the intermediate chamber again, the circulator comprising a water tank to store water supplied to the intermediate chamber, a channel to enable water present in the water tank to circulate between the intermediate chamber and the water tank, and a pump to circulate water present in the water tank between the intermediate chamber and the water tank;
a reverse osmosis (RO) filter to purify water that is directly supplied to the electrolytic bath and the water tank of the circulator;
a plurality of valves to control flow of water so that the water supplied from the RO filter is supplied directly to one of the cathode chamber and the water tank; and
a cooling apparatus configured to reduce the temperature of the water in the water tank and comprising any one of a fan and a cooler using a refrigerant or a thermoelectric semiconductor, the water in the water tank being from both the RO filter and the circulator,
wherein the cathode chamber and the intermediate chamber are both provided with an inlet through which water is supplied, and an outlet through which water is discharged,
a cation exchange membrane is provided between the cathode chamber and the intermediate chamber, and
the water tank comprises an outlet through which water stored in the water tank is discharged outside.

US Pat. No. 10,167,205

EXPLOSIVE SEPARATION OF IMPURITIES FROM WASTE WATER IN FREEZE CRYSTALLIZATION SPRAY CHAMBERS

EnisEnerGen, LLC, Hender...

1. A wastewater purification system comprising:a. a chamber having a top and a bottom;
b. one or more wastewater nozzles positioned near the top of the chamber;
c. an intake duct to supply chilled air into the chamber;
d. one or more exhaust ducts to remove the chilled air from the chamber;
e. one or more perforated receptacles positioned near the bottom of the chamber to collect solid byproducts;
f. a watertight receptacle at the bottom of the chamber to collect a liquid product;wherein wastewater enters the chamber as wastewater droplets via the one or more wastewater nozzles, and wherein the wastewater undergoes freeze separation due to heat exchange with a high mass flow of the chilled air between the intake duct and the one or more exhaust ducts;wherein the chilled air is sourced from one or more systems selected from the group consisting of: a transportable compressed air energy storage system, a transfer line compressed air energy storage system, a one-stage free spooling compander system, a two-stage free-spooling compander system, liquid nitrogen system, a climate wherein chilled air is available, or any combination thereof;wherein the chilled air enters the chamber at approximately ?175 degrees Fahrenheit and is exhausted from the chamber at approximately ?25 degrees Fahrenheit;wherein the one or more exhaust ducts exhaust the chilled air to a centrifuge to remove ice particles, and wherein the centrifuge exhausts ice-free chilled air to a gas turbine generator set, and wherein the ice-free chilled air provides the gas turbine generator with an electrical output increase of approximately 30 percent.

US Pat. No. 10,167,204

GRAVITY FILTER DESIGNS CONFIGURED FOR INCREASED RESIDENCE TIME

Helen of Troy Limited, S...

1. A water filter pitcher assembly comprising:a pitcher body comprising a pitcher floor and a pitcher sidewall extending from the pitcher floor; and
a pour tray coupled to the pitcher body, the pour tray comprising:
a pour tray floor;
a pour tray sidewall extending upward from the pour tray floor; and
a filter housing extending below the pour tray floor, the filter housing comprising a housing floor, a housing sidewall extending between the housing floor and the pour tray floor, and at least one filter housing outlet disposed along one of more of the housing floor and the housing sidewall;
a filter media cartridge disposed inside the filter housing comprising filter media, wherein the filter media cartridge further comprises a cartridge floor spaced above the housing floor, a cartridge sidewall extending away from the cartridge floor, and at least one filter media cartridge outlet disposed along one or more of the cartridge floor and the cartridge sidewall; and
a riser spaced between the housing sidewall and the cartridge sidewall and extending vertically above the cartridge floor, and wherein the riser forms a conduit volume that surrounds a bottom portion of said cartridge sidewall.

US Pat. No. 10,167,202

ENHANCED METAL RECOVERY THROUGH OXIDATION IN LIQUID AND/OR SUPERCRITICAL CARBON DIOXIDE

KING ABDULLAH UNIVERSITY ...

11. A method comprising: oxidizing a metal-containing feedstock in a reactor with liquid and/or supercritical fluid carbon dioxide and at least one oxidant, wherein the oxidant is free of complexing agent and optionally the metal-containing feedstock is not subjected to ultrafine grinding, wherein aqueous alkali solution is added to the reactor.

US Pat. No. 10,167,200

SYNTHESIS OF MOLECULAR SIEVE SSZ-41

Chevron U.S.A. Inc., San...


US Pat. No. 10,167,198

METHOD FOR PRODUCING FLAKE GRAPHITE, AND FLAKE GRAPHITE

SEKISUI CHEMICAL CO., LTD...

1. A method for producing exfoliated graphite, comprising steps of:preparing a composition which comprises graphite or primary exfoliated graphite and a polymer and in which the polymer is fixed to the graphite or primary exfoliated graphite; and
pyrolyzing the polymer contained in the composition to exfoliate the graphite or primary exfoliated graphite and remove the polymer by burning the polymer off such that it disappears through pyrolysis of the polymer,
wherein in the step of preparing the composition, the polymer is grafted on the graphite or primary exfoliated graphite in the composition in which the polymer is fixed to the graphite or primary exfoliated graphite.

US Pat. No. 10,167,197

METHOD FOR PRODUCING ZIRCONIUM TUNGSTEN PHOSPHATE

NIPPON CHEMICAL INDUSTRIA...

1. A method for producing zirconium tungsten phosphate, comprising using a mixture of a tungsten compound and an amorphous compound containing phosphorus and zirconium as a reaction precursor and calcining the reaction precursor at 900 to 1300° C.

US Pat. No. 10,167,196

METHOD OF CONVERSION OF RED PHOSPHOROUS TO SOLUBLE POLYPHOSPHIDES

The Florida State Univers...

1. A method for producing polyphosphide anions soluble in organic solvents, comprising:providing red phosphorus or a composition of black phosphorus and red phosphorus;
providing an alkali metal alkoxy compound or alkali metal alkyl thiolate compound suspended in an organic solvent;
wherein the alkali metal is sodium or potassium;
allowing the red phosphorus and alkali metal or alkali metal compound to react, wherein the reaction uses reflux or an in-line packed column method;
where the in-line packed column method comprises:
providing a packing column;
loading the packing column with the red phosphorus or composition of black phosphorus and red phosphorus in an inert environment;
purging the packing column with an inert gas;
setting a pressure regulator on the packing column to at least 1 bar;
heating the packing column to a preselected temperature, where the preselected temperature is at least the boiling point of the alkali metal alkoxy compound or alkali metal alkyl thiolate;
suspending the alkali metal alkoxy compound or alkali metal alkyl thiolate compound in the organic solvent;
flowing the organic solvent through the packing column;
flowing the alkali metal alkoxy compound or alkali metal alkyl thiolate compound in the organic solvent through the packing column; and
forming a compound containing the alkali metal and polyphosphide anions.

US Pat. No. 10,167,195

CONTINUOUS BORON NITRIDE NANOTUBE FIBERS

BNNT, LLC, Newport News,...

1. A process for producing aligned boron nitride nanotube (BNNT) fibers, the process comprising:feeding nitrogen gas to a chamber at an elevated pressure and flowing the gas through the chamber in a first direction;
thermally exciting a boron feedstock in the chamber to form boron micro-droplets downstream of the boron feedstock in the first direction;
establishing a heat distribution profile to form a BNNT growth zone in the chamber downstream of the boron feedstock in the first direction, wherein BNNTs self-assemble from the boron micro-droplets and nitrogen gas in the growth zone and flow in the first direction; and
establishing a shear force profile in the chamber to align BNNT fibers flowing from the growth zone in the first direction.

US Pat. No. 10,167,194

REDUCING GAS GENERATORS AND METHODS FOR GENERATING REDUCING GAS

LG FUEL CELL SYSTEMS INC....

1. A method of generating a reducing gas, comprising:receiving air into an oxidant system;
dividing the received air into a first air stream and a second air stream;
separating nitrogen from the first air stream with a nitrogen generator to produce a nitrogen rich stream and an oxygen rich stream;
discharging the oxygen rich stream to atmosphere;
combining at least a portion of the nitrogen rich stream with the second air stream to form an oxidant;
receiving the oxidant, a pressurized flow of a recycle gas from a recycle pump, and a hydrocarbon fuel into a merging chamber;
discharging a feed stream including the oxidant, the recycle gas and the hydrocarbon fuel from the merging chamber;
reforming the feed stream in a reformer to yield a reducing gas; and
extracting a portion of the reducing gas to form the recycle gas,
wherein the merging chamber and reformer are discrete.